IMPAACT  P1090  
 
 
 
A PHASE  I/II, OPEN -LABEL  TRIAL TO  EVALUATE THE  SAFETY, 
TOLERABILITY, PHARMACOKINETICS AND ANTIVIRAL AC TIVITY OF  
ETRAVIRINE (ETR) IN ANT IRETROVIRAL  (ARV) TREATM ENT-EXPER IENCED 
HIV -1 INFEC TED INFANTS AND CHILDR EN, A GED ≥2 MONTHS  TO <6 YEARS  
 
A Multi center,  Domestic & Intern ational  Trial  of 
the Inter national  Mater nal Pediatric  Adolescent  
AIDS Clinical  Trials  Group (IMPAACT)  
 
Sponsored by: 
The Nation al Instit ute of Allergy  and Infectious  Diseases  
(NIAID)  
and 
The Eunice  Kennedy  Shriver  National  Institute  of Child  Health  and Human  
Develop ment 
(NICH D) 
 
Pharmaceutical  Support  Provided  by Janssen 
R&D IND # 113,895 Held  by DAIDS  
 
The IMPAACT HIV Treat ment Scienti fic Committee  Chair:  Elaine  Abra ms, MD  
Protocol  Chair:  Richard  Rutstein,  MD 
Protocol  Co Chairs:  Andrew Wiznia, MD  
 Ram Yogev, MD  
NIAID Medical  Officer:  Ellen  Townley,  MSN 
NICHD M edical  Officer:  Jack Moye , MD  
 
Clinic al Trials Specialists:   Megan  E. Valentine,  MPA
 Kathryn  Lypen,  MPH  
 
 
 
 
 
 
 
 
Version 5.0 
10 March  2016
P1090  PROTOCOL  TEAM ROSTER  
 
IMPAACT P1090  Page 2 of 113 10 March  2016  
Version 5.0  All questions  concerning  this protocol should  be sent via e-mail to 
impaact.teamp1090@f strf.org . Questions concerning  clinical  manage ment of study  subjects  
and all communication  regarding adverse  experiences  should  be addressed  to the P1090 core  
protocol  team  at impaact.p1090c mc@fstrf.or g. Remember to include  the subject’s  PID when 
applicable.  
 
A response should  generally  be received  within  24 hours (Monday - Friday).  For protocol 
registration  questions,  e-mail protocol@tech -res.com  or call  301-897-1707.  Protocol  
registration material  can be sent electronically  to epr@tec h-res.com  or via  fax at 1-800-418-
3544 or 301 -897-1701.For EAE  questions,  e-mail RSCSafetyOffice@tech -res.com  or call  1-
800-537-9979 or  1-301-537-9979 or fax  1-800-275-7619 or 1 -301-897-1710.To  order  study  
agent,  call the Clinical  Research  Products Manage ment Center at (301) 294 -0741. For 
rando mization  or enroll ment questions,  contact  the Data  Manage ment Center  at 716-834-0900 
or by email  at sdac.rando m.desk@fstrf.org . 
 
Protocol  Chair  
Richard  Rutstein,  M.D.  
Children 's Hospit al of Philad elphia  
34th & Civic  Center  Boulevard  
Philadelphia,  PA  19104  
Phone:  (215) 590 -1466  
Email: rutstein@e mail.chop.edu  
 
Protocol  Vice  Chairs  
Andrew Wiznia,  M.D. 
Jacobi  Medical  Center  
1400 Pelham  Parkway South  
Bronx, NY  10461  
Phone:  (718) 918 -4664  
Email: awiznia@aeco m.yu.edu  
 
Ram Yogev, M.D.  
CMRC Chi ldren's  Memorial  Hospital  
Northwestern  University  Medical  School  
225 E.  Chicago  Ave, Box  155 
Chicago,  IL 60611 -2605  
  Phone:  (312) 227 -6280  
  Email: ryogev@luriechildrens.org  
 
NIAID  Medical  Officer  
Ellen  Townley,  MSN  
NIAID Maternal,  Adolescent  & Pediatric  
Research  Branch  
BG 5601FL  RM 8B37  
5601 Fishers Lane  
Rockville,  MD 20852  
Phone:  (240) 292 -4784  
Email: ellen.townley@nih.gov  NICHD M edical  Officer  
Jack Moye, Jr., MD  
National Children’s Study  
Eunice Kennedy Shriver  
National Institute of Child Health & Human 
Development  
National Institutes of Health, DHHS  
Bldg. 6100 Rm. 3A01 MSC 7510  
9000 Rockville Pike  
Bethesda, MD  20892 -7510  
Phone: (301 -594-8624  
Email: john.moye@nih.hhs.gov  
 
Clinic al Trials Specialists  
Megan  E. Valentine,  MPA 
IMPAACT  Operations  
FHI 360  
359 Blackwell  St 
Durha m, NC 27701  
Phone:  (919) 544 -7040, Ext.  11186  
Fax: (919) 544 -0207  
Email: mvalentine@fhi360.org  
 
Kathryn  Lypen,  MPH 
IMPAACT  Operations FHI 360  
359 Blackwell  St 
Durha m, NC 27701  
Phone:  (919) 544 -7040, Ext.  11684  
Fax: (919) 544 -0207  
Email: klypen@fhi360.org  
 
 
 
 
 
IMPAACT P1090  Page 3 of 113 10 March  2016  
Version 5.0  Protocol  Virologist  
Paul Palumbo, M.D.  
Dartmouth-Hitchcock  Medical  Center  
One Medical  Center  Drive  
Lebanon,  NH 03756  
Phone:  (603) 650 -8840  
Email: paul.palu mbo@dart mouth.edu  
 
Protocol  Statisticians  
Terence  Fenton,  Ed.D.  
Statistical & Data  Anal ysis Cent er 
Harvard  School  of Public  Health  
651 Huntington  Avenue  
Boston,  MA  02115  
Phone:  (617) 432 -3027  
Email: fenton@sdac.harvard.edu  
 
Carmelita Alvero,  M.S.  
Harvard  School  of Public  Health  
FXB Building,  Room  501 
651 Huntington  Ave 
Boston,  MA  02115  
Phone:  (617) 582 -7265 Email: 
calvero@sdac.harvard.edu  
 
Protocol  Data  Manager  
Bobbie  Graha m, B.S. 
Frontier  Science  and Technology  
Research  Foundation  
4033 Maple  Road  
Buffalo,  NY  14226 -1056  
Phone:  (716) 834 -0900, ext.  7265  
Email: graha m.bobbie@fstrf.org  
 
Aaron Atlas, B.S.  
Protocol Data Manager  
Frontier Science & Technology Research  
Foundation  
4033 Maple Road  
Amherst, NY 14226 -1056  
Phone: 716 -834-0900 x74 22 
Fax: 716 -834-8675  
E-mail: atlas@fstrf.org  
 Protocol  Pharmacist 
Katheri ne Shin,  Pharm.D. Phar maceutical  
Affairs Branch  (PAB) DAIDS,  NIAID  
5601 Fishers Lane, Room 9D30A  
Rockville , MD 2085 2 
Phone:  (240) 627-3047  
Email: KaShin@niaid.nih.gov  
 
Protocol  Pharmacologis ts 
Jennifer  Kiser, Phar m.D. 
University  of Colorado  Denver 
Skaggs School  of Phar macy and 
Pharmaceutical  Sciences  
12850 E  Montview  Blvd,  V20-C238  
Aurora, CO  80045  
Phone:  (303) 724 -6131  
Lab: (303) 724 -6132  
Email: jennifer.kiser@ucdenver.edu  
 
Laboratory  Technologist  
Bill Kabat  
Infectious  Disease  Laboratory  
Deming Room  3012 Mailbox  82 
Ann &  Robert  H Lurie  Children's Hospit al 
of Chicago  
Chicago,  IL 60611  
Phone:  (312) 227 -6290  
Email: bkabat@luriechildrens.org  
 
Laboratory  Data  Manager  
Oswald Dadson , M.S. 
Frontier  Science  and Technology  Research  
Foundation  
4033 Maple  Road  
Amherst,  NY 14226  
Phone:  (716) 834 -0900, ext.  7238 
Email: dadson@ fstrf.org 
 
Westat  Clinical Research  Associate  
Kathryn  Myers, B.A., CCRP 
Westat 
1441 West Montgo mery Ave. #215  
Rockville,  MD 20850  
Phone:  301-610-8803  
Fax: 301-279-4545  
Email: kathrynmyers@west at.com  
 
 
 
IMPAACT P1090  Page 4 of 113 10 March  2016  
Version 5.0  Investigat ors 
Cristina  Hofer, M.D. Ph.D.  
Universidade  Federal  dos Rio  de Janeiro  
Rua Lopes  Quintas,  340/106  
Jardi mBotanico  - Rio de Janeiro/RJ  
22460 -010 
Brazil  
Phone:  (+55  21) 2562 2555  
Email: cbhofer@hucff.ufrj.br  
 
Lee Fairlie, M.D.  
Shandukani Research Centre  
Wits Reproductive Health & HIV Institute  
(WRHI), University of the Witwatersrand,  
22 Esselen Street  
Hillbrow 2001 Johannesburg  
South Africa  
Phone: +27 11 358 5317  
Email: lfairlie@wrhi.ac.za  
 
Janssen R&D  Representatives  
Herta  Crauwels,  Ph.D.  
Associate  Director,  Clinical  Pharmacology 
Janssen Infectious  Diseases, BVBA 
Turnhoutseweg  30 
2340 Beerse  
Belgium  
Phone:  (+32)  14 641 -054 
Email: hcrauwel@its.jnj.com  
 
Sophie  Dedrie,  Pharm. D 
Clinical  Project  Manage ment Lead 
Janssen Phar maceutica  NV 
Turnhoutseweg  30 
2340 Beerse  
Belgium  
Office  phone:  +32-14-641751  
Email: sdedrie1@its.jnj .com 
 Ludo Lavreys,  M.D., Ph.D., M.Sc. 
Senior  Trial  Physician  
Janssen Infectious  Diseases  
BVBA  
ID&V Medical  Department  
Turnhoutseweg  30 
2340 Beerse  
Belgium  
Office  phone:  +32-14-607767  
Cell phone:  +32-473-554739  
Email: llavrey1@its.jnj.com  
 
Simon Vanveggel  
Statistical Leader Intelence  
Janssen Infectious Diseases, BVBA 
Turnhoutseweg 30  
2340 Beerse   
Belgium  
Phone: (+32) 14 641 347  
Email: svanvegg@its.jnj.com  
 
Lotke Tambuyzer, M.Sc. Clinical Virologist  
Janssen Infectious Diseases, BVBA 
Turnhoutseweg 30  
2340 Beerse  
Belgium  
Phone: (+32) 14 641744  
Email: ltambuyz@its.jnj.com  
 
  
 
 
IMPAACT P1090  Page 5 of 113 10 March  2016  
Version 5.0  GLOSSARY  
 
3TC Lamivudine  
ABC  Abacavir  
AE Adverse Event  
AIDS  Acquired  Immunodeficiency  Syndro me 
ALT  Alanine  aminotransfera se 
ART  Antir etroviral therapy  
ARV  Antiretroviral  
AST  Aspartate  aminotransferase  
ATV  Atazanavir  
AUC12h Area  under  the drug plas ma concentration -time profile  over 12 
hours  
BID bis in die (twice  daily)  
C0h plasma concentration  immediately  prior  to dosing  
C12h plasma concentration  at the end of the  12 hour dosing  interval  
Cmax Maxi mal observed  plasma conce ntration  during  a dosing  interval 
Cmin Mini mal observed  plasma  conce ntration  during  a dosing  interval 
CAP  College  of American  Pathologists  
CART  Combinati on anti-retroviral therapy 
cDNA  complementary DNA  
CL/F  Apparent  oral cleara nce 
CLIA  Clinical  Laboratory  Improve ment Amendments  
CPK  Creatinine  phosphokinase  
CRPMC  Clinical  Research  Products Manage ment Center 
DAE RS DAIDS Ad verse Experience  Reporting  System 
DAIDS  Division  of AIDS (United  States)  
DHHS  Depart ment of Health  & Human Services  
DMC  Data  Manage ment Center 
DNA  Deoxyribonucleic  acid  
DRV  Darunavir  
DSMB  Data  Safety  and Monitoring  Board  
EAE  Expedited  Adverse  Event  
EC                                   Ethics  Com mittee  
ECG                                Electrocar diogram  
EFV                                 Efavirenz  
EIA Enzy me immunoassay  
EMA  European  Medici nes Agency  
ETR  Etravirine  
EU European  Union  
FDA  Food and  Drug Ad ministration  
FPV Fosa mprenavir  
FTC  Emtricitabi ne  
GI                                    Gastrointestinal  
GM Geometric mean 
GMR  Geometric mean ratio 
HIV Human Immunodeficiency  Virus  
 
 
IMPAACT P1090  Page 6 of 113 10 March  2016  
Version 5.0   
IB Investigator’s  Brochure  
IC50 Half maximal  inhibitory concentration  
IMPAACT  Inter national  Mater nal Pediatric  Adolescent  AIDS  Clinical  
Trials  Network  
IgM Immunoglobulin  M  
ICF Infor med consent  form  
IQ Inhibitory  quotient  
INR Inter national  normalized  ratio 
IRB Institutional  Review  Board  
ISRP  Independent  Safety  Review  Panel  
IUD Intrauterine  device  
LAR  Legally  authorized  representative 
LDH  Lactate  dehydrogenase  
LPV  Lopinavir  
NIAID  National  Institute of Allergy and Infectious  Diseases  
NICHD  National  Institute of Child  Health  and Human Develop ment  
NIH National  Institutes of Health  
NNRTI  Non-nucleoside  reverse  transcriptase  inhibitors  
NVP  Nevirapine  
OBR  Optimized background  regimen 
OHRP  Office  of Human Research  Protecti ons 
PCR  Polymerase  Chain  Reaction  
PI Protease  inhibitor  
PID Patie nt identifier  
PK Pharmacokinetic  
PMTCT  Prevention  of Mother  to Child  Trans mission  
PRO  Protocol  Registration  Office  
QD Quaque  die (Once  a day)  
RAL  Ralteg ravir 
RAM  Resista nce associated  mutations  
RSC  Regulatory  Support  Center  
RE                                 Regulatory  entity 
RNA                               Ribonucleic  acid 
RTV                                Ritonavir  
SADR  Suspected  adverse  drug reaction  
SAE  Serious ad verse event 
SDMC  Statistical and Data Manage ment Center 
sdNVP  Single  dose nevirapine  
SMC  Study  Monitoring  Committee  
SUSAR  Suspected,  unexpected  serious  adverse reaction  
Tmax time at which  Cmax occurs  
T1/2 terminal elimination  half-life 
TB Tuberculosis  
TDF  Tenofovir  disoproxil  fumarate  
TID Ter in die (three  times a day) 
TPV  Tipranavir  
ULN  Upper li mit of no rmal 
 
 
IMPAACT P1090  Page 7 of 113 10 March  2016  
Version 5.0  US United  States  
WB Western  blot 
Vd Apparent  volume of distribution  
ZDV  Zidovudine  
  
 
 
IMPAACT P1090  Page 8 of 113 10 March  2016  
Version 5.0  TABLE  OF CONTENTS  
GLOSSARY  ................................ ................................ ................................ ................................ .....................  5 
SCHEMA  ................................ ................................ ................................ ................................ .......................  11 
IMPAACT  P1090  ................................ ................................ ................................ ................................ ..........  11 
1.0 INTRODUCTION  ................................ ................................ ................................ ............................  13 
1.1 Background  ................................ ................................ ................................ ................................ ........  13 
1.2 Etravirine  Background  ................................ ................................ ................................ .......................  13 
1.3 Clinic al Studies ................................ ................................ ................................ ................................ .. 14 
1.4 Rationale  ................................ ................................ ................................ ................................ ............  26 
2.0 STUDY O BJECTIVES  ................................ ................................ ................................ ....................  26 
2.1 Primary Objectives  ................................ ................................ ................................ .............................  26 
2.2 Secondary  Objectives  ................................ ................................ ................................ .........................  27 
3.0 STUDY D ESIGN  ................................ ................................ ................................ ..............................  27 
3.1 Description  of Cohorts  ................................ ................................ ................................ .......................  28 
3.2 Optimized Background  Regi men ................................ ................................ ................................ ....... 28 
3.3 Mini -Cohorts  ................................ ................................ ................................ ................................ ...... 31 
3.4 Full Coh orts................................ ................................ ................................ ................................ ........  32 
3.5 Cohort III ................................ ................................ ................................ ................................ ............  33 
3.6 Long  Term  Safety  Follow -Up ................................ ................................ ................................ ............  34 
3.7 Early  Discontinuation  ................................ ................................ ................................ .........................  34 
4.0 SEL ECTION AND ENROLL MENT  OF SUBJECTS  ................................ ................................ . 34 
4.1 Inclusion  Criteria  ................................ ................................ ................................ ................................  34 
4.2 Exclusion  Criteria  ................................ ................................ ................................ ...............................  36 
4.3 Concomitant Medication Guidelines  ................................ ................................ ................................ .. 37 
4.4 Enroll ment Procedures  ................................ ................................ ................................ .......................  38 
4.5 Co-enroll ment Procedures  ................................ ................................ ................................ ..................  39 
5.0 STUDY TRE ATME NT ................................ ................................ ................................ ...................  39 
5.1 Drug Regimens,  Administration  and Duration  ................................ ................................ ...................  39 
5.2 Dosing and  Administration  ................................ ................................ ................................ ................  40 
5.3 Drug For mulation  ................................ ................................ ................................ ...............................  41 
5.4 Drug  Supply,  Distribution  and Pharmacy ................................ ................................ ...........................  41 
5.5 Long  Term  Safety  Follow -up ................................ ................................ ................................ .............  42 
6.0 SUBJ ECT MANAG EMENT ................................ ................................ ................................ ...........  42 
6.1 Toxicity  Manage ment ................................ ................................ ................................ ........................  42 
6.2 Subject  Manage ment ................................ ................................ ................................ ..........................  48 
6.3 Definition  of Virologic  Failure for Subject  Manage ment ................................ ................................ ... 48 
6.4 Viral  Resistance  Testing  ................................ ................................ ................................ .....................  49 
6.5 Permitted Changes  to the ARV Opt imized Background  Therapy  During the  Study  ..........................  49 
6.6 Concerns  Regarding  Non-Adherence  ................................ ................................ ................................ . 50 
6.7 Etravirine  Dose Changes  Due to  Increases  in Body  Weight  ................................ ..............................  50 
6.8 Criteria  for Etravirine  (Study  Drug) Discontinuation  ................................ ................................ .........  51 
6.9 Criteria  for Study  Discontinuation  ................................ ................................ ................................ ..... 51 
7.0 EXP EDITED ADV ERSE EVENT REPORT ING ................................ ................................ ........  52 
7.1 Adverse Event  Reporting  to DAIDS  ................................ ................................ ................................ .. 52 
 
 
IMPAACT P1090  Page 9 of 113 10 March  2016  
Version 5.0  7.2 Reporting  Require ments for this  Study  ................................ ................................ ..............................  52 
7.3 Grading  Severity  of Events  ................................ ................................ ................................ ................  52 
7.4  Expedited  AE Reporting  Period  ................................ ................................ ................................ .........  53 
8.0 STATI STICAL  CONSIDERAT IONS ................................ ................................ ...........................  53 
8.1 General  Design Issues  ................................ ................................ ................................ ........................  53 
8.2 Endpoints  and Outco me Measures  ................................ ................................ ................................ ..... 55 
8.3 Rando mization  and Stratification  ................................ ................................ ................................ ....... 56 
8.4 Sample Size and Accrual  ................................ ................................ ................................ ....................  56 
8.5 Monitoring  ................................ ................................ ................................ ................................ .........  57 
8.6 Analyses  ................................ ................................ ................................ ................................ .............  62 
9.0 CLINICAL PHA RMACOLOGY  PLAN ................................ ................................ ........................  65 
9.1 Pharmacology  Objectives  ................................ ................................ ................................ ...................  65 
9.2 Primary and Secondary  Data  ................................ ................................ ................................ ..............  65 
9.3 Study  Design, Modeling  and Data  Analysis  ................................ ................................ .......................  65 
9.4 Population  Pharmacokinetic  Study Design,  Modeling  and Data  Analysis  ................................ .........  69 
9.5 Anticip ated Outco mes ................................ ................................ ................................ ........................  70 
10.0  HUMAN SUBJECTS  ................................ ................................ ................................ .......................  70 
10.1  Institutional  Review  Board  and Infor med Consent  ................................ ................................ ............  70 
10.2  Subject  Confidenti ality ................................ ................................ ................................ .......................  71 
10.3  Study  Discontinuation  ................................ ................................ ................................ ........................  71 
11.0  PUBL ICATION OF  RES EARCH FINDINGS  ................................ ................................ .............  71 
12.0  BIOHAZARD CON TAINMENT  ................................ ................................ ................................ ... 71 
13.0  REF ERENCES  ................................ ................................ ................................ ................................ . 73 
APPENDIX IA: SCHEDULE OF EVALUATIONS - Cohort  I ................................ ................................  76 
APPENDIX IB: SCHEDULE OF EVALUATIONS – Cohort  II ................................ ..............................  79 
APPENDIX IC: SCHEDULE OF EVALUATIONS – Cohort  III ................................ ............................  82 
APPENDIX ID: SCHEDULE OF EVALUATIONS FOR FOLLOW UP OF SUBJECTS WHO 
DISCONTINUE ETRAVIRINE (OFF STUDY DRUG – ON STUDY)  ................................ ...... 85 
APPENDIX IE: SCHEDULE OF EVALUATIONS FOR LONG -TERM SAFETY FOLLOW -UP OF 
SUBJECTS RECEIVING STUDY -PROVIDED ETRAVIRINE  ................................ ................  87 
APPENDIX II: PLANNED LABORATORY TEST ING ON COLLECTED  SPECIMENS  .................  89 
APPENDIX III: ETRAVIRINE DRUG DOSING TABLE  FOR ORAL TABLET  ................................  90 
APPENDIX IV: VISIT SCHEDULE FOR RA SH MANAG EMENT IN PED IATRIC SUBJECTS  .... 92 
APPENDIX V: GRADING FOR PR AND QTc  INTERVALS ................................ ................................ . 93 
APPENDIX VI: SUPPLEMENTAL TOXICITY TABLE  FOR G RADING S EVERITY  OF 
NEU ROLOGIC ADV ERSE  EVENTS  ................................ ................................ ...........................  94 
APPENDIX VII -A: SUPPLEMENTAL TOXICITY TABLE  FOR G RADING  SEVERITY  AND 
MANAGEMENT  OF ADU LT AND PEDIA TRIC CUTANEOUS ADVERSE EXPERIEN CES
 ................................ ................................ ................................ ................................ ............................  95 
APPENDIX VII -B: SUPPLEM ENTAL  TOXICITY  TABLE FOR G RADING S EVERITY  AND 
MANAGEMENT OF ADULT  AND PED IATRIC A CUTE SYSTEMIC ALLERGIC  
ADVERSE  EXPERIENCES  ................................ ................................ ................................ ............  97 
 
 
IMPAACT P1090  Page 10 of 113 10 March  2016  
Version 5.0  APPENDIX VIII: SAMPLE INFORMED CONSENT  ................................ ................................ .............  98 
APPENDIX IX: FACT SHEET and TEMPLATE CONSENT FORM for SPECIMEN STORAGE AT 
REPOSITORIES FUNDED BY THE NATIONAL INSTITUE OF CHILD HEALTH AND 
HUMAN DEVELOPMENT ( NICHD)  ................................ ................................ .........................  110 
 
  
 
 
IMPAACT P1090  Page 11 of 113 10 March  2016  
Version 5.0  SCHEMA  
 IMPAACT  P1090   
 
A PHASE  I/II, OPEN -LABEL  TRIAL TO  EVALUATE THE  SAFETY, TOLERABILITY, 
PHARMACOKINETICS AND ANTIVIRAL AC TIVITY OF  ETRAVIRINE (ETR) IN 
ANT IRETROVIRAL  (ARV) TREATM ENT-EXPER IENCED HIV -1 INFEC TED 
INFANTS AND CHILDR EN, A GED ≥2 MONTHS  TO <6 YEARS  
 
 
 
DESIG N: Phase I/II,  multi -center,  open -label, pharmacokinetic  and safety  study.  
 
SAMPLE  SIZE: It is expected  that approximately  50 subjects  will be accrued,  to yield  a 
minimum of 36 evaluable  subjects  (a minimum of 12 subjects  in each 
cohort ). Up to 18 subjects may be enrolled into Cohort I.  
*See section 8.1 for  definition of e valuable subjects 
 
The total sample  size will depend  upon the  number needed  to complete  the 
dose finding  stage  of the  study,  the number of subjects  who discontinue  
the study  and the number of subjects  required  for regulatory  approval  of 
etravirine  in these  populations.  
 
POPULATION:  HIV-infected  treatment-experienced  infants  and children  aged  ≥ 2 months 
to < 6 years  of age.  
 
STRATIF ICATION:  This is a sequenti al study which  started accrual with the oldest age cohort 
and will progress down to  the youn gest age cohort. Cohort III will open 
with the activation of Version 5 .0. 
 
Children will be str atified by age,  as follows: 
 
 Cohort  I: ≥ 2 year  to < 6 years  who are treatment experien ced* 
 Cohort  II:  ≥ 1 year  to < 2 years  who are treatment experien ced* 
 Cohort  III: ≥ 2 months  to < 1 year  who are  treatment  experienced*, † 
 
*Treat ment experienced c hildren on  a failing c ombination antiretro viral regimen 
(containing at least 3 ARVs)  for at least 8  weeks OR Treatment  experienc ed children on a 
treatment interru ption of at least 4 wee ks with a  history of  virologic fai lure while on  a 
combination antiretro viral regimen (containing at least  3 ARVs)  
 
† subjects below 6 months of age will only be enrolled upon availability of initial safety 
and PK data from subjects between 6 months and 1 year of age.  
 
REGIMEN:  Etravirine  (ETR)  will be administe red as 25 mg scored  tablets and/or  100 
mg tablets  swallowed  as a whole  or dispersed  in an appropriate  liquid 
vehicle  (see Section  5.2). ETR  will be started concurre ntly with an 
optimized background  regimen (OBR), while  OBR will  be based  on 
clinical status, treatment history,  resistance  data and availability  of 
appropriate  pediatric  dosing  and formulations.  Refer to Section  3.1 and 
Table  6 for further  infor mation  on regi men design  per cohort.  
 
 
 
IMPAACT P1090  Page 12 of 113 10 March  2016  
Version 5.0  STUDY DURATION:  Mini mum of 48 weeks  
 
Long  Term  Safety  Follow -up: 
Subjects  who successfully  complete  48 weeks of ETR  treatment  
will continue  to receive  ETR  throughout  the study,  and be followed  
(see Appendix  IE) for up to  5 years  as part  of long -term safety  
follow -up. 
 
 
PRIMARY OBJECTIVES:  
 
1.   To  evaluate  the steady  state pharmacokinetics  of ETR  in combination  with an OBR in  
HIV-infected  children aged  ≥ 2 months  to < 6 years.  
 
2.   To  deter mine the safety and tolerability  of ETR  in combination  with an OBR in  children 
aged  ≥ 2 months to < 6 years,  through  48 weeks of therapy.  
 
3.   To  deter mine the appropriate  dose of  ETR  in combination  with an OBR for children  aged  
≥ 2 months  to < 6 years.  
 
 
 
SECONDARY OBJ ECTIVES:  
 
1. To assess the  antiretroviral  activity  of ETR  containing  regimens through  48 weeks 
of therapy.  
2.   To  deter mine the immunological  changes  (change  in CD4 percent  and absolute  count; 
CD4/CD8 r atio and percent)  through  48 weeks of ETR  therapy  in combination  with an 
OBR.  
3.   To  deter mine changes  in viral drug resistance  during  48 weeks of ETR  therapy  
in co mbination  with an OBR.  
4.   To  assess the  relationship  between  ETR pharmacokinetics  and the antiviral  activity  and 
safety  of ETR  containing  regimens. 
5.   To  explore  the relationship  between  subject -specific  gene  CYP profile , 
sex, age, weight, race, HIV regimen (e.g., boosted PI) and HIV response 
markers  and phar macokinetics  of ETR.  
  
 
 
IMPAACT P1090  Page 13 of 113 10 March  2016  
Version 5.0  1.0 INTRODUCTION  
 
 
1.1 Background  
 
Nevirapi ne (NVP) and  efavire nz (EFV), the  two most  widely  used NNRTI drugs, have  a low 
genetic  barrier  for the  develop ment of drug r esistance mutations,  so that  a single  amino acid 
substitution  in the viral reverse  transcriptase  (RT),  such as K103N, leads  to profound reduction in  
viral susceptibility to both drugs, conferring  cross resistance  with other agents  in this class. A mong 
HIV-infected  Thai children  failing  a non-nucleoside  reverse  transcriptase  inhibitor  
(NNRTI) based  regimen, 97% had  NNRTI -related resistance. The most common NNRTI rel ated 
mutations  were Y181C/I, in  58% of subjects,  and 34% of subjects  had the K103N  mutation  (1). 
 
Short  term use of these  NNRTIs can  select  for NNRTI resistance  mutations  even  after a single dose, 
as has been  documented  for NVP when u sed to prevent maternal  to child  transmission (PMTCT). A 
meta-analysis  estimated NVP resistance  in 52.5% of infants  exposed  only to single dose (sd) NVP 
and in 16.5% of infants  receiving  sdNVP w ith other  postnatal  antiretrovirals  (2). 
 
Early  detection  of NNRTI resistance  mutations  among  infants  at 6 to 8 weeks of life  who had 
perinatal  exposure  to sdNVP has  been  reported  at 46% for a  Ugandan  cohort  (3) and 87% for a 
Malawian  cohort  (4). Similar confirmatory  reports  have  emerged from South  Africa  (5) and India 
(6).  In the  P1060 IMPAACT treatment  study,  12% of PMTCT -exposed  infants  who were  6 to 36 
months  of age  at enroll ment had baseline  resistance  to first gener ation NNRTIs (15/18  carried  
the Y181C mutation,  and 3/18 the K103N) (7). The trial demonstrated  superiority  of a 
lopinavir/ritonavir -based  first line treatment regimen in infants  when compared  with a NVP - based  
regimen  in the setting  of prior  sdNVP -exposure  and led to changes  in the WHO pediatric treat ment 
guidelines  (8).  The  duration  of persistence  of these  NNRTI  mutations  in individuals receiving  
MTCT  prophylaxis  regimens is not known and  is the subject  of ongoing  studies.  
 
With the widespread  use of first generation  NNRTIs (NVP and  EFV) as co mponents  of 
combination  antiretroviral  therapy  (cART),  NVP as a  component  of neonatal  PMTCT  treatment 
regimens, and infant  exposure  to NVP during  breastfeeding,  the number of children  harboring virus 
with one or two NNRTI -resistance mutations  will continue  to increase.  Thus, there  is an urgent  
need  to develop  alternative  therapeutic  options  for newly  diagnosed  neonates  and infants exposed  to 
sdNVP containing  regimens, as well  as for infants  and children failing  their present cART  
regimens.  
 
 
1.2 Etravirine  Background  
 
1.21 General  
 
ETR  (TMC125 from  Janssen R&D) is  a second  generation  NNRTI  and has a  diarylpyri midine- 
based  structure  providing  molecular  flexibility  relative  to other NNRTIs, allowing  ETR to maintain  
its binding  affinity  for HIV -1 reverse  transcriptase  despite  binding site changes  induced  by the  
presence  of common  NNRTI  resistance  mutations.  ETR exhibits  potent  in vitro anti-HIV acti vity 
against  wild type and against HIV isol ates with NNRTI resi stance mutations  such as K103N, 
Y181C and  Y188L (9) (10). 
 
 
 
IMPAACT P1090  Page 14 of 113 10 March  2016  
Version 5.0  1.22 Preclin ical Studies  
 
 
Preclinical  studies  noted  EC50 values  for wild -type laboratory  and primary HIV-1 isolates  of 0.9 to 
5.5 nM (0.4 to  2.4 ng/mL)  with little or no loss  of activity  against  HIV-1 variants  with the most  
common  NNRTI -related  mutations.  During in vitro testing,  ETR  showed potent  antiviral  
activity  against  a panel  of > 6000 reco mbinant  clinical  isolates  resista nt to at least one of the  first 
generation  NNRTIs, w ith EC 50 values  below  10nM for 83% of isolates  and below  100nM for  
98% of isolates  (9).  In addition,  ETR was noted  to have  an increased  genetic  barrier  to the 
develop ment of resistance  compared  to first generation  NNRTIs. Non -clinical  safety  evaluations 
demonstrated  that ETR  was safe  for use in  clinical testing.  
 
 
1.23 Pharmacokinetics  
 
ETR  absorption  is increased  50% when taken  with a meal (11); peak  plasma concentrations  occur 2 
to 4 hours post  dose. The  absorption  is not affected  when the  drug is  taken  with proton  pump 
inhibitors  or H 2 blockers  (12).  ETR  is a weak  inducer  of CYP3A4 and  a weak  inhibitor  of P-
glycoprotein,  CYP2C9 and  CYP2C19.  Therefore  it is subject  to drug-drug interactions  that may 
result  in lower  serum  concentrations  of drugs metabolized  by CYP3A4 such as HIV protease  
inhibitors,  if not boosted  with ritonavir,  and higher  concentrations  of drugs metabolized by 
CYP2C9 and/or  CYP2C19 and/or  transport ed by P-glycoprotein  (13-16). 
 
 
 
1.3 Clinic al Studies 
 
 
1.31 Adult  Studies  
 
Trial  TMC125 -C228  established  PK para meters  for ETR  administered  as for mulation  F060, 200 mg  
BID in  treatment experie nced HIV-1 infected  adults  who were  curre ntly recei ving a boosted PI 
(primarily LPV/rtv)  (17).  For mulation  F060 is  the commercial 100-mg tablet  formulation.  
 
In January  of 2008 ETR  was approved  by the  US Food and  Drug Ad ministration  (FDA) for 
antiretroviral  treatment-experienced  adults  at a dose of 200 mg  BID, with  similar European Union 
approval  in August 2008. The  approvals  were based  on the  results  of the  DUET -1 and  
DUET -2 studies  in treatment experienced  HIV-1-infected  adults  (18). The DUET studies  consist of 
two Phase III dou ble- blind,  placebo -contr olled rando mized trials  of ETR,  with an OBR that 
included  darunavir/ritonavir  (600/100  mg BID) plus  other  antiretrovirals  in treatment 
experienced  adults.  In an  intent  to treat (ITT) pooled  24 week  analysis  (N = 1203), ETR  was 
superior  to placebo  with respect  to the following  endpoints:  viral load reduction  to < 50 copies/ mL 
(60% vs. 40%), viral  load < 400 copies/ mL (74% vs. 53%) and  mean viral load reduction  (2.4 vs. 
1.7 lo g10 copies/ mL). The 48-week  efficacy  results  were  consi stent in the demonstration  of a 
statistically  significant superior  efficacy  for ETR  versus placebo  (19).  The  proportion  of subjects  
with viral load < 50 copies/mL  at week  96 was 57.4% in  the ETR  group and  36.3% in  the placebo  
group (19).  Genotypic  analyses  identified  seventeen  ETR  resistance associated  mutations  (RAMs)  
predictive  for decreased  virologic  response  to ETR  and a weighted genotypic  score  has b een 
developed  (20). 
 
 
 
IMPAACT P1090  Page 15 of 113 10 March  2016  
Version 5.0  Population  pharmacokinetic  analysis of week  48 data  from  DUET -1 and  DUET -2 revealed  an ETR  
mean AUC 12h and C0h of 5506ng •h/mL and 393 ng/mL  respectively , at a dose of 200 mg BID (21).  
Neither  AUC 12h nor C 0h were correlated  with virologic  suppression or adverse  events (AEs). Other  
factors,  including  baseline  viral load,  CD4 cell  count,  number of active  agents  in the background  
regimen, fold change  in EC50 to ETR  and adherence  were  more important deter minants  of virologic  
success (18, 22) . The adult  dose is  200 mg BID. The  formulation used for the  clinical trials, and for 
commercial  use, is a tablet  contain ing 100 mg of ETR.  The tablets  may be dispersed  in water or 
other  liquid  to facilitate  administration  (see Section  5.2) (23). 
 
 
1.32 Pediatric  Studies  
 
Phase I trial  (TMC125 -C126)  
 
A Phase I, open -label,  dose-ranging  trial (TMC125-C126)  to evaluate  the pharmacokinetics  and 
short -term safety  and tolerability  of ETR  at steady -state in HIV-1 infected  children  who were 
virologically  suppressed has been  completed.  The objective  of this  trial was to obtain  dose 
recom mendations  of ETR  per body weight  in treatment-experienced  HIV-1 infected  children   6 
years  old and weighing   20 kg (24). 
 
ETR  was ad ministered  as a 100 mg tablet  and/or  as a scored  25 mg tablet  developed  for pediatric 
use. The  trial population  was co mprised  of sub jects taking  a stable  ARV regi men that included 
lopinavir/ritonavir  (LPV/rtv) and a minimum of 2 NRTIs, with  or with out enfuvirti de. Trial 
TMC125 -C126  was conducted  in two sequential  stages:  in Stage  I the dose of ETR  was 4 mg/kg 
BID (dose derived  from  allometric scaling)  and in Stage  II the  dose of ETR  was 5.2 mg/kg  BID 
(represe nting a 30% increase  from  4 mg/kg  BID).  In each  Stage,  at least 20 virolo gically suppressed 
(VL <  50 copies/ mL) children  on a LPV/rtv -containing  regimen received  ETR  for 7 days followed  
by an  intensive  12-hour phar macokinetic  assess ment of ETR  on Day 8 (24). 
 
Table  1. Summary  of Adverse  Even ts in TMC125 -C126  
 
Severity  of AE Number of subjects  (%) 
Stage  I 
4 mg/kg Stage  II 
5.2 mg/kg 
Grades  1 or 2 14 subjects  (66.7%)1 9 subjects  (42.9%)4 
Grade  3 1 subject2 0 
Grade  4 1 subject3  
SAEs  Grade  1 influenza during  follow-up 
1 Five subjects (23.8%) had an AE  that was considered at least p ossibly related to ETR.  One sub ject was re ported 
with Grade 2 maculo -papul ar rash, whi ch was considered very likely re lated to ETR.  
2 Grade 3 increased blood  creatinine  
3 Grade 4 increased blood triglyceri des 
4 Six subjects  (28.6%) had an AE  that was  considered at  least possibly rel ated to ETR.  One subject  was reported with 
Grade 1 rash, which was considered pr obably likely related  to ETR.  
 
Safety  analysis  from  Stage I showed that  ETR  at 4 mg/kg and 5.2 mg/kg BID was generally  safe 
and well tolerated  (Table  1). The majority  of adverse  events were  Grade  1 (mild) or Grade  2 
(moderate)  in severity.  No deaths  were  reported.  No relevant  difference  was observed  between the  
age groups. 
 
 
 
IMPAACT P1090  Page 16 of 113 10 March  2016  
Version 5.0   
Pharmacokinetic 
parameters 
Mean  (SD)  
tmax: median  (range)   
TMC125 -C126 
Stage  I 
4 mg/kg BID  
TMC125 -C126 
Stage  II 
5.2 mg/kg BID  
TMC125 -C228 
200 mg BID  
DUET  trialsa 
200 mg BID 
 
N 19c 20 27 574 
tmax (h) 4 (2-8) 4 (2-6) 4 (3-8) - 
Cmax (ng/mL) 495 ±  453 757 ±  680 451 ±  232 - 
Cmin (ng/mL) 184 ±  151 294 ±  278 185 ±  128 393 ±  391d 
AUC12h (ng·h/ mL)  
4050 ±  3602   
6141 ±  5586   
3713 ±  2069   
5506 ±  4710  
GMRb 1.02 1.58   
 Table  2 displays  a comparison  of the  PK para meters for both  stages  of the  pediatric  dose-ranging 
studies  with those  from  the adult  study  of ETR  200 mg BID with  LPV/rtv  (TMC125 -C228) and the  
adult  studies  of ETR  200 mg BID with  DRV/rtv (DUET).  
 
Table  2:  Pharmacokine tic Parameters  of ETR  at two Doses  in HIV -1 Infected Subjects  between the  
Ages  of 6 and 17 years, Inclusive,  at Day 8 (TMC125 -C126), and in HIV-1 Infected  Adult Subjects  
(TMC125 -C228;  Day 8 and DUET  Trials  population  PK).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Population  PK at  Week 48.  
b Relati ve to TMC 125-C228 (protocol-specified  comparison). 
c N=18 for AUC12h d C0h (ng/mL) 
 
The exposure  of ETR,  expressed  as Cmin and AUC12h, after administration  of ETR  4 mg/kg  BID to 
children  and adolescents  on a LPV/rtv  conta ining regimen was co mparable  with the exposure of ETR  
administered  as 200 mg BID in  adults  on a LPV/rtv  containing  regimen, although  the 
90% CIs were  outside  80 to  125% for both  Cmin and AUC12h. No age  or weight  difference  was 
noticed  within  this dosing  group. When ETR  was administered  as 5.2 mg/kg BID in  children  and 
adolescents,  higher  Cmin and AUC12hvalues  were  observed  compared  to administration  of ETR  as 
200 mg BID in adults.  Only the  upper  limit of the 90% CI was outside  80 to  125% for both  Cmin and 
AUC 12h. Further more, the exposure  was higher  for the younger  children  (6 to 12 years)  in 
comparison  to the adolescents  (12 to  17 years),  although  the range  in the exposure  was large  in both  
groups. The  higher  exposure  in younger  children  was related  to 1 outlier;  no apparent  cause could  
be established  for this  higher  exposure.  When  compared  to adults  receiving  DRV/rtv  with ETR,  the 
ETR  exposures achieved  in children  and adolescents  on LPV/rtv  with 5.2 mg/kg BID ETR  dose 
were  comparable  (pooled  DUET results).  
 
Based  on the  general  concern  for u nder dosing  of ARVs in  the pediatric  population  (25-28), the 
higher  exposures of ETR  achieved  with ETR  5.2 mg/kg  BID and  the overall  safety  and tolerability  
during  Stage II, the  selected  dose of ETR  in children  aged  6 to 17 is  5.2 mg/kg  BID, which  was also  
confir med in a further  trial (PIANO).  
 
Phase I/II  trial (TMC125 -C213, PIANO)  
 
Further  long-term safety, tolerability,  antiviral activity  and pharmacokinetics  of the selected  dose 
was collected  in trial TMC125 -C213 (Pediatric  Trial  with Intelence  as an  Active  NNRTI Option, 
PIANO). T his was an  open -label  trial in 101 t reatment-experienced  HIV-1 infected  children  and 
adolescents  6 to 17 years  of age,  who were  receiving  ETR  5.2 mg/kg BID (up to  a maxi mum of 
200mg BID)  in combination  with an investigat or-selected  OBR co mprising of select  boosted  PI 
 
 
IMPAACT P1090  Page 17 of 113 10 March  2016  
Version 5.0  in combination  with NRTIs over  48 weeks (29). 
 
The 48 week  safety and tolerability  data with ETR in PIANO further  confirm the favorable 
benefit/risk  analy sis in treatment-experienced pediatric  patients.  ETR  was generally  safe and 
well tolerated  in the studied  treatment-experienced  HIV-1 infected  pediatric  population  up to  
Week  48 with  a safety  profile  comparable  to that observed  in the adult  HIV 1 infected  population 
and no new safety  findings  were  identified.  The Week  48 phar macokinetic  results re-confirm that 
pharmacokinetic  exposure  achieved  in the pediatric  population  (6 – 17 years)  with etravirine  5.2 
mg/kg  BID is  comparable  to that in the adult population.  The Week  48 analysis  also provides 
further  confir matory  evidence  of an  effecti ve viral suppression in  treatment-experienced  
pediatric  patients  taking  ETR.  
 
A population  pharmacokinetic  model of ETR  for the pediatric  population  was developed  based on 
a previously  developed  population  pharmacokinetic  model of ETR  used in  adults, supple mented  
with rich and spars ely sampled pharmacokinetic  data from  pediatric  subjects  (6 to 
< 18 years).  This model consisted  of a sequential  zero- and first-order  absorption  process with  a 
lag-time and one-compartment disposition.  A covariate  effect  of weight  on volu me of distribution  
(Vc/F) and  clearance  (CL/F) is included in the model.  
 
Using the  population  pharmacokinetic  model and sparse sa mpling data from  study  TMC125 - 
C213,  ETR  pharmacokinetic  parameters  for all  subjects  were  derived  using  Bayesian  feedback. A 
total of 313 spars ely sampled  ETR  plasma concentration -time data were  available  from 78 
subjects.  ETR  plasma concentrations  were  assumed  to be at steady -state.  Data  for 4 subjects were  
excluded  from  analysis  due to lack of dosing  infor mation  (2 subjects)  or ETR  plasma 
concentrati ons below  the lower  limit of quantit ation at all time-points (2 subjects).  Therefore, 
pharmacokinetic  parameters  of ETR  were  avail able in 74 subjects.  Table  3 summarizes  the ETR 
AUC12h and C0h from  the ISRP analysis , overall  and by age  cohort , with pediatric  and adult 
historical  controls  for comparison  (TMC125 -C126  and pooled  DUET, respectively).  
 
In general,  the pharmacokinetics  of ETR  when  administered  at 5.2 mg/kg BID (i.e.,  100 mg BID 
for 16 to  < 20 kg;  125 mg  BID for 20 to  < 25 kg;  150 mg BID for 25 to  < 30 kg and  200 mg BID 
for ≥ 30 kg) were  comparable  in children  (≥ 6 to  < 12 years)  and adults. In the  adolescents  (≥ 12 to  
≤ 17 years),  slightly  lower  ETR  exposures were  observed  relative  to adults.  Of note,  most of these  
adolescents  (91%, 43 out  of 47 adolescents)  were  on the  adult  dose of ETR  (200 mg  BID).  
 
 
IMPAACT P1090  Page 18 of 113 10 March  2016  
Version 5.0  Table  3: Population  Pharmacokinetics  of ETR  (AUC12h and C0h) by Age Cohort  when  ETR is Dosed 
at 5.2 mg/kg BID 
 
  
N AUC 12h (ng•h/mL) 
Mean  (SD)  Median  (Min  - Max)  
PIANO  (TMC125 -C213 )1    
≥6 to <12 years 27 5260  (2845) 5090  (1722 - 13628) 
≥12 to ≤17 years 47 4568  (4761) 3622  (113 - 29039)  
All subjects  74 4820  (4157) 3990  (113 - 29039)  
 
Pediatric  dose finding  
(TMC125 -C126)    
≥6 to <12 years 11 7713  (7160) 4559  (2967 – 27060) 
≥12 to ≤17 years 9 4219 (1575) 4300 (1924 – 7142) 
All subjects  20 6141  (5586) 4407  (1924 – 27060) 
Adults  (Pooled DUET)  575 5506  (4710) 4380  (458 – 59084) 
  
N C0h (ng/mL) 
Mean  (SD)  Median  (Min  - Max)  
PIANO  (TMC125 -C213 )1    
≥6 to <12 years 27 334 (222) 332 (38 - 996) 
≥12 to ≤17 years 47 299 (378.2) 195 (2 - 2291) 
All subjects  74 312 (328.7) 246 (2 - 2291) 
Pediatric  dose finding  
(TMC125 -C126)    
≥6 to <12 years 11 453 (442) 273 (88 – 1620) 
≥12 to ≤17 years 9 247 (155) 204 (115 – 627) 
All subjects  20 360 (352) 241 (88 – 1620) 
Adults  (Pooled DUET)  575 393 (391) 298 (2 – 4852) 
1 ISRP  analysis 
 
The median  baseline  viral load was 3.9 log 10 copies/ mL, and the median  baseline  CD4+ cell count 
was 385x106 cells/L.  
 
The virologic  response  rate was evaluated  in pediatric  subjects  receiving  ETR  in combination  with 
other  ARVs.  Virologic  response  was defined  as achieving  a confir med undete ctable  viral load (<50 
copies/ mL). 
 
The primary analysis  was perfor med at  Week 24, when  all subjects  had completed the  24-week 
assess ment or discontinued earlier.  The final analysis  was perfor med when  all subjects  had 
completed  the Week 48 assess ment or discont inued  earlier.  An overview  of the key efficacy 
findings  at 48 weeks in  the PIANO study is given  in Table  4. 
 
 
 
 
 
 
 
IMPAACT P1090  Page 19 of 113 10 March  2016  
Version 5.0  Table  4: Virologic  Response  to ETR  at Week  48 in Treatment -experienced  HIV -1 Infected Pediatric  
Subjects  (PIANO  Final  Analysis)  
 
 
 
Effica cy Out come Measure   
Children  
≥6-<12 years 
N=41  
Adolescents  
≥12-<18 years 
N=60  
All subjects  
 
N=101 
<50 c opies/ mL (NC=F), n (%) 28 (68.3) 29 (48.3) 57 (56.4) 
<50 c opies/ mL (TLOVR),  n (%) 28 (68.3) 26 (43.3) 54 (53.5) 
<400 copies/ mL (TLOVR),  n (%)  28 (68.3)    36 (60.0)  64 (63.4) 
Decrease  in VL vs  BL of ≥1.0 log10, n (%)    27 (65.9)    34 (56.7)    61 (60.4) 
Change in log 10 VL, Mean ( SE) -1.67 (0.219) -1.44 (0.163) -1.53 (0.132) 
CD4+ Cell Count 
Change in CD4+ cell cou nt, Mean  (SE) +178 (39.7) +141 (27.0) +156 (22.7) 
BL: Baseli ne; VL:  Viral L oad; NC=F: no n-completer e quals fail ure; TLOVR: t ime to loss of virologic resp onse; SE: 
stand ard error, vs: versus, CD4+: Cluster of  differe ntiation 4 p ositive 
 
At  Week  24,  51.5%  of  all  pediatric  subjects  had  a  confir med  undet ectable  viral  load 
<50 copies/mL.  The proportion  of pediatric  subjects with  viral load <400 copies/ mL was 65.3%. 
The mean change  in viral load from  Baseline  to Week 24 was -1.51 log 10 copies/ mL, and the mean 
CD4+ cell count  increase  from  Baseline  was 112x1 06 cells/L.  
 
At  Week  48,  53.5%  of  all  pediatric  subjects  had  a  confir med  undet ectable  viral  load 
<50 copies/mL.  The proportion  of pediatric  subjects  with viral load <400  HIV-1 RNA  copies/ mL 
was 63.4%.  The mean change  in HIV-1 RNA  from  Baseline  to Week 48 was -1.53 log 10 copies/mL, 
and the mean CD4+ cell count  increase  from  Baseline  was 156x1 06 cells/L.By  age group,  virologic 
response  at Week  48 was 68.3%  in children and  48.3%  in adolescents. Sensiti vity analyses  
(including  observed  case, TLOVR  and TLOVR  non-VF censored  analyses, and  snapsh ot approac h) 
showed  that these  results were  robust  and not driven  by the imputation method.  
 
Eighty -three  percent of  the children  and 92% of adolescents  exper ienced  at least 1 adverse e vent 
(AE).  By preferred  term,  the most commonly  report ed AEs (in at least 10.0%  of all subjects)  were 
upper  respiratory  tract infection  (24.4%  in children  and 28.3%  in adolescents), diarrhea  (12.2% and  
18.3%),  cough  (12.2%  and 13.3%),  vomiting (9.8%  and 11.7%)  and rash (individual preferred ter m; 
4.9% and  15.0%).  
 
Most  AEs were  grade  1 or 2 in severity.  Grade 3 or 4 AEs occurred  in 6 (14.6%)  children  and 
8 (13.3%)  adolescents.  Each  of the grade  3 or 4 AE preferred  terms, except thrombocytopenia  and 
hypertriglyceride mia (both  in 2 subjects),  were  reported  in only 1 subject.  Only  2 subjects  (both 
children) were reported with a grade 4 AE (both  thrombocytopenia).  Both  grade  4 AEs were 
conside red not related  to ETR  
 
No fatalities  were  reported.  Five subjects,  all adolesce nts, reported  at least one SAE  (abnor mal 
lymphocyte  morphology  and oligoclonal  immunoglobulins at  electrophoresis;  carba mazepine 
toxicity;  ETR overdose;  treatment nonco mpliance, drug  resistance  and weight  decreased; ulcerative  
keratitis).  The subject  with the overdose  was inadvertently treated  with ETR  250 mg instead  of 200 
mg bid for 50 days without  safety  consequences. All  SAEs, except  the overdose (considered  very 
likely  related  to ETR), were  considered  not related  to ETR. A limited number of subjects  in each age 
group had AEs leading  to permanent  discontin uation of treatment with ETR: 
 
 
IMPAACT P1090  Page 20 of 113 10 March  2016  
Version 5.0  2 (4.9%)  children  and 6 (10.0%)  adolescents.  One adolescent  permanently  discontinued  treatment 
because  of an  SAE (drug resi stance).  
 
Skin events  were  the most  frequently  report ed events  of interest. ‘Rash cases’, referring  to a 
grouped  term combining all  rash-related  AEs except  events  considered ‘severe  cutaneous 
reactions’,  were  reported  in 6 (14.6%)  children  and 17 (28.3%)  adolescents.  Consistent  with other 
drug-related rashes,  rashes with ETR  occurred  early during  treatment, with a  median  time to first 
onset  of 10 days;  were  self-limiting,  with a median duration of  7 days;  and were  usually  grade  1 or 
2 in severity.  One subject  in each age group  developed a  grade  3 rash.  Four  subjects  (1 child and  
3 adole scents)  discontinued  treatment because  of rash.  No grade  4 rashes or rash related  SAEs were  
reported. Other  relevant  skin events  of interest included 1 case of erythe ma multi forme 
(grouped  under severe  cutaneous  reactions)  and 1 case each of hype rsensitivity  and urticaria 
papular  (grouped  under  angioede ma). The inciden ce of neuropsychiatric events  of interest, 
pancre atic events,  lipid-related eve nts and neoplas ms was low (≤ 2%).  There  were  no hepatic, 
cardiac  and bleeding  events  of int erest reported  in this study.  
 
A slightly  higher  frequency of  rash was observed  in the PIANO  study  compared  to the DUET 
studies  in adults  and therefore,  a multivariate a nalysis  was perfor med on the pooled  data of the 
Week 48  data of the DUET  studies  and the Week 24  data of the PIANO  study to investigate  risk 
factors  for developing  rash when  treated with ETR. The results of this analysis consistently showed 
that being  female, but not age or  participation  in the PIANO  study  (a partial  surrogate  for age),  is a 
risk factor  for developing  rash.  No other  risk factors  could  be firmly identified.  This is also seen in  
the Week 48 PIANO  data:  Rash  ≥ grade  2 was reported in  13/64  (20.3%)  of females  vs 2/37 
(5.4%)  of males;  discontinuations due  to rash were reported  in 4/64 (6.3%)  of females vs 0/37 
(0%)  of males. Most  often,  rash was mild to moderate,  of macular/papular  type, and occurred  in 
the second  week  of therapy.  Rash  was mostly  self-limiting and generally  resolved  within 1  week 
on continued  therapy.  
 
Mean  changes  over time in the clinical laboratory  parameters  were  small in either  age group  and 
were  gener ally not considered clinically  relevant. There  was an increase over time in total 
cholesterol,  low-density  lipop rotein  (LDL)  and triglycerides, as  seen with many other  ARV 
regimens. The majority  of treatment-emergent  laboratory  abnor malities  were  grade 1 or 2 in 
severity.  The most common  treatment-emergent  graded  laboratory  abnor malities were  related  to 
lipid related  parameters,  and mainly  included  increases  in total cholesterol  (50.0%  in children  and 
38.8%  in adolesce nts) and LDL  calculated  (31.6%  and 25.0%).  All abnor malities in  total 
cholesterol  and LDL  were  grade  1 or 2 in severity  with the exception  of 1 adolescent who  had a 
grade  3 increase  in LDL  chole sterol. 
 
There  were  no clinically significa nt changes  over time in vital signs,  nor findings  suggestive  of 
delayed  sexual  maturation.  The mean age-adjusted  z-scores  for height,  weight  and body  mass 
index  remained  stable  over time. 
 
Taken  together,  the administration  of ETR  at a weight -based  dose revealed  no new findings 
compared  with the known ETR  safety  profile  in HIV-1 infected  adults.  
In conclusion,  the safety  analysis  shows that  ETR  is generally  safe and well tolerated in treat ment-
experie nced HIV-1 infected  children and adolescents  aged  6 to 17 years.  There were no cli nically  
relevant differences  with the safety  profile  in adults.  No new safety  signals  or consistent  patterns in 
 
 
IMPAACT P1090  Page 21 of 113 10 March  2016  
Version 5.0  the incidence of adverse  events  (AEs) were  detected  in the pediatric population  studied.  These  safety  
results  represent  the clinical  basis to  start the clinical  trial in chil dren below  the age of six years.  
 
Data  from  the initial  P1090 mini-cohort  and rationale  for revised  ETR  dose 
 
At the  start of the  P1090 trial,  the ETR  starting  dose for the  first (mini)-cohort  was 5.2 mg/kg BID, 
based  on data  from  the TMC125 -C213  trial in children  aged  6 to 17 years.  The first 6 children  
enrolled  in P1090 received  this dose, and  the ETR  exposu re was assessed at  an intensive PK visit  
performed between  1-2 weeks after  initiating  ETR.  The aim was to achieve  similar exposures 
compared  to those  in adults  (geometric mean AUC12h of the  cohort  between  3618 - 
5879 ng.h/mL  corresponding  to 80% -130% of the  geometric mean AUC12h observed  in adults).  
 
The observed  geometric mean ETR  AUC 12h for the  first six children  was 2576 ng.h/mL.  Two of the  
six children  had an individual  AUC 12h below  2350 ng.h/mL  and had dose increases  per protocol  
(see Section  9.34). Short -term safety  and antiviral activity data did not reveal  any concerns.  
 
Based  on the  combined  pharmacokinetic  data,  even  though  the mini-cohort  had passed the 
appli cable criteria  at that time of no more  than 2 subjects  with AUC 12h <2350  ng.h/mL,  and no 
safety  or efficacy  concerns,  it was e vident  that with the 5.2 mg/kg dose, the  probability  of meeting  
the necessary  criteria  for the  overall  cohort  (n=12,  geometric mean AUC 12h 3618 -5879 ng.h/ mL) 
would be  very low. Therefore,  it was decided  to modify  the ETR  dosing  regimen for the  cohort,  
prior to recruiting  additional subjects.  
 
To deter mine the most appropriate  dosing  regimen,  a modeling  and simulation  approach  was 
applied.  For this,  a population  pharmacokinetic  model  of ETR  for the pediatric  population  was used 
which  is structurally  based  on a previously  developed  ETR population  pharmacokinetic model  in 
adults,  using  all rich and sparsely  sampled pharmacokinet ic data from  pediatric  subjects (6 to  17 
years  from  studies  TMC125 -C126  and TMC125 -C213  [PIANO]; 2 to  6 years  from  the first  mini-
cohort  in P1090 [all  doses, all  samples]). The model consists  of a sequential  zero- and first -order  
absorption  process with  a lag-time and one-compartment disposition,  includes  a covariate  effect  of 
body weight  on volu me of distribution  (Vc/F) and  clearance  (CL/F),  and an allo metric exponent  for 
CL/F  and Vc/F of 0.75 and  1.00, respectively.  
 
Standard  graphical  and numerical evaluation  techniques  (goodness -of-fit plots,  including observed  
versus population  and individual  predict ed ETR  plasma concentrations,  and conditional weighted  
residuals  versus ti me since  first dose a nd time since  last dose), showed that  the model 
fit the data with high precision  and minimal bias. So far,  no impact of age  on the  ETR CL/F  has 
been  observed.  It was also  shown specifically  for the 6 subjects  already  enrolled  in P1090 that their  
ETR  pharmacokinetic  parameters  were  well estimated with the model.  Therefore,  the final model  
was considered  suitable for further  simulations to evaluate  potential  dosing  regimens for the  
pediatric  population  of interest  for P1090.  
 
The model was used to  evaluate  several  potenti al weight -based  dosing  regimens, with the intent to  
achieve  ETR exposures si milar to those  observed  in adults.  From  these simulations,  the weight -
based  ETR  dosing  regimens likely  to result in similar ETR  exposures as those  observed  in adults  
were  selected  for each  weight band.  This is presented  in Figure  1, which  shows the  median 
simulated  ETR  AUC 12h (with  80% prediction  interva l) by weight,  for different  ETR  mg/kg  doses 
across different  weight  bands. This  dosing  regimen is also in line with the currently  approved ETR 
 
 
IMPAACT P1090  Page 22 of 113 10 March  2016  
Version 5.0  
dosing  regimen for children  aged  6 years  and above,  as of 16 kg of body weight  (reference: US  
Package  Insert  revised  08/2014).  
 
Figure  1: Simulated  ETR  Exposures  (AUC 12h) By Body  Weight  for Differ ent ETR  BID Doses, Ai med 
at Achieving  a Geometric  Mean  ETR  AUC 12h Similar  to That  in Adults.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The solid colored lines represent the median simulated  AUC12h and the shaded  areas  represent  the 
80% prediction interval. The two sol id horizontal li nes represent  80% and 130% of the geometric 
mean AU C12h in adults; t he two dashed horizontal li nes represent  60% and 150% of the geometric mean AU C12h in 
adults; the lowe r dotted line represents the 10th percentile of t he adult AU C12h. 
 
Based  on the  above  described  approach,  the revised  ETR  dosing  regimen is presented  in 
Appendix  III. 
 
To evaluate  the proba bility of success for this  regimen, 10000 virt ual trials  with 12 pediatric 
subjects  each were  simulated.  The virtual  pediatric  subjects  were  rando mly sampled from  a 
database  built based  on WHO’s age -gender -body  weight  distributions,  assuming equal probabilities  
for gender  and a uniform  age distribut ion. With this, it was deter mined that for this dosing  regimen 
(Appendix  III), t here is a very high probability  to achieve a geometric mean exposure  (AUC 12h) 
across the age cohort that is similar to that observed  in adults  (i.e., 80% probability  for a geometric 
mean AUC12h within  80-130% of adult  geometric mean exposure;  96% probability  for a geometric 
mean AUC12h within 60-150%).  
The inter-individual  variability  for apparent  clearance  in the population  PK model is 62%. Given 
this rather  high value,  exposures in  the study  are expected  to be as variable.  Increasing  the target 
band  for the  AUC12h from  80-130% to  60-150% of the geometric  mean AUC12h in  adult  would 
provide  a more suitable  criterion.  Also, individual  exposures are  anticipated  to fall in range  of the 
exposures observed  in adults,  which have  been  shown to  be safe and efficacious.  Across previous  
trials  of ETR  in HIV-infected  adults  and children,  there  was no  observation  of a PK/PD relationship  
for adverse  events  of interest,  nor was ETR  exposure  found to  be a significant prognostic  factor  for 
virologic  response.  
 
 
 
IMPAACT P1090  Page 23 of 113 10 March  2016  
Version 5.0  Also in  the currently  enrolled  pediatric  subjects  in the P1090 study,  there  have  been  no significa nt 
safety  concerns.  There  was one  case of virologic  failure,  which  was first  noted  approxi mately  32 
weeks after  start of dosing  (and confir med at Week 40). The  reason  for the  virologic  failure  is not 
clear,  but it is unlikely  to be related  to ETR  exposure  and there  was no evidence  of ETR resistance.  
The observed  ETR  AUC12h for this  subject at the inten sive PK visit  (6165 ng.h/mL) was above  the 
mean exposure  in adults, and also based  on the  sparse sa mpling  at later visits,  there was no 
indication  of low ETR  exposures. All  other  subjects  in the trial have  had a good virologic response.  
 
Data from the second P1090 mini -cohort and a) rationale for opening Cohort  III and b) dose 
selection for Cohort III  
 
As described in the section above, modelling of the initial mini -cohort led to a revision in the 
dosing for study participants and adoption of weight based dosing.  Results from the second mini -
cohort of Cohort I suggest that  this approach is appropriate a nd that the weight -based population 
PK model used for dose selection can thus be assumed to be adequate. Estimation of the allometric 
exponents in the model revealed no significant improvement of the model compared to fixed 
theoretical values (3/4 for CL/F  and 1 for V/F). This suggests that the standard theoretical model 
for pharmacokinetics in pediatric populations is applicable  to ETR. 
[http://www.ncbi.nlm.nih.gov/pubmed/18336053  / ; 
http://onlinelibrary.wiley.com/doi/10.1111/j.1365 -2125.2010.03802.x/pdf ] 
 
Introduction of a maturation function did not show any significant improvement in the model 
based on the current data. As maturation is known to exist, these results suggest that the available 
data are insufficient to estimate the effect of age on the P K of ETR.  Therefore, additional data in 
younger patients is needed  (Cohorts II and III) . 
 
Given the uncertainties around maturation of CYP metabolism in subjects aged <1 year, some 
additional precautions are taken  for Cohort III : 
 6 months to < 1 year: the  dose (in mg/kg) is reduced  by 25% compared to what the model 
suggests to adjust for possible ongoing maturation of enzymatic metabolism   (30) 
 2 months to < 6 months: subjects in this age group will only be included once there are 
available data on subjects aged 6 months to 1 year  
 
Safety of the weight -based dosing in the younger participants is anticipated to be acceptable based 
on the safety data collected so far among subjects in Cohorts I and II .  The latter was opened 30 
October 2015  and, based on input from participa ting sites in late 2015, the expectation is that there 
will be at least 2 and likely 6 participants already enrolled in Cohort II by the time of release of 
Version 5.0.  There are adequate safeguards included in the protocol, which include:  
 Intensive  PK evaluation with individual dose adjustment  if needed and continuous safety 
monitoring on an individual level,   
 Close monitoring of PK data and continuous safety monitoring on a cohort level;  
 Additional safety monitoring rules for first 6 patients entering cohorts II and III combined.  
 
In conclusion, the added scientific value of the collected data -and the precautions taken to ensure 
safety and efficacy of the compound in this age group - justif ies an early enrollment of Cohort III.   
 
 
 
 
IMPAACT P1090  Page 24 of 113 10 March  2016  
Version 5.0  Other  Available  Data  
 
In a Spanish  cohort  of five  children  (5 to  12 years  old) and 18 adolescents  (13 to  18 years  old) of 
whom  22 had a history  of NNRTI -based CART  failure with proven  genotypic  NNRTI resistance 
mutations,  salvage  regimens including  ETR  at 5.2 mg/kg BID (for chil dren) and 200 mg BID 
(for adolescents)  and (in 21 of the  patie nts) OBR with  at least 2 acti ve agents, 87% a chieved  
HIV-1 RNA< 400 copies/ mL and 78% achieved  HIV-1 RNA< 50 copies/mL  by 8 months.  Mild (3 
adolescents)  or moderate  (2 adolescents)  rash was observed  only in adolescents  but not in children,  
and therapy  was otherwise  well tolerated (31). 
 
Table  5. Adverse  Even ts Summary  (Adult  Studies  Phase  IIb /III Pooled  Analysis)  
 
AEs during trea tment period 
n (%)  Week 48  
Placebo DUET 
N = 604 Week 48  
ETR DUET 
N = 599 ETR Selected  
Dose  
N = 1043 All ETR  
 
N = 1223 
Treatment  duration (weeks ), 
Medi an (range) 51.0 
(3 - 80) 52.3 
(2 - 85) 51.7 
(0 - 271) 52.3 
(0 - 271) 
Subject y ears of exposure  556.8 583.4 1125.1 1476.2 
Any AE 580 (96.0) 575 (96.0) 990 (94.9) 1164 (95.2) 
Any Grade 1 or 2 AE 
Grade 1 
Grade 2 573 (94.9) 
512 (84.8) 
425 (70.4) 564 (94.2) 
511 (85.3) 
445 (74.3) 973 (93.3) 
877 (84.1) 
751 (72.0) 1143 (93.5) 
1040 (85.0) 
888 (72.6) 
Any Grade 3 or 4 AE 
Grade 3 
Grade 4 211 (34.9) 
190 (31.5) 
64 (10.6) 199 (33.2) 
177 (29.5) 
59 (9.8) 347 (33.3) 
311 (29.8) 
106 (10.2) 434 (35.5) 
387 (31.6) 
135 (11.0) 
Treat ment-related  AEa 285 (47.2) 320 (53.4) 557 (53.4) 671 (54.9) 
Death 20 (3.3) 12 (2.0) 21 (2.0) 26 (2.1) 
Any SAE 141 (23.3) 118 (19.7) 205 (19.7) 254 (20.8) 
AE leading to temporary stop 57 (9.4) 64 (10.7) 131 (12.6) 161 (13.2) 
AE leading to permanent s top 34 (5.6) 43 (7.2) 101 (9.7) 127 (10.4) 
Most Common  AEsb 
Diarrhea 
Nausea 
Heada che 
Injection site reacti on 
Fatigue 
Nasopharyngitis 
Upper respira tory tract 
infection  142 (23.5) 
77 (12.7) 
77 (12.7) 
75 (12.4) 
57 (9.4) 
63 (10.4) 
 
56 (9.3) 108 (18.0) 
89 (14.9) 
65 (10.9) 
63 (10.5) 
48 (8.0) 
66 (11.0) 
 
44 (7.3) 202 (19.4) 
175 (16.8) 
127 (12.2) 
109 (10.5) 
107 (10.3) 
111 (10.6) 
 
94 (9.0) 266 (21.7) 
214 (17.5) 
168 (13.7) 
144 (11.8) 
140 (11.4) 
133 (10.9) 
 
123 (10.1) 
AEs of interest  
Any skin event of interest 
Rash (any type) 110 (18.2) 
66 (10.9) 159 (26.5) 
115 (19.2) 288 (27.6) 
207 (19.8) 353 (28.9)c 
249 (20.4) 
Any neuropsychiatric e vent of 
interest  
Nervous  system  events of 
interest  
Psychiatric  events  
205 (33.9) 
 
119 (19.7) 
 
118 (19.5)  
181 (30.2) 
 
103 (17.2) 
 
100 (16.7)  
338 (32.4) 
 
191 (18.3) 
 
196 (18.8)  
427 (34.9)d 
 
249 (20.4) 
 
248 (20.3) 
Any hepatic event 37 (6.1) 39 (6.5) 86 (8.2) 103 (8.4) 
 
 
IMPAACT P1090  Page 25 of 113 10 March  2016  
Version 5.0  Any cardiac event 
Coronary artery disorders 44 (7.3) 
8 (1.3) 42 (7.0) 
11 (1.8) 92 (8.8) 
16 (1.5) 124 (10.1) 
28 (2.3) 
Any pancreatic event 27 (4.5) 24 (4.0) 38 (3.6) 51 (4.2) 
Any bleeding event 39 (6.5) 33 (5.5) 59 (5.7) 76 (6.2) 
N: number of subjects;  n: number of subjects  with observations  
a   defined  as possibly, probably  or very likely  related  to treatment in the opinion  of the invest igator 
b   > 10% of subjects  in the All ETR  group 
c      Of the total skin rashes,  1.5 % were Grade 3;there  were no Grade 4 skin rashes  
d      Of neurops ychiatric events,  0.7%  were  Grade  3; 0.2% (1 patient  had a Grade  4, and it was a suicide).  
 
Addition al Safety Data  
 
Safety  data derived  from  pooling  of the  results  of 1,043 adult  HIV-1-infected  treatment - 
experienced  subjects  enrolled  in the Phase I II trial indicated  that ETR  is generally  safe and well 
tolerated.  The most common  AEs reported  during  ETR  treatment with the selected dose were rash 
(any type,  16.9%;  Grade  2 to 4 rash 9%), diarrhea  (any Grade  1: 9.4%;  Grade  2 to 4: 5.2%), nausea  
(any Grade,  13.9%), and  headache  (Grade 1: 2.2%;  Grade  2 to 4: 2.7%).  
 
With the exception  of rash, the  incidence  of AEs and  laborat ory abnor malities  were  generally 
comparable  to placebo.  Table 5 describes  these  results.  
 
A recent  double-blind placebo-controlled  trial of ETR  400 mg  QD versus EFV in  HIV-infected 
adults,  naïve  to ART, compared  neuropsychiatric  side effects  in the two ar ms. At week  12, 
16.5% of ETR  treated  subjects  reported  at least one grade 1 to 4 treat ment related neuropsychiatric  
AE, compared  to 46.2% in  the EFV treated  subjects;  for grade  2 to 4 AEs, the incidence  was 5.1% 
in the ETR  arm and 16.7% in  the EFV arm  (32). 
 
Twenty -six subjects  (2.1%) died  during  the study  while  on ETR; 25 of which  were  judged  not, or 
unlikely,  related  to ETR  therapy.  One death,  due to myocardial  infarction  with cardio  respiratory 
failure,  in a subje ct with risk factors for pre mature  coronary  artery  disease,  was consi dered possibly  
related  to ETR  therapy  (18). 
 
The rashes tended  to be mild to moderate;  they usually  occurred  in the second  week  of therapy, and  
resol ved within  1 to 2 weeks on continued  therapy.  In the adult  phase  III trials,  the cu mulative  
incidence  of Grade  3 and  4 rashes  was 1.3% for subjects  on ETR  and 0.2% for those on placebo.  A 
total of 2% of subjects  discontinu ed study  due to rash. There  were  no cases  of Stevens  Johnson 
Syndro me (SJS) or toxic  epide rmal necrolysis  (TEN)  reported  due to ETR  in any  of the  Phase 
IIb/III  studies  (18). 
 
In August of 2009, the  FDA issued a  warning  to physicians,  related  to the occurrence  of severe, 
potentially  life threateni ng, and fatal skin rashes (erythe ma multiforme, SJS and  TEN)  linked  to 
ETR  use during  the post marketing  period.  Prescri bing infor mation  has been  updated  to reflect this  
infor mation.  The rate of SJS and  TEN  was <  0.01% each.  The hypersensitivity  reactio ns manifested  
as rash along  with constitutional  findings.  At times, evidence  of impending  organ failure  existed.  
The current  recommendation  is to stop ETR  at the onset  of severe  skin rash, with careful  clinical  
monitoring  (13). 
 
As of February 12th, 2016, fourteen participants between the ages of 2 to 6 years have been 
 
 
IMPAACT P1090  Page 26 of 113 10 March  2016  
Version 5.0  enrolled into P1090.  To date, adverse events have been primarily unrelated to study product; none 
raised concerns regarding the safety of ETR in this population. Specifically, there has been no 
reported skin rashes related to study med, nor any safety events related to EK Gs obtained on the 
day of pharmaco kinet ic testing.  
 
 
1.4 Rationale  
 
There  is increasing  use of NNRTI -based regi mens as initial  therapy  for HIV-1 infected  children, 
especially  in areas  where  HIV-1 exposed  newbo rns receive  NVP as part  of PMTCT  regimens 
and/or  daily  NVP for prevention  of breastfee ding trans mission  (33).  Though  NNRT I-based CART  
regimens are effecti ve, first generation  NNRTI ag ents have  a low genetic  barrier  to the 
develop ment of resistance.  
As a result,  there  are an increa sing number  of treatment-experienced  infected  infants  and chil dren 
who have  failed, or will  fail, their initial regimen. The majority  of these  infants, at the ti me of 
virologic  failure to a NNRTI based  regimen,  will have mutations  associ ated with resistance  to first 
generation  NNRTIs  (7).  Similarly,  a high percentage  of infected  infants exposed  to NVP as a  
component  of PMTCT  regimens will harbor  virus with  NNRTI  related resistance  mutations. (3-7). 
Failure or intolerance  of LPV/rtv  based  regimens, especially  among infants  and children  with prior  
NNRTI exposure  (as treatment or for PMTCT),  leaves  few or no alternative  treatment options  (7). 
 
ETR,  a second  generation  NNRTI, approved  for ad ult use, has a  higher  genetic  barrier  to HIV drug 
resistance  than EFV or NVP and retains  activity  against  EFV and  NVP drug resistant  HIV-1 
isolates  harboring  the K103N and  Y181C  mutations  (9, 10) . The drug dosing  and tolerability have  
been  established  in adult  registration  studies. Skin rash was the  main treatment-limiting significant  
adverse  event.  It was seen  in up to  20% of subjects,  with 1 to 2% of subjects  showing Grade  3 or 4 
severity  (18).  Phase I/II  trials  of ETR  in children  aged  6 to 17 years  of age de monstrated  acceptable  
safety  and tolera bility, and established suggested  dosing  for this  age group (24). See Section  1.32.  
 
We propose to  investigate  ETR,  in combination  with at least 2 active  ARVs, one  of which  must be  
a boosted  PI, for treat ment experienced  HIV-1 infected  infants  and children  aged  2 months  to 
< 6 years.  
 
2.0 STUDY O BJECTIVES  
 
 
2.1 Primary Objectives  
 
2.11 To evaluate  the steady  state pharmacokinetics  of ETR  in combination  with an OBR in  
HIV-infected  children aged  ≥ 2 months  to < 6 years.  
 
2.12 To deter mine the safety  and tolerability  of ETR  in combination  with an OBR in  children 
aged  ≥ 2 months to < 6 years,  through  48 weeks of therapy.  
 
2.13 To deter mine the appropriate  dose of  ETR  in combination  of an  OBR for children  aged  ≥ 
2 months  to < 6 years.  
 
 
 
 
IMPAACT P1090  Page 27 of 113 10 March  2016  
Version 5.0  2.2 Secondary  Objectives  
 
2.21 To assess the  antiretroviral  activity  of ETR  containing  regimens through  48 weeks of 
therapy.  
 
2.22 To deter mine the immunological  changes  (change  in CD4 percent  and absolute  count; 
CD4/CD8 r atio and percent)  through  48 weeks of ETR  therapy  in combination  with an 
OBR.  
 
2.23 To deter mine changes  in viral drug res istance  during  48 weeks of ETR  therapy  in 
combination  with an OBR.  
 
2.24 To assess the  relationship  between  ETR pharmacokinetics  and the antiviral  activity  and 
safety  of ETR  containing  regimens. 
 
2.25 To explore  the relationship  between  subject -specific  gene  CYP profile , sex, 
age, weight, race, HIV regimen (e.g., boosted PI) and HIV response 
markers  and phar macokinetics  of ETR.  
 
3.0 STUDY D ESIGN  
 
This is a Phase I/II,  multicenter,  open  label  48 week study  of ETR  in combination  with at least 2 
active  agents  (a boosted  PI and  at least one additional  active  drug), for  treatment experienced HIV -
1-infected  infants  and children  ≥ 2 months  to < 6 years  separated  by age  into three  cohorts.  
 
The study  will, in a sequential  manner,  accrue  subjects  for an  initial  dose finding  intensive  PK 
component  for age  related  cohorts.  It is expected  that up to  50 subjects  will be accrued,  to yield 
data from  at least 36 evaluabl e1 subjects  with a minimum of 12 subjects  for each  of the  three 
cohorts,  who were  started  on the  final approved  dose for that  cohor t. The total sample size will 
depend  upon the  number needed  to complete  the dose finding  stage  of the  study,  the number of 
subjects  who discontinue  the study  and the number of subjects  required  for regulatory  approval of 
ETR  in these  populations.  Up to 18 subjects may be enrolled into Cohort I.  
 
The P1090 core  protocol team  will be responsi ble for reviewi ng the PK and  safety  data and 
approving  the dose selection  for each  full and mini-cohort.  The P1090 core  protoc ol team  will 
consist  of the  protocol  chair  and co-chairs,  clinical trials specialist,  NIAID and  NICHD Medical 
Officers,  data manager,  pharmacologists,  pharmacist,  statisticians  and Janssen R&D 
representatives.  
 
 
 
 
1NOTE:  For the Week 24 (or Week 48) a nalysis, e valuable will be defined as  having been treated exclus ively on the 
dose determined to be  optimal for a giv en age cohort and having eit her co mpleted  24 (or 48) wee ks of exposure to the 
study drug or having been classi fied as a safety fail ure, due to a study drug related  adverse event occurring during the 
first 24 (or 48) weeks of treat ment. 
  
 
 
IMPAACT P1090  Page 28 of 113 10 March  2016  
Version 5.0  This study  is designed  to deter mine the appropriate  ETR  dose for HIV-1-infected  infants  and 
children and to evaluate the PK, safety  and tolerability  of ETR  in this population.  ETR  will be 
administered  as 25 mg scored  tablets  and/or  100 mg  tablets swallowed  as a whole  or dispersed  in an  
appropriate  liquid  vehicle (see Section  5.2). 
 
3.1 Description  of Cohorts  
 
Subjects  will be stratified  by age  and will under go viral phenotype  and genotype  evaluations  as 
described  in Table  6 below.  
 
 
3.2 Optimized Background  Regi men 
 
As described  in Table  6, OBR for treat ment experienced  subjects  must consist  of at least two active  
agents,  a boosted  PI and  at least one additional  active  drug, in  addition  to ETR.  
 
Prior to  the enroll ment visit (entry),  the proto col team  must  be notified  and approve  the proposed 
OBR reg imen. OBR should  be based  on clinical  status, treatment  history,  resistance  data as well as 
availability  of dosing  guidelines  and appropriate  pediatric  formulations.  
 
 
 
IMPAACT P1090                                                                              Page 29 of 113    10 March 2016  
Version 5.0   
Table  6. Description  of Cohorts  
 
Cohort  
Descr iption of Su bject  
Drug Regimen  
Phenotyping / 
Genotyping Information   
Comme nts Anticipated Accr ual 
 
Mini 
Cohort To 
complete a 
full cohort Total 
cohort 
size 
 
I  
≥ 2 year to < 6 years who are 
treatment experienc ed  
ETR  
+ OBR 
(1 active 
boosted 
PI+ at least 1 
other active 
drug)  
HIV genotype and 
phenotype assays should 
be performed in real t ime 
and results available prior 
to starting  study drug  
Subjects will be enr olled provi ding the 
phenotypic assay results indicate a <  10 
fold change in sensitivity to  ETR   
6  
6  
Up 
to  
18 
 
II  
≥ 1 year to < 2 years who are 
treatment experienc ed  
ETR  
+ OBR 
(1 active 
boosted 
PI+ at least 1  
other active 
drug)  
HIV genotype and 
phenotype assays should 
be performed in real t ime 
and results available prior 
to starting  study drug  
Subjects will be enr olled provi ding the 
phenotypic assay results indicate a <  10 
fold change in sensitivity to  ETR   
6  
6  
12 
 
III  
≥ 2 months  to < 1 year who 
are treat ment exp erienc ed1  
ETR  
+ OBR 
(1 active 
boosted 
PI+ at least 1 
other active 
drug)  
HIV genotype and 
phenotype assays should 
be performed in real t ime 
and results available prior 
to starting  study drug  
Subjects will be enr olled provi ding the 
phenotypic assay results indicate a <  10 
fold change in sensitivity to  ETR   
6  
6  
12 
 
1.  Subjects below 6 months of age will only be enrolled upon availability of initial safety and PK data from subjects between 6 months and 1 year of age.
 
 
IMPAACT P1090                Page 30 of 113 10 March  2016  
Version 5.0  Figure  2: Algorithm  for Cohort  Management  as of Version 5.0   
 
 
 

 
 
IMPAACT P1090                Page 31 of 113 10 March  2016  
Version 5.0  The investi gator-selected ARVs in  the OBR will  be used in  doses th at are speci fied in the individ ual 
package  inserts.  Brand  name ARVs and generics  with tentative approv al from the US FDA may be 
prescribed.  For a  list of ten tatively  approved  generics,  please  consult 
http://www.fda.gov/InternationalProgra ms/FDABeyondOurBordersForeignOffices/AsiaandAfric  
a/ucm119231.htm  
 
If the  site intends  to use study  products  not marketed in the United  States,  sites should  consult  the DAIDS 
SOP on “U se of Study  Products Not M arketed  in the United  States”  (Jun 24, 2011). It  is the  sites 
responsibility  to ensure that they are in compliance  with this policy.  Please  refer  to 
http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Docu ments/NonFDAa  
pprovedProducts.pdf  
 
Applicable  procedures  and treatment guidance  based on package  inserts  of the  selected  ARVs should  be 
respected.  Proposed OBR regi mens for individ ual subjects  will need  to be approved  by the  protocol  team  
prior  to the enroll ment (entry)  visit.  
 
 
3.3 Mini -Cohorts  
 
Under prior versions of the protocol, e nroll ment moved in a sequential  manner,  from  the oldest  cohort  to 
the next youngest cohort (Cohort  I Cohort  II).  Upon release of Version 5.0, the team will consider 
opening Cohort  III while the first mini -cohort of Cohort II may still be enrolling based on available PK 
and safety data to ongoing participants . Subjects below 6 months of age will only be enrolled upon 
availability of initial safety and PK data from subjects of  at least 6 months of age and less than 1 year of 
age (see Figure 2 and  Section 3.5) . 
 
All cohorts  will begin with enrollment into an initial  mini-cohort  of 6 subjects.  Intensive  PK on initial  dose 
will be performed on Day 14 (±  4 days) (to allow  ETR  levels  to reach steady-state) and  the mini-cohort  
will be followed  for 4 weeks to  assess safety.  
 
For all  cohorts, plasma concent rations of ETR  will be assayed  in real time (within  two weeks of sa mple 
receipt)  by the protocol  specified  IMPAACT phar macology  laboratory.  After  the sixth subject  is enrolled,  
enroll ment into that cohort  will pause  so that the pharmacokinetics  (PK) and safety  data can be analyzed.  
The safety  criteria  are described  in Section  8.52 and  PK criteria  are described  in Section  9.0. 
 
The P1090 core protocol team will review the PK and safety results of each mini -cohort, and if acceptable, 
enrollment will resume, at that dose, to complete enrollment of the remainin g 6 slots.   
 
Subjects who pass screening but cannot enroll because the mini -cohort is filled, will join a waiting list and 
will be given first priority to enroll when the remaining six slots are opened for that cohort.  NOTE:  
Screening labs must be repeated if the subject is on the waiting list for ≥ 60 days.  
 
In the  rare event  where  the results  of a single  subject’s  intensive PK are  extre mely low, AND the site  
clinician/protocol  team  strongly  suspect  non-adherence,  an additional  subject  may be enrolled i nto the 
mini-cohort to replace the non-adherent  subject.  The non-adherent  subject  may remain on study  and on 
study  drug ( ETR), if the site investigator  agrees  it is in the best interest of the  subject,  but this subject  will 
not be considered  for dose-finding  or safety  final analysis.  
 
 
IMPAACT P1090                Page 32 of 113 10 March  2016  
Version 5.0  If the  PK or safety  monitoring  results  of the  mini-cohort  suggest that  a higher  or lower  dose is needed,  the 
new dose will  be agreed upon by the  P1090 core  protoc ol team  (upwards for inadequ ate PK values;  
downwards for sa fety failure,  or high  PK values).  Up to  6 new subjects will  be enrolled  as a new mini-
cohort,  for PK and  safety  evaluation  of the  new dose.  
 
Those  enrolled  in a failed  mini-cohort, who had  acceptable  PK para meters,  antiviral activity and safety  can 
remain on the  same dose without  dose adjust ment and will be followed  on study. Subjects  from  the failed  
mini-cohort  may be dose adjusted  to the new dose,  if feasible  and the site  investigator  and/or  protoc ol team  
belie ve this is in the best interest  of the  patient.  Such subjects  will have  truncated  intensive  PK evaluation  
(3 sa mples:  pre-dose and samples 2h and  3-5h after dosing) 7 -14 da ys after the dose change,  for sa fety 
consider ations, but will not be considered  towards the  cohort  pass/fail  criteria.  
 
Two out  of six of the  children  from  the mini-cohort  who passed the  safety  criteria  in Version  3.0 would be  
on the  same dose chosen  for the  new weight -banding  dosing  strategy  in Version 4.0. Consequently,  the 
team  agreed  that those two participa nts could be included  in considering  the Cohort  I mini-cohort  under  
V4.0; only  four additional  participants  would be  needed  to complete enroll ment into that mini-cohort.  In 
future  mini-cohorts,  if dose adjust ments need  to be made but subjects  in the prior  failed  cohorts  were on the 
same dose that  will be evaluated  in the new cohort,  the PK and safety  data for these  subjects  will be carried  
forward and  counted  towards the nu mber of evaluable  subjects  on the  final dose.  
 
Those  who need  an individual  dose adjust ment (see Section  9.34 for management of individual dose 
adjustments),  will have  a repeat 12 hour i ntensive  PK perfor med between  Day 7 to  14 following  their dose 
adjust ment. Subjects  who require  a dose adj ustment but decline  to undergo repeat  inten sive PK (see  
Section  9.34 for manage ment of ind ividual  dose adjust ments)  will have ETR  therapy  discontinued  and best 
available  therapy by th eir clinician  will be initiated. 
 
If a subject  discontinues  therapy  for a non-ETR  related  toxicity  reason  (e.g.,  drug intolerance  to an  OBR 
agent) the subject will be replaced.  Subject s discontinue d due to ETR  toxicit y will NOT b e replaced ; rather , 
they will conti nue to be counte d as failures . However , the safety data from the subject s who replac e them for 
PK purpose s will also be used when apply ing the safety guidelines  
 
3.4 Full Cohorts  
 
Once  PK and  safety  criteria  have been  met for a full cohort,  subjects  will continue  their treatment in  the 
speci fic cohort  at the selected dose. The  safety  criteria  are described  in Section  8.52. In order  to meet the 
PK criteria,  the geometric mean AUC 12h in the cohort  must be within  60 to  150% of the  geometric mean 
AUC12h in adults  (i.e. between  2713 and  6783 ng •h/mL). The recom mended  dose must be approved  by the  
P1090 core  protocol  team. If, however,  the selected  dose for  a full cohort  does not  meet the PK and  safety  
criteria,  the dose may be adjusted  for the  subjects  already  in the cohort  (as described  above) and 
additionally  new subjects  will be enrolled,  if needed,  to have  (at least) 12 su bjects in total on the  new 
starting dose. The  evaluation  of PK and  safety will then be repeated. If the starting  dose is  still not 
acceptable,  the dose sel ection  process will be repeated.  
 
Subjects  from  the failed  cohort  may be dose-adjusted  to the new dose  if the site investigator  and protoc ol 
team believes  this is in the best interest of the subje ct. These  subjects will have a truncated  intensive  PK 
evaluation  (sampling  at pre-dose and 2hr and  3-5h after  dose).  
Those  subjects  that require  an individual  dose adjust ment for high  or low AUCs (see  Section  
 
 
IMPAACT P1090                Page 33 of 113 10 March  2016  
Version 5.0  9.34 for manage ment of individual  dose adjustments),  will have  a repeat intensive  PK evaluation  
7-14 days following  their dose adjust ment. 
 
Those  subjects  from  a failed cohort  who are  not dose-adjusted  to the new dose, but  had acceptable  PK 
parameters  and antiviral  activity  and safety  can remain on the  same dose and  will be  followed  on study.  
 
Subjects  who require  a dose adjus tment  but refuse  to undergo  repeat intensive  PK (see  Section  
9.34 for manage ment of individual  dose adjus tments)  will have  ETR  therapy  discontinued  and will  be 
replaced  (but will be followed  on study  but off study  drug).  
 
If full  cohort  data are inconclusive,  the protocol  team  may decide  to enroll additional  subjects  at the  starting  
dose, and/or  the P1090 Study  Monitoring  Com mittee (SMC) may be asked  to review the  data and advise  the 
team. 
 
As enroll ment into each cohort  continues,  the study team  will review  the data via conference  call at  least 
monthly,  to ensure that the stated PK and safety  targets are acceptable.  
 
3.5 Cohort III  
 
Upon release of Version 5.0, the  P1090 core  protocol team  will review  the available PK and  safety  results  
of Cohort II to determine whether Cohort III may be opened to enrollment of infants > 6 months and < 1 
year of age.  
 
3.5.1  Available Cohort II PK and safety data are acceptable  
 
If the available PK and safety data are acceptable,  enroll ment into Cohort III will commence starting with 
infants > 6 months and < 1 year of age.  
 
In the event that Cohort III is open to accrual at the time that Cohort II completes accrual of a mini -cohort 
(N=6), accrual into both cohorts will be paused as per Section 3.3.  
 
3.5.2  Available Cohort II PK and safety data are not acceptable  
 
If available safety and/or PK data from Cohort II are unacceptable at this time, Cohort III w ill remain 
closed to enrollment; Cohort II will continue to enroll to complete the mini -cohort of six subjects .  At that 
point, the team will evaluate the mini -cohort as described in Section 3.3.   
 
If the 4 -week  safety  data from the six subjects in the Cohort II mini -cohort  are deemed appropriate,  and 
sufficient  PK data  are available  to confirm  the starting  weight -based  dose for the older infants in Cohort III  
as per Dosing Table 2 , Cohort III will open to enrollment of infants > 6 months and < 1 year of age.   
 
If the 4 -week safety data from the six subjects in the Cohort II mini -cohort are not deemed appropriate, 
and/or PK data confirm the starting weight -based dose for the older inf ants in Cohort III as per Dosing 
Table 2, Cohort III will remain closed to enrollment and a new mini -cohort will be enrolled into Cohort II 
as per Section 3.3.  
 
 
 
 
IMPAACT P1090                Page 34 of 113 10 March  2016  
Version 5.0  3.5.3 Enrollment of Cohort II is paused at time of release of Version 5.0  
 
If enrollment of Cohort II is paused for review of mini -cohort data at the time of release of Version 5.0, 
opening of Cohort III will be held until Cohort II is re -opened.  
 
Once there are sufficient data of infants > 6 months and < 1 year of age  to assess the impact of age  on the 
pharmacokinetics , enrollment of the youngest group of infants in Cohort III ( > 2 months and < 6 months 
of age) will commence . 
 
3.6 Long  Term  Safety  Follow -Up 
 
Long  term safety  follow -up is described  in Section  5.5. 
 
3.7 Early  Discontinuation  
 
Subjects  who are  withdrawn  from  study  drug within  the first 48 weeks of  study  will not enter long  term 
follow -up but will be followed for safety  for 4 weeks, as per  Appendix  ID.  Additi onally,  any AEs will be 
followed  until satisfactory clinical resolution  (i.e. value returns  back  to subjects  baseline  value)  or 
stabilization  (to be agreed upon with  the sponsor).  All grade  3 and  grade  4 lab oratory  abnor malities  as 
well as any  laborat ory abnormalities  resulting  in an  increase of 2 DAIDS Grades from baseline,  will be 
followed until they return to baseline  or within  1 Grade from baseline.  
4.0 SEL ECTION AND ENROLL MENT  OF SUBJECTS  
 
4.1 Inclusion  Criteria  
 
4.11 Confi rmed HIV-1 infection  
 
NOTE:  Results can be abstracted  from  the medical  record to meet this criterion for HIV  diagnosis.  
 
Tests  Perfor med at < 2 years  of age  
 
An in fant will be considered to be infected  with HIV if  TWO separ ate peripheral  blood 
speci mens from  different  days are  drawn and each speci men is positi ve by at  least one of the 
following  assays:  
 HIV DNA PCR 
 Plasma HIV RNA (quantitati ve or qualitative)  
 HIV total  nucleic  acid tests 
 
At least  one of the  above  tests must be done  in a VQA -certified  laboratory  that is approved  to 
perform  the assay for protocol  testing.  If the  mother or infant  is receiving  antiretroviral  drugs, 
then an HIV DNA assay may be more  sensitive.  
 
Tests  Perfor med at ≥ 2 years  of age  
 
Docu mentation  of HIV-1 infection  is defined as positi ve results from two samples collected  at 
different  time points.  All samples tested  must be whole  blood,  serum  or plas ma. For studies 
 
 
IMPAACT P1090                Page 35 of 113 10 March  2016  
Version 5.0  conducted  under  an IND, all  test methods  should  be FDA -approved if  available.  If FDA - approved  
methods  are not available,  test methods  should  be verified  according  to GCLP and approved  by the  
IMPAA CT central  laborat ory. 
 
 Sample #1 may be tested  by non -study public  or PEPFAR progra ms. However, both  the 
result  and the assay date  must  be recorded  in subject’s  charts.  Source  documentation 
[patient’s  medical  record/chart,  Ministry  of Health  (MOH) r egisters, laboratory  results, 
etc.] must be available  if requested.  
 Sample #2 must  be perfor med in a CAP/CLIA -approved  laboratory  (for U.S. site s) or in a 
laboratory  that operates  accor ding to GCLP guidelines  and participates  in appropriate  
exter nal quality assurance program  (for intern ational sites). 
 
Acceptable  Tests  
 
Sample #1 may be tested  using  any of the  following:  
 Two rapid  antibody  tests from  different  manufacturers  or based  on different  principles and  
epitopes.  
 One EIA OR Western  Blot OR immuno fluorescence  OR chemiluminescence  
 One HIV DNA P CR 
 One quantitative  HIV RNA PCR (above  the limit of detection)  
 One qualitative  HIV RNA PCR  
 One HIV culture  (prior  to August 2009)  
 One total  HIV nucleic  acid test 
 
If Sample #1 is  positive,  then collect  and test Sample  #2. S ample #2 may be tested  using  any of the  
following:  
 Rapid  antibody  test. If this  option  is used in  combination  with two rapid  tests for Sample  
 #1, at  least one of the  three  rapid  tests must be FDA -approved and  the third  rapid  test must 
be from  a third  manufacturer  or based  on a third  principle  or epitope.  
 One EIA OR Western  Blot OR immuno fluorescence  OR che miluminescence  
 One HIV DNA P CR 
 One quantitative  HIV RNA PCR (above  the limit of detection)  
 One qualitative  HIV RNA PCR  
 One HIV culture  (prior  to August 2009)  
 One total  HIV nucleic  acid test 
 
4.12 Age ≥ 2 months  to < 6 years  old at study  entry.  NOTE:  For subjects  who were  born at  ≤ 
37 weeks gestational  age, the subject  must  be at least 12 weeks of age,  AND ≥ 46 weeks post -
conceptual  age at study  entry.  
 
4.13 HIV-1 RNA viral  load > 1,000 copies/ mL (within the previous  90 days prior  to screening)  AND an 
HIV-1 RNA v iral load > 1,000 copies/mL  at screening.  
 
4.14 Treat ment experienced  children  on a failing combination  antiretroviral  regimen (containing  at least 
3 ARVs)  for at  least 8 weeks OR Treatment  experie nced children  on a tre atment interruption  of at 
least 4 weeks with a history  of virologic  failure  while  on a co mbination  antiretroviral  regimen 
 
 
IMPAACT P1090                Page 36 of 113 10 March  2016  
Version 5.0  (containing  at least 3 ARVs).  
 
4.15 Ability  to swallow  ETR  whole  or dispersed  in an appropriate  liquid (see Section  5.2). 
 
4.16 Parent  or legal  guardian  able and willing  to provide  signed  informed consent  and to have the  
subject  followed  at the clinic site. 
 
4.17 Availability  of sufficient  active ARV drugs to  create  an OBR consistent  with protocol require ments 
(as outlined  in Table  6). 
 
 
4.2 Exclusion  Criteria  
 
4.21 Evidence  of phenotypic  resistance  to ETR  at screening.  Phenotypic  cutoffs  of > 10 for loss of 
sensitivity  for cohorts  I, II, III. 
 
4.22 Known history  of HIV -2 infection  in subject  or subject’s  mother.  
4.23 Diagnosis of a  new CDC Stage  C (per 1994 Revised  Classification  System  for Hum an 
Immunodef iciency  Virus Infection  in Children  Less than  13 Years of Age) criteria  or opportunistic  
or bacterial  infection  diagnosed  within  30 days prior  to screening  and not conside red clinically  
stable. 
 
4.24 Prior history  of malignancy.  
 
4.25 Any clinically  significant  diseases  (other  than HIV infe ction)  or clinically  significant findings  
during  the screening  medical  histo ry or physical  examination  that, in the investigat or’s opinion,  
would place  the subje ct at an unacce ptable  risk of injury;  render the  subject  unable  to meet the 
require ments of the  protocol;  compro mise the outco me of this  study;  or lead  to the child  being  
ineligible  for participation.  
 
4.26 Current  ≥ Grade 3 of any  of the  following  laboratory  toxicities  at screening:  neutrophil count,  
hemoglobin,  platelets,  AST, ALT,  lipase,  serum  creatinine.  
 
4.27 Current  or anticipated  use of any  disallowed  medications  (see Section  4.32).  
 
4.28 Subject’s  family is unlikely to adhere to the study  procedures,  keep  appoint ments, or is planning  to 
relocate  to a non-IMPAACT study  site during  the study.  
 
4.29 History of non-adherence  with ARV  medications  that in the investigator’s  opinion  could a ffect the 
ability of the subject  to comply  with the protoc ol/procedu res. 
 
4.210   Subject  is currently  participating,  or has participated  within  the previous  30 days prior  to screening,  
in a study  with a compound  or dev ice that is not commercially  available.  
 
4.211   Grade  3 or higher  QTc or PR interval  prolongation  from  the ECG at  screening  (see Appendix  V). 
 
NOTE:  Subject  may proceed  to entry based  on site investigator  grading of ECG.  If official central  
 
 
IMPAACT P1090                Page 37 of 113 10 March  2016  
Version 5.0  ECG reading  indicates  Grade  3 or higher  QTc or PR interval  on the  screening  ECG that was not  
recognized  by the site investigator,  the Team will inform the site investi gator, and the subject  will 
be taken  off study  treatment. 
 
 
4.3 Concomitant Medication Guidelines  
 
4.31 Precautionary  Medicati ons 
 
The following  medications  should  be avoided,  if possible,  and alternati ve treatments sought. Please  contact 
the protocol  team  at impaact.tea mp1090@fstrf.org  if treatment with any of these medications  is necessary 
for clinical  care.  
 
 Clopidogrel  
 Clarithro mycin when u sed for the  treatment of Mycobacterium  avian  complex  (MAC) - other  
indications  are acceptable  
 ≥ 14 days of all  inhaled/intranasal  cortico steroids, except  for fluticasone  (see disallowed meds 
below),  for subjects  taking  ritonavir -boosted  PIs 
 Rifabutin,  when co mbined  with a boosted  protease  inhibitor  
 Any drugs not  recom mended  in the package  insert  under  conco mitant medications.  
 
4.32 Disallowed  Medications  
 
Anticonvulsants:  
 Carba mazepine  
 Oxcarbaza pine 
 Phenytoin  
 Fosphenytoin  
 Phenobarbital  
 
Anti-infectives:  
 Rifampin 
 Rifapentine  
 
Antir etrovirals: 
 Darunavir  use in  subjects  < 3 years  old 
 Fosa mprenavir/ritonavir  (etravirine  increases  fosamprenavir  exposure  posing  a potential safety  
issue)  
 Maraviroc  
 Saquinavir/ritonavir  
 Tipranavir/ritonavir  (tipranavir/ritonavir  significantly decreases etravirine)  
 Ritonavir,  used as sole  PI therapy  
 Unboosted PIs including  nelfinavir  (drug interaction  unknown – etravirine  may increase nel finavir)  
 Other  NNRTIs 
 
 
Cortico steroids: 
 
 
IMPAACT P1090                Page 38 of 113 10 March  2016  
Version 5.0   ≥ 14 days of continuous  use of inhaled  fluticasone  (for subjects  taking ritonavir -boosted  
PIs) 
 ≥ 7 days of oral  or IV  steroids  
 
Other:  
 Products containing  St. John’s  wort (Hypericu mperforatum ) 
 Any drugs contraindicated  in the packa ge insert  under  conco mitant medications  
 
 
4.4 Enroll ment Procedures  
 
Prior to  implementation  of this  protocol, and any subsequent  full version  amendments,  each site must  have  
the protocol  and the protocol  informed consent  form(s) approved,  as appropriate,  by their  local institutional 
review  board  (IRB)/et hics committee (EC)  and any other  applicable regulatory  entity  (RE).  Upon recei ving 
final approval,  sites will submit all required  protoc ol registration  docu ments to the DAIDS Protocol  
Registration  Office  (DAIDS P RO) at  the Regulatory  Support  Center  (RSC).  The  DAIDS PRO will  review  
the submitted protocol registration  packet  to ensure  that all of the required  docu ments have  been  received.  
 
Site-specific  infor med consent  forms (ICFs)  WILL be revie wed and approved  by the  DAIDS PRO and  
sites will receive an Initial Regist ration  Notification  from the DAIDS PRO that indicates  successful  
completion  of the protocol  registration  process. A copy  of the  Initial Registration  Notification  should  be 
retained  in the site's regulatory  files.  
 
Upon recei ving final IRB/EC  and any other  applicable RE approval(s)  for an  amendment,  sites should  
implement the amendment  immediately.  Sites  are required  to submit an amendment regi stration packet  to 
the DAIDS PRO at  the RSC.  The  DAIDS PRO will  review the submitted protocol  registration  packet  to 
ensure  that all the required  docu ments have  been  received.  Site- specific  ICF(s) WILL NOT be reviewed 
and approved  by the  DAIDS PRO and  sites will recei ve an Amendment  Regi stration Notification when t he 
DAIDS PRO receives  a complete  registration packet.  A copy  of the  Amendment  Registration  Notification  
should  be retained  in the site's regulatory  files.  
 
For additional  infor mation  on the  protocol  registration  process and  specific  docu ments required for initial  
and amendment registrati ons, refer to the current  version  of the  DAIDS Protocol Registration  Manual.  
 
Sites  interested  in screening  or enrolling  subjects  in IMPAACT P1090 must send an  email to the team  at 
impaact.tea mp1090@fstrf.org   indicating the candidate’s  PID# (if  no PID is  assigned,  the age  of the  
subject  is sufficient),  cohort  number and prior  ART experience.  If the  participant  has a milestone  birth day 
that will chan ge cohort  assignment, it is the site's responsibility  to notify  the 
DMC data  manager  to request  a cohort  assign ment change.  
 
Sites  should refer  to subjects medical  charts  to ensure potential  eligibility.  Slots  will be granted based  on 
the date a slot was requested.  Sites  must receive  authorization  from  the protocol  team before  proceeding  
with screening.  
 
Enroll ment slots will be granted  only for a study  candidate  who:  
 Receives  permission  to proceed  with the screening  visit 
 
 
IMPAACT P1090                Page 39 of 113 10 March  2016  
Version 5.0   Accepts  the slot and completes  the screening  visit within  two weeks of receipt  of the  slot (Sites  
MUST e mail the protoc ol team  to accept the slot and to complete  the Screeni ng visit)  
 Meets  the study  inclusion  criteria  
 
Sites  should  contact  the protocol  team  at impaact.tea mp1090@fstrf.org  with any screening ti meline  
deviations.  A slot  may be recalled  if deviations  from  the timeline  are not approved  by the protocol  team. 
Sites  need  to inform  the protocol  team  of the  proposed opti mized background regi men (OBR) at  least 24 
hours prior  to enroll ment. Enroll ment is contingent  upon the  protocol team  and site agreeing  on the  OBR.  
Sites  with study  candidates  who are  granted  a slot but fail to enroll will be required  to complete an  
enroll ment failure  form  which  will collect  general failure -to-enroll  information.  
 
 
4.5 Co-enroll ment Procedures  
 
Co-enroll ment is permitted except  for protoc ols that would violate  the exclusion  criteria. Co- enroll ment in 
P1074 is  strongly  encouraged.  With the exception  of P1074, all  co-enroll ments in protocols  require  the 
prior  approval of the  P1090 protocol  team  and the co-enroll ment protocol tea ms. 
 
5.0 STUDY TRE ATME NT 
 
Study  treatment is defined  as etravirine  (ETR)  25 mg and 100 mg tablet s. Both  will be provided by the  
study.  Darunavir  100 mg/mL suspension, darunavir  75 mg tablets,  and darunavir  150 mg tablets,  will be 
provided  through  the study  if not reasonably  available  locally.  (NOTE:  Darunavir may only be used in  
children  ≥ 3 ye ars.). Other antiretrovirals (ARVs) will  not be provided through  the study.  
 
The subjects  will be accrued  into the study  for an  initial  dose finding  intensive PK component  for age  
related  cohorts.  It is anticipated  that appro ximately  50 subjects  will be accrued, to yield  at least  36 
evaluable  subjects with a minimum of 12 subjects  for each  of the  three  cohorts,  whose initial  dose was the  
final optimal dose deter mined for their  age cohort.  The total sample size will depend  upon the  number of 
subjects  needed  to complete  the dose finding  stage  of the  study  and the  number of subjects  who 
discontinue  the study.  
 
Subjects  enrolled  into the study  will be stratified  by age,  as descr ibed in Section  3.1 and  Table  6. In all  
cohorts,  ETR  will be started  concurre ntly with an optimized ARV b ackground  regimen (OBR).  
 
This study  is designed  to deter mine the appropriate  ETR  dose for HIV -1 infected  infants  and children  and 
to evaluate  the PK, safety  and tolerability  of ETR  in this population.  
 
5.1 Drug Regimens,  Administration  and Duration  
All subjects  enrolled  into the study  will be stratified  by age  into one of three  cohorts.  
Cohort  I: ≥ 2 year  to < 6 years  who are treatment experienced  
 ETR  25 mg and/or  100 mg  tablet(s)  
 Subjects  will take the specified  dose of ETR  tablet(s)  orally  twice  daily  within  30 minutes 
following  a meal per Dosing Table  1 in Appendix  III 
 
 
 
IMPAACT P1090                Page 40 of 113 10 March  2016  
Version 5.0  Cohort  II: ≥ 1 year  to < 2 years  who are treatment experienced  
 ETR  25 mg and/or  100 mg  tablet(s)  
 Subjects  will take the specified  starting  dose of  ETR  tablet(s)  orally  twice  daily  within  30 minutes  
following  a meal, per Dosing Table  1 in Appendix  III 
 
Cohort  III: ≥ 2 months  to < 1 year  who are  treatment  experienced 
 ETR  25 mg and/or  100 mg  tablet(s)  
 Subjects  will take the specified  starting  dose of  ETR  tablet(s)  orally  twice  daily  within  30 minutes  
following  a meal, per Dosing Table  2 in Appendix  III 
 
ETR  will be administered  as 25 mg scored  table ts and/or  100 mg  tablets  swallowed  as a whole  or dispersed  
in an appropriate  liquid vehicle  following  a meal. Refer to Section  3.1 and  Table  6 for further  infor mation  
on regi men design  per cohort.  
 
Study  Duration:  Minimum  of 48 weeks  
Long  Term  Safety  Follow -up: See Section  5.5 
 
 
5.2 Dosing and  Administration  
 
ETR  will be dosed orally  accor ding to the dosing table in Appendix  III. The  investi gator will be notified  by 
the P1090 Protocol  Team  in case there  would be  any change  in the dosing  table  (see Appendix  III). 
 
ETR  tablets  should  be swallowed  whole  with a sufficient  amount  of water  or other  liquid  within  
30 minutes  following  a meal. Subjects  unable  to swallow the  tablets  whole  may disperse  the tablets  in a 
container  with a minimum of 5 mL  (1 teaspoon)  of water.  One minute should  be allowed  for the  tablet (s) to 
be dispe rsed, stirring will aid in the dispe rsion.  The disper sed tablet (s) in water  may be further  diluted  with 
a bever age (see list below) not to exceed 30 mL (2 tablespoons)  total volume.  The recommendation  for 
administration  to infants is to disperse  the tablet  in approxi mately  10 mL of liquid  (e.g. formula  or milk). 
Once  dispersed,  subjects  should drink  the dispersion  immediately.  
 
The container  should  be rinsed  with a minimum of 5 mL (1 teaspoon)  of water  or other  beverage and  the 
rinse completely  swallowed  to ensure  the entire  dose is  consu med. This step may be repeated  as needed.  
The dispe rsion should  be consu med complet ely and immediately;  it is not allowed  to administer  a portion.  
 
Subjects  must avoid  the use of wa rm or hot  (> 40°C)  beverages  and carbonated  drinks when swallowing  
study  drug. ETR  can be dispersed  in the following  beverages  without  compromising drug stability:  
 Water  that is safe to drink  (sterile  water  will be provided  by the  study  staff, as appropriate)  
 Miner al water  that is safe to drink 
 Orange  juice  
 Milk  (whole  milk, skim  milk or chocolate  milk) 
 Various infant  formula 
 
5.21 Missed Doses  
 
Any missed ETR  study  drug dose should  be taken  by the  subject  if it is within  6 hours of the scheduled  
missed dosing  time. 
 
 
 
IMPAACT P1090                Page 41 of 113 10 March  2016  
Version 5.0  5.22 Vomited Doses  
 
If the  subject  vomits the ETR  study  drug dose within  15 minutes  of taking  the dose, then  another full  dose 
should  be taken  by the  subject.  
 
5.3 Drug For mulation  
 
ETR  100 mg  tablet  and 25 mg scored  tablet:  store at 25°C  (77°F);  with excursions  permitted to 
15°to  30°C  (59° to 86°F) [see  USP controlled  room  temperature].  Store  in the original  bottle. Keep  the bottle  
tightly  closed  in order  to protect from  moisture.  Do not  remove  the desiccant pouches.  
 
Darunavir  (Prezista®)  100 mg/mL oral suspens ion: store  at 25°C  (77°F);  with excursions per mitted to 15° 
to 30°C  (59°-86°F).  Do not  refrigerate  or freeze.  Avoid exposure  to excessive heat.  Store in the original  
container.  Shake  well before  each use. 
 
Darunavir  (Prezista®)  75 mg and 150 mg tablets:  Store  at 25°C (77°F);  with excursions per mitted to 15° 
to 30°C  (59°-86°F).  
 
 
5.4 Drug Supply,  Distribution  and Pharmacy 
 
ETR  100 mg  tablet  and 25mg scored  tablet  are provided  by Janssen R&D  and supplied  through the  study.  
 
Darunavir  100 mg/mL suspension, and  darunav ir 75 mg and 150 mg tablets  are provided  by Janssen R&D  
and supplied  through  the study  for OBR purpo ses if not reasonably  available locally.  
 
Study  Product  Acquisition  
 
ETR  100 mg  tablets  and ETR  25 mg scored  tablets  will be available through the NIAID Clinical  
Research  Products Manage ment Center (CRPM C).  Darunavir  100 mg/mL  suspension, darunavir  
75 mg tablets,  and darunavir  150 mg tablets  will be available  through  the NIAID  Clinical Research  
Products Manage ment Center (CRPMC) for OBR purposes if  not reasonably  available locally.  
 
The IMPAACT phar macist can obtain  the study  product  by following  the instructions  in the manual  
"Phar macy Guidelines  and Instructions  for DAIDS Clinical  Trials Networks" in  the section  Study  Product  
Control.  
 
The optimized background  regimen to be used in  this study  (with  the exception  of darunavir,  as noted)  will 
not be provided  by the  study  and must be obtained  by non -study prescription  (see Section  3.2). 
 
5.41 Study  Product  Accountability  
 
The IMPAACT site  pharmacist is required  to maintain  complete  records  of all  study  products received  from  
the CRPMC and  dispensed.  All unused study  products  must  be returned  to the CRPMC after the study  is 
completed  or ter minated  at U.S. sites.  
 
Non-U.S. sites  will receive  instructions regar ding the final disposition  of any  remaining  study products.  
The proced ures to follow  for accounta bility can be found in  the manual,  “Phar macy Guidelines  and 
 
 
IMPAACT P1090                Page 42 of 113 10 March  2016  
Version 5.0  Instructions  for DAIDS Clinical  Trials  Networks” in  the section  entitled  “Study Product  Manage ment 
Responsibilities.”  
 
 
5.5 Long  Term  Safety  Follow -up 
 
Provided  that the overall  data for this drug app ear to be generally  favora ble, each subject  who successfully  
completes  48 weeks of ETR  treatment  will continue  to receive  study  drug through the  study,  and be 
followed  on study  for long -term safety  follow -up (see Appendix  IE) for up to  5 years  or until  any one or 
more  of the  following  events occur within  the 5 years:  
 The age-appropriate  formulations  provid ed by the  study  are available  locally  from another  source;  
OR 
 The subject  is no long er deriving  benefit; OR  
 The subject  meets a protocol -defined reason  for discontinuation;  OR 
 Pharmaceutical  develo pment of ETR  for that  age cohort  is terminated  
 
Subjects  in countries  where  ETR, darunavir  100 mg /mL suspension, darunavir  75 mg tablets,  and 
darunavir  150 mg tablets  continue  to be unavaila ble locally at the end of the  planned  5 year  long- term 
safety  follow -up program  will be provided  the drug eit her through  a P1090 prot ocol a mendment or through  
other  sources, such as another  Janssen R&D -sponsored program, govern ment progra ms, and aid and 
assistance  progra ms. It is also expected  that such progra ms will be in place  in all countries  where  study  
sites are located  within the planned  5 year  duration  of long -term safety  follow -up phase.  
 
Once  subjects  enter  the Long  Term  Safety  Follow -up phase,  they will be seen in clinic  every  12 weeks for 
safety  visits  and laboratory  evaluations  until one of the  above  criteria  are fulfilled,  as per  Appendix  IE.  
Sites  should  record any laboratory  results, diagnoses  etc. that are recorded  as part  of standard  of care  as 
well as perfo rm the study  mandated  HIV-1 RNA assay (See  Appendix IE).  
 
6.0 SUBJ ECT MANAG EMENT  
 
 
6.1 Toxicity  Manage ment 
 
The DAIDS Table  for Grading  the Severity  of Adult and Pediatric  Adverse Events,  (DAIDS AE Grading  
Table), Version 1.0, Dece mber 2004, Clari fication  August  2009, must  be used and  is available  on the  RSC 
website  at (http://rsc.tech -res.co m/safetyandphar macovigilance /). 
 
Manage ment of adverse  experiences  will be according  to the best clinical  practice  and the judg ment of the  
site investigator.  Alternate  explanations  for clinical  and laborat ory abnormalities must  be sought.  
Laboratory  normal ranges  will be the institutional  values.  However, if  a site does not  have  an age-specific  
normal range/value  for a particular  laboratory,  the site should use the latest  edition of the  Harriet  Lane  
Handbook for  normal ranges/values  and docu ment this for monitoring  purposes. Abnormal clinical and 
laboratory  findings should  be followed  until resolution  to < Grade  2. 
 
The toxicity  manag ement guidelines  are for eve nts for which  a relationship  to study  drugs cannot be  
excluded.  Clinical  or labora tory adverse  events  (AEs) that  are definitely  unrelated  to study drug(s) may not 
 
 
IMPAACT P1090                Page 43 of 113 10 March  2016  
Version 5.0  result  in study  drug interrupt ion. General  guidelines  for study  drug suspected adverse  drug reactions  
(SADRs) are  provided  below:  
 
6.11 Reporting  
 
 Grade  1: All study  drug SADRs should  be recorded  on Case  Report  Forms (CRFs) at each  visit. 
 
 Grade  2: All study  drug SADRs should  be recor ded on CRFs at  each visit.  Inform  team monthly  
whether  toxicity  has resolved  or not.  
 
 Grade  3 or 4:  
o The protocol  team  must be notified  of study  drug SADRs within  24 hours at 
impaact.p1090c mc@fstrf.org  
o The investi gator should attempt to confirm any unexpected  labora tory test results as soon as 
possible  but always within  72 hours to  deter mine if the result  was spurious.  
o Expedited  Adverse  Event  (EAE)  reporting  must be done  within  72 hours of the  initial result.  
Reporting  will occur  whether  the value  is confir med or if confirmatory results are  not available  
within  72 hours.  
 
6.12 General  Manage ment Guidelines  
 
NOTES:  
 All antiretroviral  therapy  including  study  drug should  be started  or stopped  together whenever  
possible,  except  for when one  antiretroviral  agent  can be substituted  for another  within  the same 
class,  when the  etiology  of the  toxicity  can be deter mined.  
 If a subject  is pending  a safety  event  analyses  or resolution,  additional safety  tests may be required  
by the  team. 
Grade  1 
Continue  study  drug;  routine  monitoring.  
Grade  2 
 
Continue  study  drug;  monitor  closely  with more frequent  visits;  as per  site investigator,  work -up to  exclu de 
other causes.  
 
Grade  3 
 
NOTE:  Grade 3 triglycerides  and cholesterol  events will NOT require  the subject  to stop study drug or 
OBR.  
 The protocol  team  should  be notified  of a Grade  3 event  at impaact.p1 090cmc@fstrf.org . 
 Study  drugs can  be continued  at the discretion  of the site investigator/clinician  while awaiting  a 
repeat  assess ment/confir mation  of an abnor mal laboratory  test as soon as  possible  (within  72 
hours).  
 If the  repeat  assess ment confir ms Grade 3 toxicity,  AND if  the investigator  considers  the event  to 
be at least possibly  related  to study  drug, ETR  should  be withheld  and any abnor mal laboratory  
values  should  be followed  weekly  (Except  in Grade  3 cholesterol and  triglyc erides).  
 
 
IMPAACT P1090                Page 44 of 113 10 March  2016  
Version 5.0   OBR should  be held at the discretion  of the  site investigator.  
 If the toxicity  resolv es to ≤ Grade  2 within  21 days, ETR  (and OBR if  applicable)  can be restarted.  
 If the Grade  3 toxi city persists for >  21 days, or recurs  at a ≥ Grade 3 after  re-introduction of ETR;  
ETR  must be permanently  discontinued.  
 
Grade  4: Non-Life-Threatening  Toxicity  
 
 Study  drug (ETR)  and conco mitant antiretrovirals  (OBR) should  be discontinued im mediately  
unless the  clinician  and P1090 core  protocol  team,  believe that withholding OBR and/or  ETR  
would be  harmful to the subject  and that continuing  the drugs  would pose little  additional risk. 
 Sites  should attempt to confirm any unexpected  laboratory  results  as soon as possible,  but always  
within  72 hours of the event  to deter mine if these  results  were  spurious.  
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 If the  repeat  assess ment confir ms Grade 4 toxicity,  ETR  should  be permanently discontinued,  
HOWEVER, for Gra de 4 adverse  events  that are deter mined to be unrelated to  study  drug, the  
investigator  should  contact  the team  to deter mine when study  drug may be  safely  resumed. 
 If the  repeat  assess ment shows Grade  3 toxicity,  continue  to hold ETR  and follow abnor mal 
laboratory  values  weekly.  
 If the toxicity  resolv es to ≤ Grade  2 within  21 days, all  study drugs can  be restarted.  
 If ≥ Grade  3 toxicity  recurs  after re-introduction  of ETR,  the study  drug (ETR)  must be 
permanently  discontinued.  
 
Grade  4: Life-Threatening  Toxicity  
 
 Study  drug (ETR)  and conco mitant antiretrovirals  (OBR) should  be discontinued im mediately.  
 Sites  should attempt to confirm any unexpected  laboratory  results  as soon as possible,  but always  
within  72 hours of the  event  to deter mine if these  results  were  spurious.  
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 If the  repeat  assess ment confir ms Grade 4 toxicity,  ETR  should  be permanently  discontinued,  
HOWEVER, for Gra de 4 adverse  events  that are deter mined to be unrelated  to study  drug, the  
investigator  should  contact  the team  to deter mine when study  drug may be  safely  resumed. 
 
6.13 Manage ment of Cutaneous  Adverse Events  
 
Since  cutaneous  adverse  events  are of particular  interest  for this  drug, the  following  guidelines on 
monitoring  and management should  be follo wed. The table  in Appendix  VII-A illustrates these  grading  
and manage ment guidelines.  Additionally,  please  refer  to Appendix  IV which describes  the visit schedule  
for manage ment of cutaneous  adverse  events.  
 
NOTE:  These manag ement  guidelines  are NOT ap plicable to rashes with  clear alternative etiology,  such as 
chicken  pox, i mpetigo  and cutaneous  HSV.  
 
Grade  1 cutaneous  reaction/rash  is defined  as localized  macular  rash.  
 
Grade  2 cutaneous  reaction/rash  is defined  as diffuse  macular,  maculopapular  or morbilliform rash or 
target  lesions.  
 
 
 
IMPAACT P1090                Page 45 of 113 10 March  2016  
Version 5.0  Subjects  with Grade  1 or Grade  2 rash may continue ETR  or temporarily  interrupt  therapy  at the 
investigator’s  discretion.  Close  clinical  follow  up is  recom mended  to monitor  progression of rash. All  
subjects  with Grade 2 rash must  be seen by a dermatologist  within  24 to  48 hours.  
 
Grade  3 cutaneous  reaction/rash  is defined  as: 
 
 Diffuse macular, maculopapular  or morbillifo rm rash with  vesicles  or limited number of bullae  
 Cutaneous  reaction/rash  with superficial  ulceration  of mucous  membrane  limited to 1 mucosal  site 
 Cutaneous  reaction/rash  with at least 1 of the  following:  
o Elevations  of ALT/AST  > 2 x baseline  but at least 5 x upper  limit of laboratory nor mal 
range  (ULN)  
o Fever  ≥ 38°C  or 100.4oF 
o Serum  sickness -like reaction  
o Eosinophil  count  > 1000/mm³  
 Subjects  experiencing a Grade  3 rash or cutaneous  event  must have  ETR  discontinued per manently;  
but should  remain on study  for safety  follow -up. 
 OBR should  be held at the discretion  of the  site investigator.  
 Subjects  must also be evaluated  by a dermatologist  within  24 to  48 hours.  
 The protocol  team  should  be notified  of a Grade  3 event  at impaact.p1090c mc@fstrf.or g. 
 
Grade  4 cutaneous  reaction/rash  is defined  as: 
 
 Extensive  or generalized  bullous  lesions  
 Stevens -Johnson syndro me (SJS)  
 Ulceration  of mucous  membrane  involv ing 2 or more  distinct  mucosal  sites 
 Toxic  epider mal necrolysis  (TEN)  
 Subjects  experiencing a Grade  4 rash  or cutaneous  event  must have  ETR  discontinued per manently;  
but should  remain on study  for safety  follow -up. 
 OBR should  be held at the discretion  of the  site investigator.  
 Subjects  must also be evaluated  by a dermatologist  within  24 to  48 hours.  
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1090c mc@fstrf.or g. 
 
NOTE:  Topical  corticosteroids,  topical  anti-pruritic  agents, and oral H1-antihista mines (such as cetirizine,  
diphenhydramine,  hydroxyzine  and levocetirizine  but excluding  astemizole and ter fenadi ne) will be 
allowed at the investi gator’s discretion  for all  grades of rashes.  
 
6.14 Manage ment of Acute  Syste mic Allergic Reaction 
 
The table  in Appendix  VII-B illu strates these  grading and manage ment guidelines. Grade  1 
Locali zed urticaria with no medical  interve ntion indicated.  Subject  may continue  intake  of ETR.  
 
Grade  2 
 
Locali zed urticaria with medical  intervention  needed,  or mild angioede ma with no medical intervention  
indicated.  Subject  may continue  intake  of ETR.  
 
 
IMPAACT P1090                Page 46 of 113 10 March  2016  
Version 5.0   
Grade  3 
 
Generalized  urticaria  or angioede ma with medical  interve ntion indic ated; or sy mptomatic  mild 
bronchospasm.  
 Subjects  with Grade  3 acute  syste mic allergic  reactions  will be permanently  discontinued from  the 
investi gational medication  (ETR)  and background  regimen but will be followed on study  on a  
modified  schedule  (Appendix  ID) for safety  outco mes. 
 Subjects  will be treated  as clinically  appropriate  per the local  physician.  
 
Grade  4 
 
Acute  anap hylaxi s; life-threaten ing bronchospas m; laryngeal  edema. 
 Subjects  with Grade  4 acute  syste mic allergic  reactions  will be permanently  discontinued from  the 
investigational  medication  (ETR)  AND background  regimen (OBR) but  will be followed  on study  
on a modified  schedule  (Appendix  ID) for safety  outco mes. 
 Subjects  will be treated  as clinically  appropriate  per the local  physician.  
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 
6.15 Manage ment of Abno rmal QTc or PR intervals  noted  onECG  
 
NOTE:  Please  refer  to Appendix  V for grading  of abno rmal QTc or PR intervals  by ECG.  Any subject  
who is  permanently  discontinued  from  the investigati onal medica tion (ETR)  because  of toxicity  will be 
followed  on study  on a modified  schedule  (Appendix  IE) for safety  outco mes. Subjects  will be treated  as 
clinically  appropriate  per the local  physician.  
 
Grade  1 
Continue  study  drug;  routine  monitoring. Grade  2 
 
Continue  study drug;  work -up to  exclude  other  causes according  to judgment  of site  investi gator. Grade  3 
 Study  drugs may be continued  at the discretion  of the site investigator/clinician.  
 Based  on the  local  investigator  reading  of the  ECG, sites  should  request  a turnaround ti me of 24 
hours for the  ECG from  the centralized  reading  service.  
 If the  central  ECG reader  confir ms a Grade  3 ECG abnor mality (QTc  and/or  PR inter val), ETR  
must be permanently  discontinued.  
 For Grade  3ECG  abnor malities  that are deter mined to be unrelated  to study  drug, t he investigator  
should  contact  the team  to deter mine whether  study  drug may be safely  resumed. 
 
Grade  4: Non-Life-Threatening  Toxicity  
 
 Subjects  experiencing a Grade  4toxicity  must have  ETR  discontinued.  
 OBR should  be held at the discretion  of the  site investigator.  
 Based  on the  local  investigator  reading  of the  ECG, sites  should  request  a turnaround ti me of 24 
hours for the  ECG from  the centralized  reading  service.  
 
 
IMPAACT P1090                Page 47 of 113 10 March  2016  
Version 5.0   The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 If the  central  ECG assess ment confir ms Grade  4 ECG abnor malities  (QTc and/or  PR interval),  ETR  
must be permanently  discontinued.  OBR should  be held at the discretion of  the site investi gator. 
 For Grade  4ECG  abnor malities  that are deter mined to be unrelated  to study  drug, t he investigator  
should  contact  the team  to deter mine whether  study  drug may be safely resu med. 
 If subjects  are disco ntinued from  ETR,  they will still be followed on study  on a modified schedule  
(Appendix  ID) for sa fety outco mes. Subjects  will be treated as clinically appropriate  per the local  
physician.  
 
Grade  4: Life-Threatening  Toxicity  
 
 Subjects  experiencing a life-threate ning Grade 4toxicity  must have  ETR  discontinued  
 OBR should  be held at the discretion  of the  site investigator.  
 Sites  should  request  a turnaround  time of 24 hours for the  ECG from  the centralized reading  
service. 
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 For confirmed  drug-related,  life-threatening  Grade  4 QTc  or PR interval  SAEs, study medication  
must  be permanently  discontinued.  
 For life -threatening  Grade  4 ECG abnormalities  that are deter mined to be unrelated  to study  drug, 
the investigator  should  contact  the team  to deter mine whether  study  drug may  be safely  resumed. 
 If subjects  are disco ntinued from  ETR,  they will still be followed on study  on a modified schedule  
(Appendix  ID) for sa fety outco mes. Subjects  will be treated as clinically appropriate  per the local  
physician.  
 
6.16 Manage ment of Neurologic  Adverse Events  
 
NOTE:  Please  refer  to Appendix  VI for grading  abnor mal neurologic  adverse  events. Grade  1 
Continue  study  drug;  routine  monitoring.  
 
Grade  2 
 
Continue  study drug;  work -up to  exclude  other  causes according  to judgment  of site  investi gator. Grade  3 
 Subjects  experiencing a Grade  3toxicity  must have  ETR  discontinued  
 OBR may  be discontinued  at the discretion  of the  site investigator.  
 The protocol  team  should  be notified  of a Grade  3 event  at impaact.p1 090cmc@fstrf.org . 
 For Grade  3 adverse  events  that are determined to be unrelated  to study  drug, the investigator  
should  contact  the team  to deter mine if/when  the study  drug may be safely resu med 
 If the event  is consid ered to be ‘definitely related,’  ‘probably  related’  or ‘possibly  related’  
 to study  drug, AND is  resolved  to grade  2 or less, AND the  site physician  feels  it is in the subjects  
best interest  to re-try the drug, the  investigator  should  contact  the team  to deter mine if/when  the 
study  drug may be safely  resumed 
 If subjects  are permanently  disconti nued from  ETR,  they will still be followed on study on a  
modifi ed schedule  (Appendix  IE) for safety  outco mes. Subjects  will be treated  as cli nically  
appropri ate per the local  physician.  
 
 
IMPAACT P1090                Page 48 of 113 10 March  2016  
Version 5.0   
Grade  4: Non-Life-Threatening  Toxicity  
 
 Subjects  experiencing a Grade  4 adverse event must  have  ETR discontinued  temporarily  
 OBR should  be held at the discretion  of the  site investigator.  
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 For Grade  4 adverse  events  that are determined to be unrelated  to study  drug, the investigator  
should  contact  the team  to deter mine when/if  study  drug may be safely  resumed. 
 If the event  is considered  to be definitely  related,  probably  related  or possibly  related  to study  drug, 
ETR  should  be permanently  discontinued.  
 If subjects  are disco ntinued from  ETR,  they will still be followed on study  on a modified schedule  
(Appendix  ID) for sa fety outco mes. Subjects  will be treated as clinically  appropriate  per the local  
physician.  
 
Grade  4: Life-Threatening  Toxicity  
 
 Subjects  experiencing a Grade  4 toxicity  must have  ETR  discontinued  permanently;  but should  
remain on study  for safety  follow -up. 
 OBR should  be held at the discretion  of the  site investigator.  
 The protocol  team  should  be notified  of a Grade  4 event  at impaact.p1 090cmc@fstrf.org . 
 If subjects  are disco ntinued from  ETR,  they will still be followed on study  on a modified schedule  
(Appendix  ID) for sa fety outco mes. Subjects  will be treated as clinically  
 appropriate  per the local  physician.  
 
 
6.2 Subject  Manage ment 
 
The DMC will  maintain a web page  informing sites as to the availa bility of enroll ment slots per cohort.  
The protocol  team,  including  the co-chairs,  medical  officers,  pharmacist,  and phar macologist,  will respond 
to sites who contact  the team  with questions  regarding  toxicity manag ement, dose modifications,  or other  
issues within  1 business day.  Team responses will include,  at a minimum, the study  team.  
 
Sites  will be given  7 days to  respond to  queries  to allow  the team  to meet Janssen R&D  data delivery  
require ments. Sites  will be contacted  by the  protocol  data manager  or co -chairs regarding  any query  
responses or data  issues  that are outstanding after 7 days.  All  dose modi ficatio ns will be recommended  by 
the protocol team. See Section  3.0 for detail ed infor mation  on the  review  process and  dose modifications  
for a mini-cohort  or full  cohort.  
 
Infor mation  on per mitted ARV changes  can be found in  Section  6.5. 
 
6.3 Definition  of Virologic  Failure for Subject  Manage ment 
 
 
NOTE:  A confir matory  (repeat)  HIV-1 RNA mea surement MUST be  perfor med within 1 to 4 weeks of 
the initial  suspected  failure  or rebound.  
 
Virologic  FAILURE or lack  of res ponse in  this study  is defined  as: 
 
 
IMPAACT P1090                Page 49 of 113 10 March  2016  
Version 5.0   
  A confi rmed HIV-1 RNA at  week  8 that  is not at least 0.5 log  lower  than the HIV-1 RNA at entry  
(unless the viral load at week  8 or later  is already  ≤ 400 copies/ mL) 
OR 
 
  A confi rmed HIV-1 RNA at  or after  week  12 that  is not at least 1 log  lower than the HIV RNA at  
entry  (unless the  viral load at week  12 or later  is already  ≤ 400 copies/ mL 
 
OR 
 
  A confi rmed HIV-1 RNA ≥ 400 copies/ mL at week  24 
Virologic  REBOUND in this study  is defined  as: 
 
For subjects  whose  nadir  was ≤ 400 copies/ mL; a confir med HIV-1 RNA >1000  copies/mL (on 2 
consecutive  measure ments at least 1 week  but no more than 4 weeks apart).  
 
Subjects,  who are  confir med as virologic  failur es (including  virologic  rebound)  as defined  above, should  
follow  the schedule  of evaluations  for V irologic  Failure  as described  in Appendix  IA – 
IC. At the  confir med virologic  failure  visit,  a speci men should  be drawn that  should  be sent for resistance  
testing  (genotyping  and phenotyping),  as described  in Appendix  IA – ID. 
 
Subjects  will then,  at the discretion  of the  subje ct’s clinician; with the approval  of the  protocol team  and 
assuming the subject  agrees  to continue; be moved  into one of the  following  three options:  
 
 Off Study  Drug – On Study:  Be taken  off study  drug and  followed  as per  Appendix  ID, 
‘Follow  up for Subjects  who Disco ntinue  Study  Provided  Etravirine;’  
 
OR 
 
 On Study  Drug – re-optimize OBR:  Have background therapy re-optimized, with the subject 
remaining on study drug;  
 
OR 
 
 On Study Drug:  Continue with no changes made to the current regimen.  
 
Any re -optimization  of backg round  therapy  that includes  exper imental  drugs must first be approved  by the 
P1090 core  team  by emailing  a request  to impaact.p1090c mc@fstrf.org . 
 
6.4 Viral  Resistance  Testing  
 
For all  subjects,  blood  samples  for viral  resistance  assays will  be collected  at screening.  In addition,  to 
evaluate  develop ment of resistance  to ETR  and to other antiretroviral  therapies,  used in  the treatment  
regimen, blood  samples will be collected  at any confir med virologic  failure  (including  virologic  rebound)  
and at any early  discontinuation  visit (if not already  obtained  at virologic  failure)  to assess dev elopment of 
resistance  to ETR  and or OBT.  (Refer  to Appendix  I for more infor mation)  
 
6.5 Permitted Changes  to the ARV Opt imized Background  Therapy  During the  Study  
 
 
 
IMPAACT P1090                Page 50 of 113 10 March  2016  
Version 5.0  Any changes  in background  ARV therapy  after initial  optimization  must be approved  by the P1090 core  
protoc ol team.  Unless the  change  is specifically  permitted,  subjects  who have  one or more  new agents  
added  to the optimized backgr ound CART  regimen will be considered  virologic  failures.  
The following  changes  to optimized backg round  therapy  are permitted during the study. However, the  
P1090 core  protocol  team  requests  that they be notified  of any of these  changes BEFORE  they occur  
(impaact.p109 0cmc@fstrf.or g). 
 
 Subjects  may discontinue  a background  ARV (if  approved  by the  P1090 tea m) and remain on study  
and on study  drug 
 Formulation  substitutions  for NRTI class  (substituting  single  agents  for fixed  dose combinations and 
vice versa  of the  same ARV,  or switchin g from  liquid  to pill/capsule  form) are allowed.  
 Formulation  substitutio ns for PI cla ss (caps ule to tablet or liquid, or vice  versa)  are permitted only  
after discussion  with the P1090 core  proto col team, including  the pharmacologists.  In certain  cases, 
repeat  PK evaluations  may be requested  
 Substit ution within  the NRTI or PI class,  for reasons of toxicity  or intolerance will be considered.  If 
approved,  the subject  will remain on study  drug, with  the new PI, but considered  as a virologic  failure  
if the change  occurs  after the week  4 visit.  
 
 
6.6 Concerns  Regarding  Non-Adherence  
 
In the  rare event  where  the results  of a single  subject’s  intensive PK are  extre mely low, AND the site  
clinician/protocol  team  strongly  suspect  non-adherence,  an additional  subject  may be enrolled i nto the 
mini-cohort to replace the non-adherent  subject.  The non-adherent  subject  may remain on study  and on 
study  drug ( ETR) but will not be considered  for dose -finding  or safety  final anal ysis. 
 
Medication  adherence  is critical  to successful  antiretro viral therapy.  In addition  to compro mising the  
efficacy  of the  curre nt regimen, subopti mal adherence  has implicati ons for li miting future effective  
regimens for subjects  with resistant  strains.  
 
Evidence  indicates  that adherence  proble ms occur  frequently  in children.  Studies  have  reported that  fewer  
than 50% of children  and/or  their caretakers  reported  full adherence  to the regimens. Although  a variety  of 
factors  have  been  associated  with adherence,  no clear  predictors  of either good or poor adherence  have  been  
consistently  identified  in children.  
As a part of this  trial, adherence  to therapy  should be stressed at  each visit, along  with continued 
exploration  of strategies  to maintain and/or  improve adherence.  
 
Multi ple methods  of deter mining  adherence  to ARV therapy  will be used simultaneously  (e.g., quantitative  
self-report, pill count s). Pill counts will take place  at each visit and will be recorded on the  drug 
accountability  form. Adherence  to the study  drug, OBR, and  assess ment of the palatability  of the  study  
drug, will  also be monitored  in the form  of questionnaires/ CRF ad ministered  by the  site staff.  
 
 
 
6.7 Etravirine  Dose Changes  Due to  Increases  in Body  Weight  
 
Confi rmed increases  in subject 's body weight  will trigger  an ETR  dose increase  as follows:  
 
 
 
IMPAACT P1090                Page 51 of 113 10 March  2016  
Version 5.0   If NO PK directed  dose change  was made following  the day 14 (±  4 days)  PK visit,  i.e., the starting  
ETR  dose f rom dosing  tables  provided an adeq uate AUC 12h, then as the subject’s  weight  incre ases 
such that  it crosses into  a higher  weight  band,  the dose will be changed  to correspond  with the new 
weight  band,  consistent  with the Dosing Table provided  in Appendix  III. 
 If an individualized  PK directed  dose ch ange was made following  the day 14 (±  4 days) PK visit,  a 
dose increase  is triggered  when the  subject 's weight  has increased  by 25% from  the weight  at the 
most  recent  AUC 12h evaluation.  Contact  the protocol  team  at impaact.p1090c mc@fstrf.org  for an  
individualized  dosing  recom mendation  based  on the subject 's pharmacokinetic  parameters.  
 
There  will be no 12 -hour phar macokinetic  studies  for dose adjust ments due to increase  in body weight.  
 
 
6.8 Criteria  for Etravirine  (Study  Drug) Discontinuation  
 
The following  are criteria  that will result  in discontinuation  of study  treatment (ETR).  Subjects who are  
withdrawn  from  study  drug within  the first 48 weeks of study  will not enter  long term follow -up, but will 
be followed  for safety  for 4 weeks, as per  Appendix  ID. 
 
Addition ally, any AEs will  be followed  until satisfactory  clinical  resolution (i.e. value retur ns back  to 
subjects  baseline  value)  or stabilizat ion (to be agreed  upon with  the sponsor).  All  Grade  3 and  Grade  4 
laboratory  abnor malities  as well  as any  laboratory  abnor malities  resulting  in an increase of 2 DAIDS 
grades  from baseline  will be followed  until they return to baseline or within  1 grade  from  baseline.  
 
 Grade  3 or higher  events  that are believed  to be related,  or possib ly related,  to study  drug 
 Treat ment with disallowed  medications  
 Grade  3 or higher  cutaneous  reactions  as ou tlined  in section  6.13, that  are not clearly rel ated to a 
specific viral illness 
 Grade  3 or higher  acute  syste mic allergic  reactions  as outlined  in section  6.14, that  are related  to 
study  drug 
 Other  Grade  3 or higher  toxicities  that don’t  resolve  to < Grade  3 
 Grade  3 or higher ECG toxicities  (QTc  and/or  PR interv al) as outlined in Section  6.15, that  are 
deemed related  to study  drug 
 Grade  3 or higher neurologic  adverse  events  as outlined in Section  6.16 
 For subjects  who have  an AUC >  4380ng.h /mL, but who cannot  be dose reduced  
 Non-adherence  to study  medication  or study  medication  administration instructions  
 New data  beco me available  that indicate  treatment shou ld be discontinued  
 Subject  declines  further  study  visits,  including  PK visits  
 
 
6.9 Criteria  for Study  Discontinuation  
 
Following  are criteria  for study  discontinuation:  
 
 The parent or legal guardian refuses to allow the subject further treatment and/or follow -up 
evaluations.  
 The investigator determines that further participation would be detrimental to the subject’s health 
or well -being.  
 
 
IMPAACT P1090                Page 52 of 113 10 March  2016  
Version 5.0   The subject fails to comply with the study requirements so as to cause harm to him/herself or 
seriously interfere with the validity of the study results.  
 
7.0 EXP EDITED ADV ERSE EVENT REPORT ING 
 
7.1 Adverse Event  Reporting  to DAIDS  
 
Require ments, definitions  and methods  for exp edited  reporting  of Adverse Events  (AEs) are outli ned in 
Version 2.0 of the  DAIDS EAE  Manual,  which  is available  on the RSC website  at: http://rsc.tech -
res.co m/safetyandphar macovigilance/ . 
 
The DAERS internet -based reporting system  must be used for expedited  AE reporting  to DAIDS.  In the  
event  of system  outages  or technical  difficulties,  expedited  AEs may be submitted via the DAIDS EAE  
Form. For questions  about  DAERS,  please  contact   CRMSSupport@niaid.nih.gov  or from within  the 
DAERS appli cation  itself. 
 
Sites  where  DAERS has not  been  implemented  will submit expedited  AEs by docu menting  the in formation  
on the  current DAIDS EAE  Form. This form is availa ble on the  RSC websit e: http://rsc.tech -
res.co m/safetyandphar macovigilance/ . For questions  about  EAE  reporting,  please contact  the RSC 
(DAIDSRSCSafetyOffice@tech -res.co m). 
 
7.2 Reporting  Require ments for this  Study  
 
 
 The SAE R eporting  Category,  as defined  in Version 2.0 of the  DAIDS EAE  Manual,  will be  used 
for this  study.  
 
The study  agent  for which  expedited  reporting  is required  is Etravirine  
 
 In addition  to the EAE  Reporting  Category  identified  above,  other  AEs that  must be reported  in an 
expedited  manner  are: 
 Erythe ma multi forme 
 Suspected  trans mission  of an  infectious  agent  by study  product  (as required  by Vol. 9A, section  5.9 
of the  Rules  Governing  Medic inal Products  in the European  Union – Guidelines  on 
Pharmacovigilance  for Medicinal  Products  for Hu man Use.  Such reporting  is required  irrespective  
of the  presence  of other  seriousness criteria.)  
 
7.3 Grading  Severity  of Events  
 
The Division  of AIDS Table  for Grading  the Severity  of Adult  and Pediatric Adverse Events  (DAIDS AE 
Grading  Table , Version 1.0, December 2004, Clarification August 2009 ) is used and  is available  on the  
RSC website  at http://rsc.tech -res.co m/safetyandphar macovigilance/ . 
 
To grade  to the severity  of any  abnor mal QTc or PR intervals,  the DAIDS  AE grading  table  for these  
events  are described  in Appendix  V. 
 
To grade  the severity  of any  neurologic  events,  sites should  use the  grading  table  in Appendix  VI. 
 
 
IMPAACT P1090                Page 53 of 113 10 March  2016  
Version 5.0   
7.4  Expedited  AE Reporting  Period  
 
 The expedited  AE reporting  period  for this  study  is as per the EAE  manual. 
 After  the protocol -defined  AE reporting  period,  unless oth erwise  noted,  only SUSARs as defined  in 
Version 2.0 of  the EAE  Manual  will be reported  to DAIDS if  the study  staff beco me aware  of the  
events  on a passive basis (from publicly  available  infor mation).  
 
NOTE:  For reporting  of all  adverse  experiences  the Investigator  will deter mine the causality  and relations hip 
to study  drug.  However, in  regards  to subject  safety  and PK evaluations  which  will support t he selection  of 
a dose for a  given  cohort,  the protocol team  will also have  input  as to  the causality  and drug relation  of 
specific  adver se experie nces. 
 
8.0 STATI STICAL  CONSIDERAT IONS 
 
 
8.1 General  Design Issues  
 
This is a Phase I/II multicenter,  open label  study  with primary objec tives of assessing  the safety/tolerability  
and pharmacokinetics  of ETR  in combination  with optimized background regi men (OBR) ad ministered  to 
HIV-infected  treatment-experienced  children  within the age range  of ≥ 2 months  to < 6 years.  
 
Hypothesis:  ETR  will be safe, well tolerated,  will have  pharmacokinetics  comparable  to adults and  will 
demonstrate  antiviral  activity when used with  an optimized background  therapy  in HIV- 
1-infected,  treatment experie nced infants  and children.  
 
The sample will be stratified  into the following  age groups:  
 
Cohort  I ≥ 2 years  to < 6 years  of age  who are  treatment experie nced*  
Cohort  II ≥ 1 year  to < 2 years  of age  who are  treatment experie nced*  
Cohort  III: ≥ 2 months  to < 1 year  who are  treatment experienced * † 
 
*Treat ment experienced c hildren on  a failing c ombination antiretro viral regimen (containing at least  3 ARVs)  for at least 8 
weeks  OR Treatment experienc ed children  on a treatment interruption of at least  4 weeks wi th a history of virologic failure 
while on  a combination antiretro viral re gimen (co ntaining at least 3 ARVs)  
†Subjects below 6 months of age will only be enrolled upon availability of initial safety and PK data from subjects between 6 
months and 1 year of age.  
 
A minimum of 12 subjects  will be enrolled  into each cohort  of the study.  Up to 18 subjects may be enrolled 
into Cohort 1. The total sample  will include  at least 36 evaluable  subjects  who have  been  treated  exclusively  
at the doses judged  to be opti mal for their  age cohorts.   
 
NOTE: For the Week 24 (or Week 48) analysis, evaluable will be defined as having been treated 
exclusively on the dose determined to be optimal for a given age cohort and having either completed 24 
(or 48) weeks of exposure to the study drug or having been classified as a safety fai lure, due to a study 
drug related adverse event occurring during the first 24 (or 48) weeks of treatment.  
 
 
 
IMPAACT P1090                Page 54 of 113 10 March  2016  
Version 5.0  Accrual  to the study  will follow  an algorithm  in which  younger  children’s  (Cohort II and Cohort III) exposure  
to the study medication  is contingent  upon the  older  age cohort  (Cohort I) having  passed the  safety  criteria.  
In addition, sufficient  pharmacokinetic  data will be requir ed to deter mine the starting  dose for the  younger 
cohort  (see Section  3.3-3.4 for details).  
 
Initial  tests of safety  and PK will examine data from  the first 6 subjects  (mini-cohort)  of Cohort  I to 
deter mine whether  Cohort  II and Cohort III will be allow ed to open  for its  mini-cohort  of 6 subjects.  
Subjects below 6 months of age will not be enrolled until there are initial  safety and PK data from subjects between 
6 months and 1 year of age . These  tests will proceed  as follows:  
 
  The PK data  for the  first six subjects  of the  Cohort  I will  be evaluated  on the  basis of blood sa mples 
taken  14 days ±4  days after  the start of therapy.  
 
  Safety will be evalu ated on the  basis of all avail able data collected  throu gh the 28th day on the  dose 
that is being  evaluated  (see Section  8.51 for the  safety  guidelines  to be used in  the dose -finding  
algorith m). 
 
  For subje cts failing  to meet PK targ ets and requiring  individ ual dose a djustments, safety will be  
evaluated  on the  basis of data  gathered  until the time of the visit at which  the dose is adjusted.  This 
will insure that, for subjects  needing  PK dete rmined dose adjust ment, adverse events  attributed to 
the starting  dose must  have  occurred  while  the subjects were  still on that dose. However, t his also 
means that for such  subjects  the safety  of the  starting  dose may be assessed on the  basis of less than  
28 days of study  drug exposure.  
 
The overall  safety  and PK data  of the  first 6 subjects  on a given  cohort  will be evaluated  with respect  to the 
guidelines  specified  in Section  8.512 and  in Section 9.0 of the  protocol.  Once  these subjects  have  passed 
both PK and  safety  criteria, 6 additional  subjects  will be accrued  to complete  each cohort  (up to 12 
additional subjects may be accrued to Cohort I) . The full cohort  must also pass the  PK and  safety  criteria  
(see Section  8.513 and  Section  9.0). If the  mini or full  cohort  fails either  the safety  or the  PK guidelines,  
then the  starting  dose will  be adjusted  in the approp riate direction,  (upwards for inadeq uate PK value s; 
downwards for sa fety failure), if this is feasible.  Subjects  in a cohort that failed  PK or safety  but were  
recei ving the same dose as that  recom mended  in the new dosing  cohort will be included  in PK and  safety 
analy sis of the new dose and additional  new s ubjects  will be enrolled as appropriate  at the new dose in  
order  to have  a mini-cohort  of 6 subjects  treated  with the new dose.  An initi al evaluation  of safety and PK 
will be made on the  basis of data from these subjects.  The evaluation  will proceed as describ ed above.  In 
the event  that the mini- or full cohort  fails the PK criteria  before  the cohort  completes accrual,  then safety  
will be evaluated  on all  available  subje cts to confirm that a dose increase  is not contr aindicated.  
 
If the  P1090 core  protocol  team  judges  a given  subject’s  PK data  to be unevaluable,  the subject will  be 
replaced for dose  finding  purposes. Note  that the subject  would be  replaced for evalu ating safety,  as well  
as PK, criteria,  since  unevalua ble PK data  would ref lect uncertainty  about appropriate  exposure  to the 
study  medication.  
The study  accrual  is designed  to yield  at least 36 evaluable  subjects  for the Week 24 (and  48) safety  
analyses, which  analyses  will occur  when  the last subject of the  last cohort  has reached week  24 (or Week 
48).  For these  safety analyses,  “evalua ble” will be defined as havi ng been treated  exclusively  on the  dose 
deter mined to be optimal for a given  age cohort  and having  either co mpleted  24 (or 48) weeks of exposure  
to the study  drug or having  been  classified  as a safety failure,  due to a study  drug related  adverse  event  
 
 
IMPAACT P1090                Page 55 of 113 10 March  2016  
Version 5.0  occurring  during  the first 24 (or 48) weeks of treat ment. Although  the primary safety  analyses  will focus 
on the  effects  of exposure  to the opti mal dose level  for 24 and  48 weeks, secondary  analyses will include  
all safety  data collected from  first subject  expos ure to 24 (or 48) weeks  and until the end of the  study.  This 
will inclu de data  representing  the final dose for each  cohort,  as well  as data  gathered  during  the dose 
finding stage  which  may represent  exposure  to doses which  have  failed.  This will also include  data from 
subjects  whose individual  doses have  been  adjusted, with results  broken  down by the  times at which  
different  dose levels were  taken. 
 
 
8.2 Endpoints  and Outco me Measures  
8.21 Primary Endpoints: 
Toxicity  Endpoints:  
 
 Termination  from  treatment  due to a suspected  adverse  drug reaction  (SADR)  
 Adverse events  of Grade  3 or higher  severity  
 Death  
 
Pharmacokinetic  Endpoint:  
 
 Failu re to meet  PK tar gets (specified  in Section  9.0) 
 
8.22 Secondary  Endpoints:  
 
 Adverse events  of Grade  3 or higher  severity  judged  to be at least possibly  attributable  to the  study  
medications  
 Confi rmed failure  to suppress plasma  HIV-1 RNA to  ≤ 400 copies  
 AND  
 Failu re to achieve  at least a 2 log  reduction  (from  baseline)  in HIV-1 RNA at  weeks 24 and/or  48 
(confir med in 1 to 4 weeks)  
 Treat ment discontinued  due to toxicity or virolo gic failure 
 Change  in optimized background  regimen due to virologic  failure  
 New onset  OI or AIDS diagnosis  
 Decline  in absolute  CD4 perce nt of > 5% any  time after 12 weeks of therapy  
 
8.23 Primary Response Variables:  
 
 Pharmacokinetic parameters - AUC12h  
 
8.24 Secondary  Response  Variables:  
 
 Plasma HIV-1 RNA (copies/ mL) 
 CD4 counts  and percent  
 CD4/CD8 r atio and percent  
 Genotypic  and phenotypic  measures  of resis tance at virologic  failure  and at early discontinuation  
 
 
IMPAACT P1090                Page 56 of 113 10 March  2016  
Version 5.0   Pharmacokinetic  parameters  - C12h and Cmax 
 
8.25 Exploratory  Response Variables:  
 
 Patient -specific  CYP gene  profiles.  
 
 
8.3 Rando mization  and Stratification  
 
There  will be no randomization.  Subjects  will be enrolled into one of the  three  cohorts  described in  the 
“General  Design Iss ues” section  above.  
 
 
8.4 Sample Size and Accrual  
 
8.41   Pharmacokinetics  
 
Sample size for this  study was esti mated using a pharmacokinetic  modeling  and simulation approach.  
Details  of this  approach  are provided  in Supple mental Document  I. Briefly,  the objectives  of this  approach  
were  to ensure  that 1) the  mean value  of ETR  apparent  oral clearance (CL/F)  has a  standard  error  <20%  on 
80% of occasions  and 2) that the 95% confidence  interval for CL/F  is 60 to  140% or 60 to  166.6% of the  
point  estimate of the  geometric mean on 80% of occasions  in each of the  above  age groups. A t hird 
approach  was develo ped and consisted  of simulation -estimation  platform  incorporating  data from  previous  
trials.  It was used to  deter mine the  number of pediatric  subjects  required  across t he age range  of 2 months  
to <6 years  to ensure the  median  estimate for CL/F  for a typical  subject  within  each age group has  a 
reported  standard deviation  <20%.  Based  on a pharmacokinetic  model adapted  for pediatric  maturation  and 
incorporating  prior  data, a minimum of 12 subjects  in each age group is  deemed sufficient  to provide  
pharmacokinetic  data for ped iatric subjects treated  with ETR.  
 
8.42  Safety  
 
Total  accrual  will depend upon the  number of subjects  who must  be accrued  to yield  a minimum of 36 
evaluable  subjects  for purposes  of the  primary  safety  analyses.  There  is some uncertainty concer ning the 
number needed  to complete  the dose finding  procedures  and the number who may be  lost to follow -up for 
reasons other  than treatment failure. Each  succe ssful age cohort will include  at least 12 subj ects. In tot al, it 
is anticipated  that approxi mately  50 subjects  may need  to be  enrolled  in the protocol  to yield  36 evaluable  
subjects  for the  weeks 24 and  48 safety  analyses . 
 
Table  7. Percent  of Subjects  Exper iencing  Grade  3+ Adverse  Events (or Grade  3+ Adverse  Even ts 
Attributed  to the Study  Medication)  with  Exact  95%  Confidence  Intervals  
N No. of Subjec ts (% ) With  Grade  
3+ Adverse Events  
95% C.I. 
12 0 (0%) 0% -- 26% 
24 0 (0%) 0% -- 14% 
36 0 (0%) 0% -- 10% 
12 1 (8%) 0.2%  -- 38% 
24 2 (8%) 1% -- 27% 
 
 
IMPAACT P1090                Page 57 of 113 10 March  2016  
Version 5.0  36 4 (11%) 3% -- 26% 
12 3 (25%) 5% -- 57% 
24 6 (25%) 10% -- 47% 
36 9 (25%) 12% -- 42% 
12 4 (33%) 10% -- 65% 
24 8 (33%) 16% -- 55% 
36 11 (31%) 16% -- 48% 
 
Table  7 presents  exact  95% confidence  interva ls around  various  potential  rates  of Grade  3+ adverse  events  
which  might  be observed  in a total sample of 36 evaluable  subjects,  a sample of 12 subjects  representing  a 
minimal sample  that might be accrued  within  any age stratum and potential  sample  size that might occur  if 
a subg roup of N =  24  was analyzed.  This table  indicates that  confidence  intervals  will be wide around  the 
minimal sample  size of 12 subjects  within  a given  stratum,  but would be  reasonably  precise  around  a 
sample  size of 36 subjects.  
 
8.5 Monitoring  
 
The study  will be monitored  intensi vely by the  core protocol team  which  will review  safety  and 
pharmacokinetic  data at least twice  a month during  the dose-finding  stage  with the aim of deter mining  the 
optimal dose for each cohort  while protecting  patient  safety.  In addition , the IMPAACT Network will  
appoi nt a study monitoring committee (SMC) to  provide  independent reviews  when necessary  to ensure  
subject  safety.  In acc ordance with IMPAACT and  DAIDS procedu res, this committee will be composed  of 
two individ uals from the Primary Scienti fic Com mittee,  one PDMC member  and a statistician,  independent  
of both the P1090 protocol  team and  drug manufacturer  (Janssen R&D).  Me mbers of said study  
monitoring  committee will have: 
 
1) No financial  interest  in the study;  
2) No planned  authorship  in publication  of study  results;  and 
3) No involve ment in the conduct  of the  study.  
 
8.51 Safety  Guidelines  
 
8.511   Evaluation  of the  Starting  Doses During the  Dose -Finding Stage  
 
The attribution  of relationship  of serious adverse  events  to study  drug for the  purposes of e mploying  the 
start,  stop and pause  rules  speci fied below  will be by consensus a mong the site investigator,  the protocol  
team  and the DAIDS medical  officers.  If unanimous  agree ment between  them  cannot  be established,  the 
relevant  data will be reviewed  by the  independent  Study Monitoring  Com mittee as described  above,  which  
will make the final judgment concerning  the relations hip between  study drug and  the adverse event.  Within 
this committee  the decision  will be deter mined by the  majority  opinion of this  study’s inde pendent  Study 
Monitori ng Com mittee cli nicians. 
 
 
 
IMPAACT P1090                Page 58 of 113 10 March  2016  
Version 5.0  Gradation  of relations hip will use the  following  terminology:  
 Not rel ated 
 Probably  not related  
 Possibly related  
 Probably  related  
 Definitely  related  
 
An event  judged  to be at least possibly  related  to the study  treatment will be considered  to be a Suspected  
Adverse  Drug Reaction  (SADR) for p urposes of the  dose finding  algorithm  which follows.  
 
8.512   First  Six Subjects  Started  at a Given  Dose Level  in Each  Cohort  
 
For each  study cohort (Cohort I, Cohorts II & III combined) , the frequency  of adverse  react ions to the 
starting  dose of the  study  medication will  be evaluated  on the first 6 subj ects. The data will extend to the 
week  4 visit  for subjects  not requiring  dose adjust ment or un til the visit on which  the dose is  adjusted,  as 
described  above. Further  accrual  into this cohort  will be contingent  upon meeting  the following  safety  
guidelines:  
 
If any  of the  first 6 subjects  has a  life threatening  SADR or any  Grade  4 event  or death  that is probably  or 
definitely  attributable  to the study  medication  or 3 or  more subjects  have  terminated  study  drug due to a 
Grade 3+ at least possibly  treatment related  SADR, stop  accrual  into this study cohort (Cohort I, Cohorts II 
& III combined) until a safety  review  by the  P1090 core  protocol team  is conducted.  If no ne of the first  6 
subjects  has experienced  a life-threateni ng SADR or a  Grade  4 event or death  that is probably  or definitely  
attributable  to the study  medication  and at most 2 of these  6 subjects  has ter minated  study  drug due  to a 
Grade  3+ at least possibly  treatment related  SADR, th en this cohort  has passed the  initial  safety  guidelines.  
If these  6 subjects  also meet the PK guidelines, accrue  more subjects  to this cohort and evaluate  the safety  
and PK results  of the  overall cohort.  
 
In cases  where  the mini-cohort  has failed  either  the safety  or phar macokinetic  guidelines,  the P1090 core  
protoc ol team  will conduct a thorough review  before  proceeding  with accrual  to the study.  All of the  
relevant  safety  and pharmacok inetic  data will be examined to deter mine whether  it is safe to continue  the 
attempt  to find an optimal dose for this  cohort.  If the  P1090 study  team deter mines that it is safe to 
proceed,  it will make speci fic changes in dosing and monitoring  procedures  which  may be indicated.  If 
there  are any concerns  regarding  safety,  the study’s Stu dy Monitori ng Com mittee will then review  all of 
the releva nt safety  and pharmacokinetic  data, along  with the recom mendations  of the  core protocol team, 
and will deter mine whether  and under  what  conditions  further  dose finding  activities  for this  cohort  may 
proceed.  
 
The protoc ol will only proceed  if this review  has led to a recommendation  that it is safe to do so. The  
safety  review  may lead to a recommendat ion that the dose be  de-escalated.  Before i mplementing  such a  
recom mendation,  the P1090 core  protocol team  will review  the PK data  to deter mine whether  a lower dose 
is likely  to achieve  adequate  drug exposure.  
 
Given  the small sample sizes  within  each cohort,  the infor mation  availa ble for preli minary safety decisions  
will be imperfect. Two types  of sa mpling  errors are  possible:  1) in a cohort  where  the true  rate of toxicity  
is too high to warrant  increased  exposure  to the current  starting  dose of the medication,  the sample data 
may pass the  safety  guidelines;  and 2) in a cohort  where  the true rate of toxicity  is low enough  that further  
 
 
IMPAACT P1090                Page 59 of 113 10 March  2016  
Version 5.0  exposure  to the current  starting  dose is  warranted,  the sa mple data may fail the guidelines.  
 
The extent  to which  the safety  guidelines  protect against  the errors described  above  can be assessed by 
examining  various  hypothetical  rates  of "true  toxicity"  which  could  occur,  if the study  medication  were  
used extensively  among the patient  population  at the dose level  under  question.  The hypothetical  
situations  presented  in the immediately  succeeding  table  range  from  conditions under  which  a given  dose 
level  would cause  a high incidence  of severe  and life threatening SADRs to  conditions  under  which  severe  
SADRs would be  relatively  rare and would not  be life threatening.  For each  of these hypothetical  
situations, we ass ume that a sample  of 6 subjects  is drawn from  the patient population  and that the safety  
guidelines,  summarized  above,  are followe d. 
 
Table  8 shows that  there  is a 78% chance  of failing  the safety  guidelines  under  conditions  in which  the true 
rate of life -threa tening  toxicity  is 5% and  the rate of non -life threatening  SADR is  50%.  Assu ming that it 
would be  undesira ble to accrue  additional  subjects at a dose that  had these  true rates  of adver se events, the 
22% chance  of NOT f ailing the safety  guidelines  would  repre sent the probability  of err or. The table  also 
shows that  there  is a 0.2 % chance  of failing, when the  true rate of non -life threatening  SADR is  only 5% 
and the true rate of life  threatening SADR is  zero.  Assu ming that the potential  benefits  associated  with 
expo sing additional  subjects to  this dose of the  drug would  outweigh  the risks associated  with this 
relatively low rate of toxicity,  failing  the safety  guidelines  under  these  conditions  would be  an error.  
  
 
 
IMPAACT P1090                Page 60 of 113 10 March  2016  
Version 5.0  Table  8. Probability  of Failing  Dose  Escalation  Guidelines  under Potential  Rates  of True  Toxicity  
True  Toxici ty Rates   
 
Probabili ty of 
Failing  Safety 
Guidelines  Non-Life Threatening  SADR  
that would  result in treatment 
discontinuat ion, exclud ing Grade  
4 events  probably or defin itely 
attributable  to study  medication   
Life Threate ning SADR  or 
Grade  4 events  probab ly or 
definitely  attributable  to study 
medication  
0.50 0.00 0.67 
0.50 0.05 0.78 
0.50 0.25 0.98 
0.25 0.00 0.17 
0.25 0.05 0.41 
0.25 0.25 0.88 
0.05 0.00 0.002 
0.05 0.05 0.27 
0.05 0.25 0.82 
0.00 0.05 0.26 
0.00 0.25 0.82 
 
 
 
8.513   Total  Group of Subjects  (Minimum of Twelve) Started  at a Given  Dose Level  of Each  Cohort  
 
The final safety  guidelines  applied  to a given starting  dose of the  study  medication  within  a cohort  will 
make use of data  from  all subjects  started  at that dose. The  data will extend to the week  4 visit  for subjects  
in the cohort  which  do not  require  PK deter mined dose adjust ments or until  the visit on which  the dose is  
adjusted,  as described above. If none  of these  subjects  has experienced  a life-threatening  SADR or a  Grade  
4 event  or death  that is probably  or definitely attributable  to the study  medication  and no more than 25% 
terminated  study treatment due to Grade  3+ at least possi bly treatment related  SADR, then  this starting 
dose will pass t he safety guidelines  for the  cohort  under  investigation.  
 
If any  of these  subjects  has a life threaten ing SADR or any  Grade  4 event  or death  that is probably  or 
definitely  attributable  to the study  medication  or more  than 25% ter minated  study tre atment due to Grade  
3+ at least possibly  treatment related  SADR, this  starting dose will fail the  safety  guidelines  for the  cohort  
under  investigation.  If this  occurs,  the core protocol  team will  review  all of the relevant  safety and 
pharmacokinetic  data in an attempt to determine whether  it is safe to continue  the attempt  to find an 
optimal dose for the  said cohort.  
 
If the  P1090 study  team  deter mines that it is safe to proceed,  it will make specific  changes  in dosing  and 
monitoring  procedures  which  may be recom mended.  If there  are any concerns resulting  from  an 
inconclusive  safety/PK  study  team  review,  the study’s independent  Study Monito ring Com mittee will then 
review all of the relevant  safety and pharmacokinetic  data and will  deter mine whether  and under  what  
conditio ns further  dose finding  activities  for this cohort may proceed.  
 
 
 
IMPAACT P1090                Page 61 of 113 10 March  2016  
Version 5.0  8.52 Study  Safety  Monitoring  
 
Since  Phase I and  Phase II stu dies are not routinely reviewed  by a Data  and Safety  Monitoring Board  
(DSMB), it  is the responsibi lity of the  Protocol  Team  to interpret  safety  data,  and make deci sions regarding  
SADRs that  are needed  to protect  subjects  from  undue  risk. In addition,  the Study  Monitoring  Committee  
descri bed above  is appointed  to provide  impartial  revie ws in situ ations  where patient safety is in question.  
 
For safety  monitoring,  a drug related  SAE is  an SAE that  is judged  to be “definitely”,  “probably”  or 
“possibly  related”  to study  drug ( ETR). 
 
The safety and tolerability  of the study agent  will be monitored  by means of adverse  events reports  and 
toxicity  reports  prese nting laboratory  and clinical  events.  It is required  that the data required  for the  
toxicity  reports  be entered  into the database  within  48 hours of the  time at which the  results of the 
labor atory tests or cli nical examinations  beco me available.  
 
Reports  compiled  by the  Data  Manage ment Center  (DMC) will  be reviewed  and discussed by the Protocol  
Team  on conference  calls held at least twice  a month during  the dose-finding  stage  and every  month 
thereafter  and by the  study ’s Study  Monitoring  Com mittee under  conditions specified  above. Data  on 
accru al, pharmacokineti cs and toxicity will be reviewed.  
 
Adverse events  will be monitored  from  scree ning onwards throughout  the follow -up period.  If the pr otocol 
team  identi fies any potentially treatment -related toxicities,  which may compro mise subject  safety,  the study  
will be paused and the Study Monit oring Com mittee will review  all rele vant data and will determine 
whether,  and under what  conditions,  the study  would be  allowed to  proceed.  
 
8.521   Rules  for Suspending  Accrual  to Assess Safety  Following  an Adverse Event  
 
Accrual  will be temporarily  suspended if  any subject  has a  life threatening  Suspected  Adverse Drug 
Reaction  (SADR), or deat h, or any  Grade  4 event  that may not be judged  to be life- threatening  but is 
judged  to be probably  or definitely  attributable  to the study  medication.  
 
Following  temporary  suspension of accrual,  the Study Monit oring Com mittee will be convened and  will 
further  review the safety  data within  48 hours of notification  of the  event  to deter mine if continuation  of 
accrual  is appropriate.  If the  Study Monitoring  Com mittee agrees  that the study drug is  likely to be safe for 
additio nal subjects,  they may allow  accrual  to resume. Regulat ory agencies  will be notified  of the  event  
and the team’s  decision  after this review  of the  safety  data has taken  place. 
 
8.522   Accrual  Rate Evaluation  
 
Accrual  to this study  will be monitored  by the  IMPAACT leaders hip in accorda nce with standard operating  
procedures.  The team  will monitor  feasibility  quarterly,  first based on site  registration and  then on accru al. 
Initially,  the team will monitor site registration monthly  to ensure that an adequate  number  of sites  have  
registered  to complete  the protocol.  If relatively  few of the  eligible sites have  registered after the protoc ol 
has been  approved for 6 months,  the team will re- assess the  feasibility  of the  protocol  and the reasons why 
sites have  not registered,  and may amend the protoc ol accordingly.  Once one-third  of eligible  sites have  
registered,  the team will assess accrual  on a quarterly  basis.  If any  cohort  during  the dose-finding  stage  has 
 
 
IMPAACT P1090                Page 62 of 113 10 March  2016  
Version 5.0  not accrued half  its subjects within 6 months  of opening,  the team  will identify  the reasons  for lack  of 
accrual and  possibly  amend the protocol  accordingly.   
 
A trial go/no -go decision point will be set approximately 2 years after opening of Cohort 2. At that time, 
an analysis across all age cohorts (irrespective of the number of enrolled subjects or length of follow -up 
within each age group and across the age groups) will be performed, for the purpose of complying with 
regulatory requirements for Janss en R&D. In addition, accrual rate and all of the relevant safety and 
pharmacokinetic data will be examined to determine whether it is safe and worth to continue the trial in an 
attem pt to find an optimal dose for C ohorts II and III.  
 
8.523   Long  Term  Follow-Up for S afety 
 
Subjects  who successfully  complete  48 weeks of ETR  treatment  will be followed  for clinical long  term 
safety follow  up every  12 weeks.  Sites  should  refer  to Section  5.5 and  Appendix  IE.  
 
8.6 Analyses  
 
8.61  Sum mary of Dose Finding  Data  
 
The analysis  of dose finding  data will consist  of descri ptive statistics summarizing  the safety and PK data  
from  the dose finding  phase  of the  study. (See Section  9.0 for PK analysis).  The safety data  will be 
analyzed  by cohort  and will present  the results of the safety  evaluations  applied  to each  starting  dose 
regimen tested  within each cohort, including  infor mation  indicating  which starting  doses have  passed or 
failed  the safety  guidelines.  For each  starting  dose within  each cohort,  every adverse  event of Grade  3 or 
higher will be listed, along  with subject  demographics, the  dose prescribed  to the patient  at the time of the 
event  and the protocol  team’s assess ment of the  probability  that this event  was due  to the study treatment 
(not related, probably  not related, possibly  related,  probably  related  or definitely  related).  
 
8.62 Analysis of Data  Representing  Exposure  to the Doses Judged to  be Optimal for Ea ch Cohort  
 
These  analyses will be stratified  by cohort.  The findings  will be prese nted in both in aggregate and  broken  
down by cohort,  with estimates bound ed by 95% confidence  limits. Given  that the small sample sizes  
within  cohorts  will provide  limited power for statistical  tests of differences across a ge cohorts,  
interpretat ion of the  results will depend  upon whether  differences  across cohorts  are great  enough  to be 
considered  to be clinically  signif icant.  If no such differences  are observed,  then the clearest  interpretation  
of the  findings  will come from  the aggregated  data, where  analyses will have the greate st statistical 
precision. However, if  results vary across cohorts to  a clinically  important  extent,  interpretation  of results  
should  take into account  the issues represented  by the  stratification  factor.  
 
8.63 Primary Analyses - performed on data through  the Week 24 and  Week 48 visit  
 
8.631   Safety  
 
The primary safety  analysis  will include  only subjects  whose total  exposure  to ETR  has been  at the  dose 
judged  to be optimal for their  cohort s. Subjects  whose doses have  been  adjusted  for inadequ ate PK will  be 
excluded.  Subjects  who have  been  removed  from treatment or have  had their  doses reduced  due to 
toxicities while  on the optimal dose will  be included  and treated  as safety  failures  in the primary safety  
 
 
IMPAACT P1090                Page 63 of 113 10 March  2016  
Version 5.0  analy sis. Additio nal analyses  will look at the combined  data from  subjects  whose doses failed  and those  
who have  been  treated  solely  at the optimal doses deter mined for their cohorts and without individual PK 
determined dose adjust ments. Sensiti vity analyses  will be perfor med to determine  whether the exclusion  of 
subjects  whose doses have  been  adjusted  creates  a selection  bias which  impacts upon any  results.  
 
Each  subje ct’s safety data will be summarized  as: the worst grade of adverse event experie nced during  the 
first 24 weeks (and  48 weeks) of expo sure to the optimal dose of the  study  treatment and  the worst grade  
of adverse  event  judged  to be at least possibly  related  to study  treatment during  this time period.  Frequency  
distributions  of these  safety  outco mes will be presented in the aggregate  and broken  down by age.  Listings  
of all Grade  3+ events  will be provided,  broken down by type  of toxicity  (hepatic,  hematologic  etc.).  
 
The proportions  of subjects  experie ncing Grade  3+ adverse  events  will be presented  in aggregate and  
broken  down by age  cohort,  with these  proportions  bounded  by exact  95% confidence int ervals.  Similar 
analy ses will present the proportions  of subjects exhibiting Grade  3+ events which  have  been  judged  to be 
at least possibly  related  to study medication,  again  bounded  by exact  95% confidence  intervals.  
 
8.632  Key Secondary  Analyses  
 
8.6321 Viral  Load  
Virologic o utcomes, based on HIV -1 RNA (copies/ml), will be asses sed at weeks 8, 12, 24 and  48.  The 
criteria for success are: at least a  0.5 lo g10reduction in HIV -1 RNA (copies/ml) at week  8, at least a 1 log10 
reduction in HIV -1 RNA (copies/ml) at week 12 and either HIV -1RNA ≤400 copies/ml or at least a  2 log 
reduction in HIV -1 RNA at weeks 24 and 48.  
 
For regulatory  submissions,  at each of these  time points  the primary definition  of virologic outco me will be 
calculated  accor ding to a Missing, Switch  or Discontin uation  = Failure  (MSDF) algorithm  – as codified  by 
the FDA’s snapshot algorith m. Subjects  may be classified  as virologic failures  if they have  missing  HIV-1 
RNA data throughout  the window surrounding the  time point of intere st. (This  window and  related  details  
will be defined  in the analysis plan.) In addition subjects  will be classified  as virologic  failures  at any of 
these  time points  if they meet any of the following  conditions  prior  to that time point:  
 
a) Discontinuation  of study  treatment due to reasons  other  than AE or death  and viral load was >  400 
copies/ mL at last available  visit.  
b) Change  in background  therapy  not allowed  in the protocol.  
c) Change  in backgrou nd ART substitutions  permitted per protoc ol unless the decision to switch  is 
docu mented  as being  before  or at the first on-treatment visit where  HIV-1 RNA is  assessed (Week  
4). 
 
Subjects  who only  discontinued  a background  ARV or who had  formula substitutions (substituting  single  
agents  for fixed  dose co mbinat ions and vice versa  of the  same ARV) in  their OBT are  not conside red as 
having  OBT changes  and will not be analy zed as vir ologic  failures. Otherwise,  virologic success will  be 
defined  as having  HIV-1 RNA ≤400 copies/ mL by the  last available  HIV-1 RNA assess ment while  the 
subject  is on-treatment within  the visit of intere st window. The  proportio ns of subjects  meeting  the criteria  
for virolo gic success  at each of these ti me points  will be bounded by exact  95%  confidence  intervals, and 
will be prese nted both in the aggregate  and broken  down by age  cohort.  
 
 
 
IMPAACT P1090                Page 64 of 113 10 March  2016  
Version 5.0  Table  9 presents  exact  95% confidence  interva ls around  various  potential  rates  of virologic success which  
might be observed  in a total sample of 36 subjects  or in subsa mples of various sizes  (N = 12, 24).  
 
Table  9. Percent  of Subjects  Meeting  Criterion  for Virologic  Success  with  Exact 95% 
Confidence  Intervals  
N No. of Subjects (%) with Undetecta ble RNA  95% C.I. 
12 1 (8%) 0.2% -- 38% 
24 2 (8%) 1% -- 27% 
36 4 (11%) 3% -- 26% 
12 3 (25%) 5% -- 57% 
24 6 (25%) 10% -- 47% 
36 9 (25%) 12% -- 42% 
12 6 (50%) 21% -- 79% 
24 12 (50%) 29% -- 71% 
36 18 (50%) 33% -- 67% 
12 9 (75%) 43% -- 95% 
24 18 (75%) 53% -- 90% 
36 27 (75%) 58% -- 88% 
12 11 (92%) 62% -- 99.8% 
24 22 (92%) 73% -- 99% 
36 33 (92%) 78% -- 98% 
 
8.6322 CD4 Response  
Change  from  baseline  to weeks 24 and  48 in  CD4 count,  CD4 percent  and CD4/CD8 ratio  and perce nt will 
be bounded  by 95% con fidence  intervals  and presented  both in the aggre gate and by age  cohort.  In 
addition,  the proportions  of subjects  exhibiting  an absolute  drop of >  5% in  CD4 perce nt from  baseline  to 
weeks 12, 24 and  48 will be presented, bounded  by 95% c onfidence intervals.  Subjects  who meet any of 
the conditions  (a) to (c) of Section  8.6321 or who have absolute  drop of > 5% in  their CD4% will  be 
considered  as treatment failures  in these  analyses.  
 
8.6323 HIV Drug Resistance  
Correlations  between  baseline  HIV genotypic  and phenotypic  drug resistance  and any subsequent  virolo gic 
failure  will be evalu ated. Subjects  will be asses sed for HIV genotypic  and phenotypic  drug resistance  to the 
OBT and ETR  at screenin g, at the time of virologic  failure  (if this  occurs)  and at early  discontinuation.  
 
8.6324 Additional Interim Analyses f or Regulatory Purposes  
To comply with regulatory requirements, additional interim analyses of data from Cohort 1 will be 
performed when at least 12 evaluable subjects have reached Week 24 and Week 48.  Also to address 
regulatory expectations, an additional analysis across all ag e cohorts will be performed through Week 48 
on at least 18 subjects. These analyses will be performed by Janssen R&D and will focus primarily on 
safety data, presented as described in Section 8.631 and pharmacokinetic data, presented as described in 
Sectio n 9.0. A secondary analysis of virologic success, as described in Section 8.6321 will also be 
presented.  These analyses will be shared with the P1090 Team.  
 
 
 
IMPAACT P1090                Page 65 of 113 10 March  2016  
Version 5.0  8.633   Exploratory  Analyses  
 
8.6331  CYP Gene  Profiles  
Descriptive  analyses  will examine the associa tion between  pharmacokinetic  parameters  of ETR  and 
subject -specific  CYP gene  profiles.  
 
9.0 CLINICAL PHARMACOLOGY  PLAN  
 
9.1 Pharmacology  Objectives  
 
The clinical  pharmacology  studies  are designed  to deter mine the steady -state pharmacokinetic (PK) profile  
and dosing  schedule  of orally  administered  etravirine  (ETR)  in HIV-1-infected chil dren ≥ 2 months  to < 6 
years  of age. ETR  PK and  dose r equire ments will be determined when given  with other  ARV agents.  All 
subjects  (in the mini cohort  and then the full cohort  for that age) will need  to undergo  an initial  12 hour 
intensive  PK study  on day  14 (±  4 days) of study drug ad ministration.  
 
 
9.2 Primary and Secondary  Data  
 
Primary: AUC 12h 
Secondary:  Cmax, C12hr, Tmax, CL/F, T1/2,Vd and PK para meters  (Cmax and C12hr) by CYP2C9 and 
CYP2C19 genotype  
 
9.3 Study  Design, Modeling  and Data  Analysis  
 
 
9.31 PK Criteria  
 
For this  study,  the area under  the plasma concentration -time curve  over 12 hours (AU C12h) of ETR,  as 
deter mined following  an observed  dose und er fed, steady -state conditions  will be the PK para meter for 
determination  of the accepta bility of the  ETR  dose, and  any individual  subject  dose adjust ments. The 
target  geometric  mean ETR  AUC12h for this  study  is between  60% and  150% of the  geometric mean 
AUC12h observed  in HIV-1-infected  treatment -experienced adults from  the DUET studies  (i.e. between  
2713 and  6783 ng •h/mL). For the  individual  subject manag ement in this study,  subjects  with an individual  
AUC 12h below  the 10th percentile  of adult  exposure  (i.e. <2350  ng•h/ mL) will be dose-adjusted in order to 
meet an AUC12h ≥  2350 ng•h/mL. 
 
No apparent  pharmacodyna mic relationship  for ETR  has been  identified  in adults,  implying  that the  plasma 
concent rations achie ved (in the DUET  studies)  were,  largely,  on the  flat portion  of the expected  sigmoid 
exposure -response  relationship.  The threshold  AUC 12h value  of < 2350 ng•h/mL representing  the 10th 
percentile of AUC in  adults  was sele cted, with the objective  of achieving  a distribution  for ETR  AUC12h 
values  in children  that appro ximates  that in HIV- infected  adults  who received  ETR  200 mg twice  daily  (in 
combination  with darunavir/ritonavir).  While the ETR AUC 12h will be the primary PK para meter for 
acceptability  of dose deter mination, the  P1090 core  protocol team  will also consider  the C12h of ETR  in 
their evaluation.  
 
 
 
IMPAACT P1090                Page 66 of 113 10 March  2016  
Version 5.0  9.32 Starting  Dose  
 
The starting  dose for ETR  in cohort  I (≥ 2 years  to < 6 years  of age)  was 5.2 mg/kg twice  daily. This  dose 
was based  on the  results  of the  analysis of trial  TMC125 -C213  (see Section  1.32). Based  on the  safety  
profile of ETR,  the concern  for under -dosing  in children  (25) (26) (27) (28) and the usual  need  for slightly  
higher  Cmax in children  to achieve  comparable  trough concentrations  (due to a faster  apparent  oral 
clearance)  the initial  starting  dose of 5.2 mg/kg twice  daily  reflected  an appropri ate balance  of these 
consid erations  based  on available  data at that  time. 
 
An evaluation  of the  PK data  from  the first 6 children  enrolled  in Cohort  I of P1090 indicated  that the 
geometric mean etrav irine exposure  (at the 5.2mg/kg BID dose for the  whole  cohort)  was lower  than 
expected,  and the chance of meeting  the required  geometric mean  etraviri ne AUC12h (comparable  to adults)  
for the  full cohort  was very  low (see  also section  1.32).  
 
All available etravirine PK data in pediatric subjects, including the P1090 subjects, were used in a 
modeling and simulation approach to better inform the choice of a revised starting dose for ETR for 
Cohort I and the starting dose for other cohorts in t his study. It was also decided that , instead of a mg/kg 
dose across all ages , it would be more appropriate to develop dosing based on weight  bands. The starting 
doses for C ohorts II and III are also informed and chosen by the resul ts of Cohort I, as detail ed in S ection 
8.1. For example, after evaluation of the first 6 subjects of Cohort I and criteria were met, Cohort I re -
opened to accrual of additional subjects to complete the full cohort. Opening of Cohort II to accrue the 
first mini -cohorts of 6 subject s was done based on the assessment by the protocol team that sufficient data 
(PK and safety) were available to appropriately inform the choice of starting dose regimen for this cohort. 
The same applies for opening of Cohort III. Within Cohort III, subjects  below 6 months of age will only 
be enrolled upon availability of initial safety and PK data from subjects between 6 months and 1 year of 
age. Appendix III gives the tables for the revised starting dose for Cohort I, starting doses for Cohort II 
and III an d guidelines about re -evaluating the dose regimen if warranted based on the PK data.  
 
9.33 Intensive  PK Evaluations  
 
All subjects  will undergo  an intensive PK study.  This PK evaluation  will be conducted  on day  
14 (±  4 days).  Subjects  should  have  taken  their ETR doses as directed  by the  study  physician, for 7 days 
prior to the intensive  PK visit,  without any missed doses.  Sites  are enco uraged  to call the subjects  family, 
the day before the intensive PK visit,  so that the site staff can confirm that the  subject  has not  missed any 
doses in  the previous  7 days.  
 
If the  subject  has missed a dose, the  intensive  PK visit should  be rescheduled  to occur  7- 14 days after  the 
last missed dose.  The site is again  encouraged  to call the subjects  family the day before  the resched uled 
intensi ve PK Visit  so the  staff can confirm  the subject  has not  missed any doses in the previous  7 days.  If 
the subject  has missed a dose, the  PK visit will be cancelled,  and the subject  will be withdra wn from  the 
study.  
 
The intensive  PK visit should  be scheduled  so that  a witnessed  dose of ETR  is taken  within a range  of 11 to  
13 hours after  their previous  dose.  Once  the subject  has arrived  at the clinic, he/she  should  be offered  a 
meal appropriate  for age. The team  suggests that  a heparin  lock be used for the  intensive  PK visit if at all 
possible.  The PK dose of medication  should  be ad ministered  within  30 minutes  following  the start of the 
meal. If the subject vomits within  15 minutes  of taking  their medication,  the dose should  be re-
 
 
IMPAACT P1090                Page 67 of 113 10 March  2016  
Version 5.0  administered.  Re-dosing  is not allowed if  the subject  vomits more than 15 minutes  after study  medication  
intake.  In the  event  that the subject  vomits  more than 15 minutes  after study  medication  intake on the  day 
of pharmacokinetic  evaluation,  that assess ment must be rescheduled.  Subjects  may resume food intake  2 
hours after  their dose of ETR  at the intensive  PK vi sit. 
 
The inten sive PK evaluation  will consist of obtaining a pre-dose plasma concent ration, and following  an 
observed  dose, post  dose plasma concentrations  at 1, 2, 4, 6, 9 and  12 hours.  To allow  for so me flexibility,  
the 9-hour sa mple can be collected  within  a window of 8 to  10 hours post -dose and  the 12-hour sa mple 
within a window of 11 to  13 hours post -dose. If necessary,  the sa mple 1 hour post -dose and/or  9 hours 
post-dose can  be deleted  to reduce  the amount of total blood  drawn from  7 samples  over 12 hours to  5 or 6 
samples, over 12 hours.  ETR  plasma concentrati ons will be determined in “real time” in a CLIA -certified  
IMPAACT pha rmacology laboratory.  The goal is for ETR  plasma concentration  information  to be 
available  for individual and  cohort  dose evaluation  within  2 weeks, or at  study  week  4. 
 
If the  protocol  team  believes  the intensive  PK was conduct ed incorrectly  or the  results inacc urate, subjects  
may be asked  to repeat  an intensive  PK vi sit on the same dose.  
 
For the  intensive PK evaluations  of ETR, the primary PK para meter will be AUC 12h. Other secondary  
parameters  that will be calculated  include  CL/F,  Vd,T1/2, Cmax, C12h and Tmax. Plasma concentrati on-time 
data will be graphically  inspected,  and standard  non-compartmental  techniq ues will  be used to assess PK 
parameters.  Cmax and C12h will be taken  as the  maximum and 12 hour observed  concentration,  respectively,  
and Tmax is the time at which  Cmax occurs.  The AUC12h will be  determined using  the linear-linear 
trapezoidal rule. CL/F  will be calculated as dose/AUC 12h.  The  terminal elimination  half-life is also a 
secondary  parameter  and will be deter mined using regression  analysis  on a minimum  of 3 points  (not 
including  Cmax) in the terminal elimination phase  when possible.  
 
9.34 Individual  Subject  Dose Evaluation  and Adjustments  
 
Doses of  ETR  will be adjusted  in an individ ual subject  to attain  an AUC 12h of < 2350 ng •h/mL. 
 
 If the  subject 's current  dose is  well tolerated  (no toxicity  ≥ Grade 3) but  AUC12h is 
< 2350 ng •h/mL, then a new dose will  be deter mined by prorating  the current  dose to attain an 
AUC12h of approxi mately  2864 ng •h/mL (the 20th percentile  of exposure  in adult s). The maximum 
dose increase  for the  initial  PK-guided dose  adjust ment would be capped  at the adult  dose of  200 
mg twice daily.  If a second  PK evaluation  again  reveals  an AUC 12h< 2350ng •.h/mL, then the dose 
may be increased  above  the 200 mg twice  daily initial  BID cap, again,  targeting  an AUC12h of 
approxi mately  2864 ng •h/mL. 
 If the  subject 's AUC12h is >4380  ng•h/mL(the  median AUC12h value  in adults receiving ETR  200 
mg twice  daily)  but current  dose is not well tolerated  (no toxicity  ≥ Grade  3) then  the dose will be 
prorated,  if possible  given availa ble dosage forms to achieve  an AUC12h of 4380 ng •h/mL. If no 
dose reduction  is possible,  then the subject  will be discontinued  from  study  treatment. 
 If a subject  has not  achieved  an AUC12h of < 2350 ng •h/mL, but is experiencing  a Grade  3 or 
greater  toxicity  that is deemed probably  or def initely  related  to study  drug, that subject  will be 
disco ntinued from  study  treatment. 
 
Although  ETR  displays  non-proportional  PK, dose adj ustments will be prorated  on a linear  scale using  
multiples  of 12.5 mg  (the smallest incremental  dose change  possible  given  the available formulation s). 
 
 
IMPAACT P1090                Page 68 of 113 10 March  2016  
Version 5.0  Initial PK-guided do se increases  will be capped at the adult dose of  200 mg twice daily.  However, if  after a 
second  PK evaluation  the subject’s  AUC12h has not  achieved  the minimum target  (2350 n g•h/mL), doses 
may exceed  200 mg twice  daily.  The core protocol  team will  communicate  all individu al dose adjustments 
to the participating  site. 
 
All subjects with an individual  dose adjust ment (not related  to weight  gain)  will have repeat intensive  12 
hour PK evaluations  performed between  Day 7 to  14 after  initiation of the  new dose.  
 
Subjects  who require  a dose adjus tment  but refuse  to undergo  repeat intensive  PK (see  Section  
9.34 for manage ment of individual  dose adjus tments)  will have  ETR  therapy  discontinued  and will  be 
replaced. 
 
9.35 Cohort  Dose Evaluation  and Adjust ment 
 
Enroll ment will be temporarily  halted after PK d ata are obtained for 6 subjects  within  a given mini cohort.  
PK para meters and 28-day safety  data will be reviewed  for these  subjects.  If safety data are acceptable,  
and the geometric mean AUC12h of the  first six is judged acceptable,  then an additional  6 subjects  will be 
enrol led to equal  N = 12 in  each full cohort. Failure  with respect  to the  safety  and/or PK guidelines  will 
result  in a dose adju stment  within this cohort,  with the sta rting dose adjusted  in the appropriate  direction.  
 
NOTE:  Please  refer  to Sections  6.6 and  6.8 if  non-adherence  is suspected.  
 
Subjects  who require  a dose adjus tment  but refuse  to undergo  repeat  intensive  PK (see  Section  9.34 for 
manage ment of individual  dose adjus tments)  will have  ETR  therapy  discontinued  and will  be replaced  
(will remain on study  but off study  drug).  
 
PK para meters  for ETR  will be summarized  and descri ptive statistics  calculated.  As stated,  the 
AUC12h for ETR  is the primary PK para meter. 
 
9.351   The  dose of ETR  will be judged  accepta ble if: 
 The ETR  dose is  tolerated 
AND  
 The geometric mean ETR  AUC 12h is between  60% and  150%  of the  geometric  mean AUC12h in HIV-
1-infected treatment-experie nced adults  from  the DUET studies  (i.e. between  2713 and  6783 
ng•h/mL) 
 
If a revised starting dose of ETR  is needed,  modeling  and simulation  will be used (i ncorporating all  
available  PK data  at that time) to propose  a revised  weight -based  dosing  table  for ETR for which  the 
calculated  chance  of success for a  given  age cohort  (i.e., geometric mean AUC12h between  60 and  150% of 
adults)  will be at least 80% (see  also Appendix  III). 
 
In making  any revision to the starti ng dose, the  team  will estimate the C12h expected  with the revised  dose.  
The goal of dose finding  is to identify  a dose that  approxi mates ETR  exposure  in adults  who receive  an 
ETR  dose of  200 mg twice  daily  (when given  with darunavir/ritonavir). The median  AUC12h in adults  is 
4380 ng •h/mL and 75th percentile  is 6339 ng •h/mL. The median C 12h in adults is 298 ng/ ml and the 75% 
percentile  is 467 ng/ ml. The team  will compare the expected  C12h with that achieved  in adults,  and may 
use this comparison  to refine  the revised starting  dose to  approximate  both the AUC12h and C12h exposure.  
 
 
IMPAACT P1090                Page 69 of 113 10 March  2016  
Version 5.0   
Any change  in the starting dose will  be communica ted by the  protoc ol team to all particip ating sites  via 
written  notification.  
 
As detailed  in Section  3.0 of the  protocol,  subjects  may be dose-adjusted  to the new dose and additional  
new subjects  will be treated at the new dose, and  safety and PK will  be evaluated  as described.  
 
If more than 2 of the  6 children  in a cohort  has an  AUC12h greater  than the 75th percentile  of adult values  
(6339 ng•h/mL) and the cohort has p assed the safety criteria,  the team will review the starting  dose and  the 
expected  distribution  of ETR  C12h and AUC 12h. This review  is to assess the goal  of objective  of achieving  a 
distribution  for ETR C12h and AUC 12h values  in children that approxi mates that in HIV-1-infected  treatment 
experienced  adults.  The team  may decide to revise  the starting  dose;  however,  there is no re quirement for 
the team to adjust  the starting  ETR  dose.  
 
If the  starting  dose for a  cohort  of older  subjects  is revised,  the protocol  team  may preemptively change  the 
starting  dose for subsequent  younger  cohort  that has not  yet opened  to enroll ment. Any change  in the 
starting dose will  be communica ted by the  protoc ol team to all particip ating sites,  with instructions  to use 
the appropriate table of starting  doses.  It  is not unreaso nable to suspect  that the three cohorts  planned  for 
enroll ment may each have  different  dosage require ments. This protocol  will deter mine appropriate  doses 
for each  of these  strata. 
 
 
 
9.36 Population  PK Evaluations  
 
Blood  samples for esti mation  of population  PK cha racteristics  of ETR  will be collected  at study weeks 4, 
8, 12, 24 and  48, and  at the deter mination  of virol ogic failure, as outli ned in the schedule  of evaluations  
(Appendix  I).  At Weeks 4 and  24, one  sample should  be timed  to fall within  a window of 1 to  4 hou rs 
following  a dose of ETR;  at week  8, one  sample should  be timed to  fall within  a window of 4 to  8 hours 
following  a dose of ETR;  and at weeks 12 and  48, one sa mple should  be timed to fall within  a window  of 8 
to 12 hours following  a dose of ETR.  ETR plas ma concentrations  will be determined  in a CLIA-certified  
IMPAACT Phar macology Laboratory  (refer  to LPC).  
 
 
9.4 Population  Pharmacokinetic  Study Design,  Modeling  and Data  Analysis  
 
For this  analysis,  the primary intere st will be the  PK charact eristics  of ETR  and these  will be evaluated  
using  NON MEM version  VII (G loboMax, Hanover,  MD). NONMEM uses mixed effects  (random  and 
fixed)  regression  to estimate population  means and variances  of PK para meters  and to identify  intrinsic  and 
extrinsic  factors,  such as body weight,  sex or conco mitant drug th at may influence  these  parameters. Base 
models  will be develop ed using  first-order conditio nal estimation  with or witho ut intera ction. A stepwise  
procedu re will be used to deter mine whether  a one- or two -compartment model  best fits the plasma  data 
under  the principle of parsi mony. A log -norm al error  distribution  will be assumed for the  description  of 
both interpatient  and intrapatient  (residual)  PK para meter variability.  If necessary,  poorly  identified 
structural  parameters,  such as t he absorption  rate constant,  may be fixed.  The following covariates  will be 
collected  at baseline  or during  follow-up visits:  sex, age,  weight,  race,  HIV regi men (e.g.,  boosted  PI) and  
HIV respon se markers.  The influence of each  covariate  on the  PK characteristics  of ETR  will be tested  
sequentially.  At each  step, the goodness of fit  plots  will also be  evaluated.  At the  end of the  analysis,  all 
 
 
IMPAACT P1090                Page 70 of 113 10 March  2016  
Version 5.0  covariates  that show an  influence  on the  parameters will  be evaluated  again  by comparison  of the full 
model (with  all factors  include d) with a model from  which  each of the  factors  is deleted  sequentially.  For 
forward addition  and backward eli mination  a decrease  in objective  function  value  by 3.84 (p  ≤ 0.05) and  
6.64 (p ≤ 0.01), respectively,  would advocate  sufficiently  influential  covariates.  P1090 data  may be  
supple mented  with other  pediatric  PK data  from  previous  etravir ine studies  (TMC125-C213, TMC125 -
C126) to  support structural  model and/or  parameter precision  if needed.  
 
NONMEM uses extended  least squares to  calcula te the objective  function  and the difference  in the  value  of 
the objective  funct ion between  models  is approxi mately chi squared  distributed.  A difference  in objective  
function  of greater  than 6.6 is  considered  significant  (6.6 corresponds to  a chi  square  for p =  0.01 with  1 
degree  of freedom)  when one  parameter is added  or the  covariate (e.g.,  body weight)  is replaced.  This is 
analogo us to the commonly  used F test  to select  among regression  models.  The primary outco me of this  
analysis is to identi fy the model that best describes  the plasma PK of ETR  and to investigate  whether  any 
of the  covariates  influences  the PK of ETR.  The final model  will include  all significant  covariates  (if any) 
and the parameter estimates for all  parameters  together with the estimates of residual  and inter-individual 
varia bility. A secondary  objective  of this  combined analy sis will be to develop  a linked population  PKPD 
model  in NONM EM to  evaluate  potential  relationships  between  these  plasma concentrati ons/PK  
characteristics  and thera peutic outco mes (i.e. response to  HIV therapy  after 
48 weeks of ETR  and adverse  events).  
 
 
 
9.5 Anticip ated Outco mes 
 
The anticipated  outco mes of the  pharmacology  evaluations  are: 
 
(1)   A description  of the  pharmacokinetics  of ETR,  when given  in combination  with other antiretroviral  
agents  including  a ritonavir -boosted  HIV PI, in  children  ≥ 2 months  to < 6 years  of age  and; 
 
(2)  Identification  of a dose of ETR,  when given  in combination  with other antiretroviral agents  
including  a ritonavir -boosted  PI, w hich achieves  etravirine  exposures in  a distribution  comparable  
to a 200 mg twice  daily  dose in  adults  (when given  with darunavir/ritonavir)  and with a comparable  
geometric  mean AUC12h. 
 
(3)  An investigation  of the  pharmacodyna mics of ETR,  given  in combination  with an OBR, after  48 
weeks of therapy.  
 
10.0 HUMAN SUBJECTS  
 
 
10.1 Institutional  Review  Board  and Infor med Consent  
 
This protocol,  the informed  consent  document (Appendix  VIII), and  any subsequent modifications  must be 
reviewed  and approved  by the IRB or EC  responsible  for oversight  of the study.  Written  infor med consent  
must be obtained  from the subject  (or parents  or legal  guardians of subjects  who cannot  consent  for 
themselves,  such as those  below  the legal  age).  The subject 's assent  must also be obtained  if he or she is 
able to understand  the nature,  significance,  and risks of the  study.  The informed  consent  will describe the 
 
 
IMPAACT P1090                Page 71 of 113 10 March  2016  
Version 5.0  purpo se of the  study, the procedures  to be followed,  and the risks and  benefits  of participation.  A copy  of 
the consent  form  will be given  to the  subject  (or parent  or legal  guardian).  
 
Each  site which  receives  US DHHS funding  and follows the  United  States  Code  of Federal Regulatio ns 
Title  45-Public Welfare,  Part 46-Protection  of Hu man Subjects  (also  known as the Common  Rule)  should  
have  on record  at the site a plan that detects and addresses any  change  in guardianship  occurring  in 
pedia tric subjects  and deter mines when  a study  subject  must have  a consent  process which  involves  a 
legally authorized representative  (LAR) other  than a family member  with guardian ship. The plan will 
include how the  site determines when a  LAR is initially  or no longer  needed  and how frequently  the LAR 
re-signs the  consent.  The plan should follow  all IRB/EC,  local,  state,  national  and/or  host country  
guidelines.  Confir mation  of such a plan  at a site should  be submitted with protoc ol registratio n materials.   
 
The team  has made a risk/benefit  analysis  for the P1090 protocol  of “greater  than minimal risk with  
prospect  of direct  benefit.”  The team  anticipates  that the study  will lead to confir mation  that this drug is  
safe for use in  infants  and young children  and to deter mination  of the  appropriate dose in  infants  and young 
children.  The approach  of sequential  cohorts  and mini-cohorts  serves to reduce the risk to  participa nts. 
 
10.2 Subject  Confidenti ality 
 
All laboratory  speci mens, evaluation  forms, reports,  and other  records  will be identified  only by a coded  
number  to maintain  subject  confidenti ality. All records will be kept in a secured area.  All co mputer  entry  
and networking  progra ms will be done  with coded  numbers  only.  Clinical in formation  will not be released 
without written  permission  of the subject,  except  as necessary  for monitoring  by the  FDA, the  Office  for 
Human Research  Protections  (OHRP), the  NIH, the  local IRB  or Ethics  Com mittee,  Janssen R&D,  host 
country  regulatory  agencies  and by the  study  staff, and  study  monitors.  
 
10.3 Study  Discontinuation  
 
The study  may be discontinued  at any time by the  NIH, the  FDA, the  IRB or EC,  Janssen R&D, OHRP or 
other govern mental  agencies  as part  of their  duties  to ensure  that research  subjects  are protected.  
 
11.0 PUBL ICATION OF  RES EARCH FINDINGS  
 
Publication  of the  results  of this trial will be governed  by IMPAACT policies.  Any presentation, abstr act, 
or manuscript  will be made available  for review  by the  pharmaceutical  sponsors prior  to sub mission.  
 
12.0 BIOHAZARD CON TAINMENT  
 
Trans mission  of HIV and  other  blood  borne  pathogens  can occur  through  contact  with conta minated  
needles,  blood, and blood products.  Respiratory  viruses are  trans mitted by droplet aerosolizati on and 
fomites. Appropriate  blood  and secretion  precautions  will be employed  by all personnel  in the collection  of 
samples and the shipping  and handling  of all  speci mens for this study,  as currently  recommended  by the 
CDC.  
 
 
 
IMPAACT P1090                Page 72 of 113 10 March  2016  
Version 5.0  All infectio us speci mens will be transported  in compliance  with Feder al Regulations  and the International  
Air Transport  Association  Dangerous Goods Regulations -Packing  Instruction  602. Refer  to individual  
carrier  guideli nes (e.g.,  Federal  Express or Ai rborne)  for specific  instructions and  to the ACTN  Guidelines  
for Shi pment and Receipt  of Category  B Biological  Substance Ship ment and ACTN In struction  for 
Overnight  Shipments docu ments at 
http://www.hanc.info/labs/labresources/ procedures/Pages/actnShippingDe mo.aspx  
  
 
 
IMPAACT P1090                Page 73 of 113 10 March  2016  
Version 5.0  13.0 REF ERENCES  
 
1. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and 
genotypic resistance mutation patterns in thai children receiving non -nucleoside reverse 
transcriptase inhibitor -based antiretroviral therapy. Pediatr Infect Dis J. 2009;28(9):826 -30. 
2. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of 
resistance to nevirapine in mothers and children after single -dose exposure to prevent vertical 
transmission of HIV -1: a meta -analysis. Int J Epidemiol. 2007;36(5):1009 -21. 
3. Eshlema n SH, Becker -Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, et al. Impact of 
human immunodeficiency virus type 1 (hiv -1) subtype on women receiving single -dose nevirapine 
prophylaxis to prevent hiv -1 vertical transmission (hiv network for prevention t rials 012 study). J 
Infect Dis. 2001;184(7):914 -7. 
4. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Resistance after 
single -dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 
2005;19(18):2167 -9. 
5. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence 
of viral resistance in HIV -infected children after exposure to single -dose nevirapine. J Acquir 
Immune Defic Syndr. 2007;44(2):148 -53. 
6. Kurle SN, Gangakhedkar  RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS. Emergence of 
NNRTI drug resistance mutations after single -dose nevirapine exposure in HIV type 1 subtype C -
infected infants in India. AIDS Res Hum Retroviruses. 2007;23(5):682 -5. 
7. Palumbo P, Lindse y JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral 
treatment for children with peripartum nevirapine exposure. The New England journal of 
medicine. 2010;363(16):1510 -20. 
8. World Health Orginization. Antiretroviral drugs for treating preg nant women and preventing HIV 
infection in infants. Switzerland: WHO Press; 2006. 88 p.  
9. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next -
generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse 
transcriptase inhibitor -resistant human immunodeficiency virus type 1. Antimicrob Agents 
Chemother. 2004;48(12):4680 -6. 
10. De Corte BL. From 4,5,6,7 -Tetrahydro -5-methylimidazo[4,5,1 -jk](1,4)benzodiazepin -2(1H) -one 
(TIBO) to Etravirin e (TMC125):  Fifteen Years of Research on Non -Nucleoside Inhibitors of HIV -
1 Reverse Transcriptase. Journal of Medicinal Chemistry. 2005;48(6):1689 -96. 
11. Scholler -Gyure M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, et al. Effects of 
differe nt meal compositions and fasted state on the oral bioavailability of etravirine. 
Pharmacotherapy. 2008;28(10):1215 -22. 
12. Scholler -Gyure M, Kakuda TN, De Smedt G, Vanaken H, Bouche MP, Peeters M, et al. A 
pharmacokinetic study of etravirine (TMC125) co -administered with ranitidine and omeprazole in 
HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508 -16. 
13. I TT. Intelence (etravirine) Package Insert. 2008.  
14. Scholler -Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM. Clinical 
pharmacokinet ics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561 -74. 
15. Kakuda TN, Scholler -Gyure M, Hoetelmans RM. Clinical perspective on antiretroviral drug -drug 
interactions with the non -nucleoside reverse transcriptase inhibitor etravirine.  Antivir Ther. 
2010;15(6):817 -29. 
16. Kakuda TN, Scholler -Gyure M, Hoetelmans RM. Pharmacokinetic interactions between etravirine 
and non -antiretroviral drugs. Clin Pharmacokinet. 2011;50(1):25 -39. 
 
 
IMPAACT P1090                Page 74 of 113 10 March  2016  
Version 5.0  17. Kakuda TN, Scholler -Gyure M, Workman C, Arasteh K, Poz niak AL, De Smedt G, et al. Single - 
and multiple -dose pharmacokinetics of etravirine administered as two different formulations in 
HIV-1-infected patients. Antivir Ther. 2008;13(5):655 -61. 
18. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Moli na JM, et al. Efficacy and safety 
of etravirine in treatment -experienced, HIV -1 patients: pooled 48 week analysis of two 
randomized, controlled trials. AIDS. 2009;23(17):2289 -300. 
19. Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, et al . Efficacy and safety of 
etravirine at week 96 in treatment -experienced HIV type -1-infected patients in the DUET -1 and 
DUET -2 trials. Antivir Ther. 2010;15(7):1045 -52. 
20. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistan ce profile of 
etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, 
controlled Phase III clinical studies. AIDS. 2010;24(4):503 -14. 
21. Kakuda TN, Wade J, Snoeck E. Pharmacolinetics and Pharmacodynamics of the NNRTI T MC125 
in treatment experienced HIV -1 infected Patients: Pooled 24 -week Results of DUET -1 and DUET -
2 15th Conference on Retroviruses and Opportunistic Infections, ; February 3 -6, 2008; Boston, 
MA2008.  
22. Kakuda TN, Wade JR, Snoeck E, Vis P, Scholler -Gyure M, Peeters MP, et al. Pharmacokinetics 
and pharmacodynamics of the non -nucleoside reverse -transcriptase inhibitor etravirine in 
treatment -experienced HIV -1-infected patients. Clinical pharmacology and therapeutics. 
2010;88(5):695 -703. 
23. Scholler -Gyure MK T, Van Solingen -Ristea R, Berchmans C, De Smedt G, . Bioavailability of the 
100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulation.  17th 
International AIDS Conference; August 3 -8, 2008. ; Mexico City2008.  
24. Konigs C F -SC, Esposito S, et al. Pharmacokinetics and Dose Selection of Etravirine in HIV -
infected Children between 6 and 17 years, inclusive. .  16th Conference on Retroviruses and 
Opportunistic Infections; February 8 -11, 2009; Montreal2009.  
25. Menson EN, Walker A S, Sharland M, Wells C, Tudor -Williams G, Riordan FA, et al. Underdosing 
of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing 
medicines to children, 1997 -2005: cohort study. BMJ. 2006;332(7551):1183 -7. 
26. ter Heine  R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, et al. A 
pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result 
in subtherapeutic concentrations. Antivir Ther. 2008;13(6):779 -87. 
27. Verweel G , Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, et al. Plasma 
concentrations of the HIV -protease inhibitor lopinavir are suboptimal in children aged 2 years and 
below. Antivir Ther. 2007;12(4):453 -8. 
28. Hirt D, Urien S, Jullien V, Firt ion G, Rey E, Pons G, et al. Age -related effects on nelfinavir and 
M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother. 
2006;50(3):910 -6. 
29. Tudor -Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, et  al. Etravirine in 
treatment -experienced, HIV -1-infected children and adolescents: 48 -week safety, efficacy and 
resistance analysis of the phase II PIANO study. HIV Med. 2014;15(9):513 -24. 
30. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McC arver DG, et al. 
Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 
2004;308(3):965 -74. 
31. Briz V, Palladino C, Navarro M, Jimenez de Ory S, Gonzalez -Tome M, Leon J, et al. Etravirine -
based highly active antiretroviral the rapy in HIV -1-infected paediatric patients. HIV Med. 
2011;12(7):442 -6. 
 
 
IMPAACT P1090                Page 75 of 113 10 March  2016  
Version 5.0  32. Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, et al. A comparison of 
neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavire nz in a 
treatment -naive, HIV -1-infected population. AIDS. 2011;25(3):335 -40. 
33. World Health Orginization. Antiretroviral therapy for HIV in fection in infants and children 
Recommendations for a public health approach. Switzerland: WHO Press; 2010.  
 
 
 
IMPAACT P1090                                                                           Page 76 of 113                 10 March  2016  
Version 5.0  APPENDIX IA : SCHEDULE OF EVALUATIONS - Cohort  I 
 
 Study  Visits  
Screen1 
 Entry  
(Day  0) Day 14 
Intensive PK Visit  Week  
4 Week  
8 Week  
12 Week 16  Week  
24 Week  
32 Week  
40 Week  
48 Early  
Study  
D/C Virologic 
failure21 
Visit  Windows   ±4 da ys ±1wk ±1wk ±1wk ±2wk ±2wk ±2wk ±2wk ±2wk   
CLINICAL  EVALUATIONS 
Informed Consent X             
History and  Physica l2 X X X X X X X X X X X X X 
CDC Classi fication X X    X  X   X X X 
Adherence / P ill Count Form   X15 X15 X X X X X X X X15 X 
Adherence phone call   X16           
Electrocardiogram  (ECG)3 X  X12, 17           
STUDY D RUG 
Distribution of Study Drug4  X    X  X X     
LABO RATORY EVALU ATIONS 
Hematology5 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Chemistries6 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 
Cholester ol/triglyceri des7  2mL    2mL  2mL   2mL   
Coagulation a ssays8 2mL     2mL  2mL      
Urinalysis9 X X      X   X X X 
Virology Evaluations 
HIV-1 RNA PCR10 3mL 3mL14 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
CYP ge notyping  X14            
HIV genotype & phenotype 4mL           4mL 4mL 
Immunology Evaluations 
Lymphoc yte subset11 2mL 2mL  2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 
Pellets / plasma for storage        2mL   2mL   
Pharmacology Evaluations 
Intensive Pharmacokinetics12   7mL           
Populati on PKs13    
 1mL18 1mL19 1mL20  1mL18   1mL20  1mL22 
TOTAL BLO OD VOLUME 14mL 10mL 13mL 9mL 9mL 13mL 8mL 15mL 8mL 8mL 13mL 12mL 13mL 
 
 
 
IMPAACT P1090                                                                           Page 77 of 113                 10 March  2016  
Version 5.0  Footnotes  
 
1. Informed consent must be ob tained prior to performing Screening evaluati ons.  The entry (Day 0) evaluations should be co mpleted wit hin 60 days 
following  scree ning. 
2. A complete history and physical s hould be done at scre ening.  At subsequent visits,  an interim  history and physical s hould be performed.  This should 
include history (including occurrence of adverse e vents since  last st udy visit and any HIV-1 associated co nditions) and physical exam (includi ng height 
[without shoes], weight [with minimal clothing ], vital si gns [temperat ure, pulse, respirat ions, blood pre ssure and head circu mference  for those  <3 years 
old]). 
3. The electrocardiogram  shou ld be read l ocally by the investigator a nd also se nt in du plicate to  the ECG ce ntral rea ding service. Turnaround time for the 
central read ing service is  72 hou rs. For  normal values  of PR  see Appendix V; any value  above the 98th perce ntile is c onsidered abnormal.  If there is 
evidence of significant abnormality on  the ECG (including ≥Gra de 3 PR or QTc i nterval, the site in vestigator should request a 24 hour turnaround on 
central read ing of the  ECG.  A local c ardiologist c an also be consulted if  the investi gator wishes.  For normal and  abnormal values of PR and QTc 
intervals for this protocol, see Appendix V.  Additional  details reg arding the ECG can be found in the  MOPs. Note that a r epeat EKG is  required at the 
time of an intensive PK  visit, i ncluding any PK-directed dose adj ustments. 
4. Study drug may be dispensed at other clinic study visits.  
5.  Hematology tests sh ould include complete bl ood count (CBC),  differe ntial and platelets.  
6. Electrol ytes (sodium, potass ium, and H CO3), glucose, creati nine, lipase, phosphorus, and LFTs.  LFTs  should include total bilirubin, indirect bilirubin, 
direct bilirubin, al kaline phosphatase,  AST,  ALT, and  albumin.  If indirect bilirubin is not rep orted by the site la boratory, it should be calculated  at the 
site and documented. 
The following (listed  in order of prefere nce) should be used to deter mine the upper limit of normal (ULN) values for indirect bilirubin. 
a. "ULN"  values reported by the  laboratory report for the test, or 
b. "ULN" values routinely used/established by the site,  or 
c. "ULN" values as per the Harriet La ne Hand book 
Sites must be consistent with t he way to xicities are e valuated  for all s ubjects in  the study; sites sh ould use the same source throu ghout the study. 
Remember to have documentation of calc ulated indirect bilirubin and source  of "ULN",  when not reported by your lab oratory. 
7. If a s ubjects la boratory res ults show ele vated cholester ol/triglyceri des AND if t he subject is ≥1 year o ld, the subject should be asked to return to clinic 
for fasting cholester ol/triglyceri des.  Children ≥1 year  to ≤2 years of ag e, should be  fasting for 4 hours. Children >2 years of ag e, should be fasti ng 
overnight. 
8. Coagulation  assays shou ld include PT, PTT  and INR. R equired only from  study sites  with access to l aboratories  with existing coagulation testi ng 
capabilities f or the tests as determined by IMPAACT.  
9. A urine dipstick  should be perfor med at each  of the  visits ind icated.  A co mplete microscopic  urine a ssessment is requ ired only if a  urine dipstick  is 
abnormal. 
10. Virology assa ys should be p erformed at an IMPAA CT/VQA approved laboratory. The Abbott plat form MUST  be used for the HIV-1 RNA assay. 
11.  Lymphoc yte subsets include CD4  and CD8 assays. 
12.  Subjects  should have  taken ETR for at least  7 consecuti ve days prior to the intensive PK, without missing a  dose.  Intensi ve PK should be scheduled so 
that a witnessed dose of ETR  is taken a pproximately 12  hours after t he pre vious dose. PK d osing wit hin a range of 11 to 13 hours after the previous dose 
is acceptable.  The team  suggests that an indwelling  catheter such as a  saline  or heparin lock be  used for the int ensive  PK. Once the subject  has arrived at 
the clinic, he/she should be offered  a breakfast appropria te for age. Within 30 minutes follow ing bre akfast, the  PK medicat ions should be  administered  
followed by the PK sa mpling at the specified t ime points.  If the subject  vomits wit hin 15 minutes  of tak ing study drug, the dose should be re peated. 
Subjects may resume fo od intake 2 hours after their dose of ETR at t he intensi ve PK  visit. One (1) mL of blood will be collected  at the f ollowing  time 
points: pre-dose,  1, 2, 4, 6, 9 and 12 h ours post dosing. To all ow for some flexibility, t he 9-hour sample can  be collected  with a  window 
 
 
IMPAACT P1090                                                                           Page 78 of 113                 10 March  2016  
Version 5.0   
of 8 to 10 hours post-dose and the 12 h our sample with  a window of 11 to 13 hours. If necessar y, the 1-hour post-dose sa mple and/or the 9-hours post- 
dose sample can be deleted  to reduce the amount of total blood drawn from 7 samples over 12 hours to 5 or 6 sa mples, over 12 hours. 
 
If a s ubject req uires individual dose adjustme nt for low  or high AUCs, they will be asked to return to cli nic to have an intensive PK evaluation  between  
Day 7-14 on the new dose. 
 
If a mini or full cohort fails, the failing subjects may have their ETR  dose ad justed.  In those cases, s ubjects will be asked to return to cli nic to have a 
truncated  intensi ve PK between Day 7 -14 on t he new dose with sa mples collected  at the following time p oints: pre-dose, 2, a nd between 3-5 hours post 
dosing. 
 
Note that a repeat EKG is  requir ed at the  time of a  PK visit  required for any of t he rea sons described above. 
 
13.  1.0mL of blood  will be collected for each of the  population  pharmacokine tic samples.  NOTE:  An absolute min imum of 0.5 mL is necessary for  
population PK sa mple. 
14.  Wherever possible, the CYP genotyping and viral l oad PCR can be r un from the same blo od sample.  The bl ood draw should be collected and  spun   
down to isolate  pellets for PBMCs (for CYP  genotyping) and the plasma can be us ed for the viral load. Otherwise, a  separate  blood tube should be 
drawn. 
15.  Sites sh ould also perform the palata bility assess ment at these visits. 
16.  Subjects  must have  taken their ETR  doses as direct ed by t he study physician,  for 7 days prior to the intensive PK visit,  without any  missed doses.  Sites 
are strongly encouraged to ca ll the subject, the day  before  the intens ive PK  visit,  so that the site staff can  confirm  that the  subject has not missed  any 
doses in the previous 7 days.  If t he subject has missed  a dose, the PK vi sit must be re-scheduled wit hin the Day 14 (± 4 days) window. 
17.  The ECG at the intensive PK visit sh ould be collected  following the 4 hour blood draw.  This time point is generally w hen the drug level is at its  highest. 
18.  At we eks 4 and 24, one  sample should be timed to fall wit hin a window of 1 to 4 hours foll owing a dose of etravirine. 
19.  At we ek 8, one sample should be  timed to fall within a window of 4 to 8 h ours following a dose of etr avirine. 
20.  At wee ks 12 and 48, one sample should be timed  to fall wit hin a window of 8 to 12 hours following a dose of etra virine.  (See Section 9.36 for 
additional infor mation). 
21.  If a subject is experienc ing virologic failure (as defined in section  6.3), a visit to  confirm  failure must be conducted be tween 1 to 4 wee ks of the initial 
suspected  failure or rebound. 
22.  At virologic failure,  one sa mple may be coll ected at any time follow ing a dose of etr avirine.  
 
 
For insufficient blood draws, priorities are as f ollows: 
Hematology (1mL); C hemistry (2mL);  Pharmacology  (intensive [7mL] or population [1mL]);Virology (HIV -1 RNA PCR – 3mL); Resista nce testi ng (HIV 
genotype and phenotype – 4mL); Lymphoc yte subsets  (2mL); CYP  genotyping (2mL); Choleste rol / triglycerides (2mL); C oagulati on assays (2mL); Plas ma/cell 
pellet  for storage (2mL) 
  
 
 
IMPAACT P1090                                                                           Page 79 of 113                 10 March  2016  
Version 5.0  APPENDIX IB : SCHEDULE OF EVALUATIONS – Cohort  II 
 
 Study  Visits  
Screen1 Entry  
(Day  0) Day 14 
Intensive 
PK Visit  Week  
4 Week  
8 Week  
12 Week  
16 Week  
24 Week  
32 Week  
40 Week  
48 Early  
Study  
D/C Virologic 
failure21 
Visit  Windows   ±4 da ys ±1wk ±1wk ±1wk ±2wk ±2wk ±2wk ±2wk ±2wk   
CLINICAL  EVALUATIONS 
Informed Consent X             
History and  Physica l2 X X X X X X X X X X X X X 
CDC Classi fication X X    X  X   X X X 
Adherence / P ill Count Form   X15 X15 X X X X X X X X15 X 
Adherence  Phone Call   X16           
Electrocardiogra m3 X  X12, 17           
STUDY D RUG 
Distribution of Study Drug4  X    X  X X     
LABO RATORY EVALU ATIONS 
Hematology5 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Chemistries6 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 
Cholester ol/triglyceri des7  2mL    2mL  2mL   2mL   
Coagulation a ssays8 2mL     2mL  2mL      
Urinalysis9 X X      X   X X X 
Virology Evaluations 
HIV-1 RNA PCR10 3mL 3mL14 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
CYP ge notyping  X14            
HIV genotype & phenotype 4mL           4mL 4mL 
Immunology Evaluations 
Lymphoc yte subset11 2mL 2mL  2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 2mL 
Pellets/ plasma for s torage        2mL   2mL   
Pharmacology Evaluations 
Intensive Pharmacokinetics12   7mL           
Populati on PKs13    1mL18 1mL19 1mL20  1mL18   1mL20  1mL22 
TOTAL BLO OD VOLUME 14mL 10mL 13mL 9mL 9mL 13mL 8mL 15mL 8mL 8mL 13mL 12mL 13mL 
 
 
 
IMPAACT P1090                                                                           Page 80 of 113                 10 March  2016  
Version 5.0  Footnotes  
 
1. Informed consent must be ob tained prior to performing Screening evaluati ons.  The entry (Day 0) evaluations should be co mpleted within 60 days 
following  scree ning. 
2. A complete history and physical should be done at scre ening.  At subsequent visits,  an interim  history and physical s hould be performed.  This should 
include history (including occurrence of adverse e vents since  last st udy visit and any HIV-1 associated co nditions) and physical exam (includi ng height 
[without shoes], weight [with minimal clothing ], vital si gns [temperat ure, pulse, respirat ions, blood pre ssure and head circu mference ]). 
3. The electrocardiogram  shou ld be read l ocally by the investigator a nd also se nt in du plicate to  the ECG ce ntral rea ding service. Turnaround time for the 
central read ing service is  72 hou rs.  For normal values  of PR see  Appendix V; any value above the 98th percentile is co nsidered ab normal.  If there is 
evidence of significant abnormality on  the ECG (including ≥Gra de 3 PR  or QTc i nterval, the site in vestigator should request a 24 hour turnaround on 
central read ing of the  ECG.  A local c ardiologist c an also be consulted if  the investi gator wishes.  For normal and  abnormal values of PR and QTc 
intervals  for this protocol, see Appendix V.  Additional  details reg arding the ECG can be found in the MOPs.  Note that a repe at EKG is req uired at t he 
time of an intensive PK  visit, i ncluding any PK-directed dose adj ustments. 
4. Study drug may be dispensed at other clinic study visits.  
5.     Hematology tests sh ould include complete bl ood count (CBC),  differe ntial and platelets.  
6. Electrol ytes (sodium, potass ium, and H CO3), glucose, creati nine, lipase, phosphorus, and LFTs.  LFTs  should include total bilirubin, indirect bilirubin, 
direct bilirubin, al kaline phosphatase,  AST,  ALT, and  albumin.  If indirect bilirubin is not rep orted by the site la boratory, it should be calculated  at the 
site and documented. 
The following (listed  in order of prefere nce) should be used to deter mine the upper limit of normal (ULN) values for indirect bilirubin. 
a. "ULN"  values reported by the  laboratory report for the test, or 
b. "ULN" values routinely used/established by the site,  or 
c. "ULN" values as per the Harriet La ne Hand book 
Sites must be consistent with t he way to xicities are e valuated  for all s ubjects in  the study; sites sh ould use the same source throu ghout the study. 
Remember to have documentation of calc ulated indirect bilirubin and source  of "ULN",  when not reported by your lab oratory. 
7. If a s ubjects la boratory res ults show ele vated cholester ol/triglyceri des AND if t he subject is ≥1 year o ld, the subject should be asked to return to clinic 
for fasting cholester ol/triglyceri des.  Children ≥1 year  to ≤2 years of ag e, should be  fasting for 4 hours. Children >2 years of ag e, should be fasti ng 
overnight. 
8. Coagulation  assays shou ld include PT, PTT  and INR. R equired only from  study sites  with access to l aboratories  with existing coagulation testi ng 
capabilities f or the tests as determined by IMPAACT.  
9. A urine dipstick  should be perfor med at each  of the  visits ind icated.  A co mplete microscopic  urine a ssessment is requ ired only if a  urine dipstick  is 
abnormal. 
10. Virology assa ys should be p erformed at an IMPAA CT/VQA approved laboratory.  The  Abbott plat form MUST  be used for the HIV-1 RNA. 
11.  Lymphoc yte subsets should include CD4 a nd CD8. 
12.  Subjects  should have  taken ETR for at least  7 consecuti ve days prior to the intensive PK, without missing a  dose.  Intensi ve PK should be scheduled so 
that a witnessed dose of ETR  is taken a pproximately 12  hours after t he pre vious dose. PK d osing wit hin a range of 11 to 13 hours after the previous dose 
is acceptable.  The team  suggests that an indwelling  catheter such as a  saline  or heparin lock be  used for the int ensive  PK. Once the subject  has arrived 
at the clinic, he/she should be offered  a breakfast appropria te for their age. Within 30 minutes  following bre akfast, the PK medications sho uld be 
administered  followed by the PK sampling at the specified t ime points.  If the subject  vomits wit hin 15 minutes  of tak ing study drug, the dose should be 
repeated. Subjects may resume fo od intake 2 hours after their dose of ETR at t he intensi ve PK  visit. One (1) mL of blood will  be collected  at the 
following  time points: pre-dose,  1, 2, 4, 6, 9 and 12 h ours post dosing. To all ow for some flexibility, t he 9-hour sample can  be collected  with a  window 
 
 
IMPAACT P1090                                                                           Page 81 of 113                 10 March  2016  
Version 5.0   
of 8-10 hours  post-dose and the 12 hour sa mple with a  window of  11 to 13  hours.  If necessary,  the 1-hour post-dose sample and/ or the 9 -hours post- 
dose sample can be deleted  to reduce the amount of total blood drawn from 7 samples over 12 hours to 5 or 6 sa mples, over 12 hours. 
 
If a s ubject req uires individual dose adjustme nt for low  or high AUCs, they will be asked to return to cli nic to have an intensive PK evaluation  between  
Day 7 -14 on the new dose. 
 
If a mini or full cohort fails, the failing subjects may have their ETR  dose ad justed.  In those cases, s ubjects will be asked to return to cli nic to have a 
truncated  intensi ve PK between Day 7 -14 on t he new dose with sa mples collected  at the following time p oints: pre-dose, 2, a nd between 3-5 hours post 
dosing. 
 
Note that a repeat EKG is  requir ed at the  time of a  PK visit required for any of t he rea sons described above. 
 
13.  1.0mL of blood  will be collected for each of the  population  pharmacokine tic samples.  NOTE:  An absolute min imum of 0.5 mL is necessary for  
population PK sa mple. 
14.  Wherever possible, the CYP genotyping and viral l oad PCR can be r un from the same blo od sample.  The bl ood draw should be collected and  spun 
down to isolate  pellets for PBMCs (for CYP  genotyping) and the plasma can be us ed for the viral load. Otherwise, a  separate  blood tube should be 
drawn. 
15.  Sites sh ould also perform the palata bility assess ment at these visits. 
16.  Subjects  must have  taken their ETR  doses as direct ed by t he study physician,  for 7 days prior to the intensive PK visit,  without any  missed doses.  Sites 
are strongly encouraged to ca ll the subject, the day  before  the intens ive PK  visit,  so that the site staff can  confirm  that the  subject has not missed  any 
doses in the previous 7 days.  If t he subject has missed  a dose, the PK vi sit must be re-scheduled wit hin the Day 14 (± 4 days) window. 
17.  The ECG at the intensive PK visit sh ould be collected  following the 4 hour blood draw.  This time point is generally w hen the drug level is at its  highest. 
18.  At we eks 4 and 24, one  sample should be timed to fall wit hin a window of 1 to 4 hours foll owing a dose of etravirine. 
19.  At we ek 8, one sample should be  timed to fall within a window of 4 to 8 h ours following a dose of etr avirine. 
20.  At wee ks 12 and 48, one sample should be timed  to fall wit hin a window of 8 to 12 hours following a dose of etra virine.  (See Section 9.36 for 
additional infor mation). 
21.  If a subject is experienc ing virologic failure (as defined in section  6.3), a visit to  confirm  failure must be conducted be tween 1 to 4 wee ks of the initial 
suspected  failure or rebound. 
22.  At virologic failure,  one sa mple may be coll ected at any time follow ing a dose of etr avirine.  
 
 
 
For insufficient blood draws, priorities are as f ollows: 
Hematology (1mL); C hemistry (2mL);  Pharmacology  (intensive [7mL] or population [1mL]);Virology (HIV -1 RNA PCR – 3mL); Resista nce testi ng (HIV 
genotype and phenotype – 4mL); L ymphoc yte subsets  (2mL); CYP  genotyping (2mL); Choleste rol / triglycerides (2mL); C oagulati on assays (2mL); Plas ma/cell 
pellet  for storage (2mL) 
  
 
 
IMPAACT P1090                                                                           Page 82 of 113                 10 March  2016  
Version 5.0  APPENDIX IC : SCHEDULE OF EVALUATIONS – Cohort  III 
 
 Study  Visits  
Screen1 Entry  
(Day  0) Day 14 
Intensive 
PK Visit  Week  
4 Week  
8 Week  
12 Week  
16 Week  
24 Week  
32 Week  
40 Week  
48 Early  
Study  
D/C Virologic 
failure23 
Visit  Windows   ±4 da ys ±1wk ±1wk ±1wk ±2wk ±2wk ±2wk ±2wk ±2wk   
CLINICAL  EVALUATIONS 
Informed Consent X             
History and  Physica l2 X X X X X X X X X X X X X 
CDC Classi fication X X    X  X   X X X 
Adherence / P ill Count Form   X17 X17 X X X X X X X X17 X 
Adherence  Phone Call   X18           
Electrocardiogra m3 X  X13, 19           
STUDY D RUG 
Distribution of Study Drug4  X    X  X X     
LABO RATORY EVALU ATIONS 
Hematology5 0.5mL 0.5mL  0.5mL  0.5mL 0.5mL  0.5mL  0.5mL 0.5mL  0.5mL  0.5mL 0.5mL  0.5mL  0.5mL 
Chemistries6 1mL 3mL 1mL 1mL 1mL 3mL 1mL 3mL 1mL 1mL 3mL 1mL 1mL 
Cholester ol/triglyceri des7  X    X  X   X   
Coagulation a ssays8 2mL     2mL  2mL      
Urinalysis9 X X      X   X X X 
Virology Evaluations 
HIV-1 RNA PCR10 3mL 3mL16 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
CYP ge notyping11  X16            
HIV genotype & phenotype 4mL15           4mL 4mL 
Immunology Evaluations 
Lymphoc yte subset12 1mL 1mL  1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Pellets/ plasma for s torage        2mL11   2mL11   
Pharmacology Evaluations 
Intensive Pharmacokinetics13   3.5mL           
Populati on PKs14    0.5mL20 0.5mL21 0.5mL22  0.5mL20   0.5mL22  0.5mL24 
TOTAL BLO OD VOLUME 11.5mL 7.5mL 8.0mL 6.0mL 6.0mL 10.0mL 5.5mL 12.0mL 5.5mL 5.5mL 10.0mL 9.5mL 10.0mL 
 
 
 
IMPAACT P1090                                                                           Page 83 of 113                 10 March  2016  
Version 5.0  Footnotes  
1. Informed consent must be ob tained prior to performing Screening evaluati ons.  The entry (Day 0) evaluations should be completed wit hin 60 days 
following  scree ning.  For children of low weight, the screening laboratory evaluations may be s plit over 2 visits . Safety labs and lymphocyte 
subsets should be obtained at the first timepoint and HIV RNA  and HIV genotyping and pheno typing  a week later . 
2. A complete history and physical s hould be done at scre ening.  At subsequent visits,  an interim  history and physical s hould be performed.  This should 
include history (including occurrence of adverse e vents since  last st udy visit and any HIV-1 associated co nditions) and physical exam (includi ng height  
[without shoes], weight [with minimal clothing ], vital si gns [temperat ure, pulse, respirat ions, blood pre ssure and head circu mferenc e). 
3. The electrocardiogram  shou ld be read l ocally by the investigator a nd also se nt in du plicate to  the ECG ce ntral rea ding service. Turnaround time for the 
central read ing service is  72 hou rs.  For normal values  of PR see  Appendix V; any value above the 98th percentile is co nsidered ab normal.   If there is 
evidence of significant abnormality on  the ECG (including ≥Gra de 3 PR  or QTc i nterval, the site in vestigator should request a 24 hour turnaround on 
central read ing of the  ECG.  A local c ardiologist c an also be consulted if  the investi gator wishes.  For normal and  abnormal values of PR and QTc 
intervals  for this protocol, see Appendix V.  Additional  details reg arding the ECG can be found in the MOPs.  Note that a repe at EKG is req uired at t he 
time of an intensive PK  visit, i ncluding any PK-directed dose adj ustments. 
4. Study drug may be dispensed at other clinic study visits.  
5. Hematology tests sh ould include complete bl ood count (CBC),  differe ntial and platelets.  
6. Electrol ytes (sodium, potass ium, and H CO3), glucose, creati nine, lipase, phosphorus, and LFTs.  LFTs  should include total bilirubin, indirect bilirubin, 
direct bilirubin, al kaline phosphatase,  AST,  ALT, and  albumin.  If indirect bilirubin is not reported by the site la boratory, it should be calculated  at the 
site and documented. 
The following (listed  in order of prefere nce) should be used to deter mine the upper limit of normal (ULN) values for indirect bilirubin. 
a. "ULN"  values reported by the  laboratory report for the test, or 
b. "ULN" values routinely used/established by the site,  or 
c. "ULN" values as per the Harriet La ne Hand book 
Sites must be consistent with the way toxicities are evaluated for all subjects in the study; sites should use the same source throughout the study. 
Remember to have documentation of calculated indirect bilirubin and source of "ULN", when not reported by your laboratory.  
7. Cholesterol/triglycerides should be tested from the sample drawn for chemistries.  If a s ubjects lab res ults sh ow elevated cholester ol/triglyceri des 
AND if the sub ject is  ≥1 year old, the sub ject should be asked to return to  clinic for fasti ng cholesterol/triglycerides.  Children ≥1 year to  ≤2 years 
of age, should be fasting for 4 hours.  Children >2 years of age, should be fasting overnight. 
8. Coagulation a ssays shou ld include PT, PTT  and INR.  Requ ired o nly from  study sites  with access to l aboratories  with existing coagulation testi ng 
capabilities f or the tests as determined by IMPAACT.  
9. A urine dipstick  should be perfor med at each  of the  visits ind icated.  A co mplete microscopic  urine a ssessment is requ ired only if a  urine dipstick  is 
abnormal. 
10. Virology assa ys should be p erformed at an IMPAA CT/VQA approved laboratory. The Abbott plat form MUST  be used for the HIV-1 RNA. 
11. Collection  of blood  for geno typing and  stored speci mens may be o mitted for the  youngest inf ants if the necess ary volume of blood is difficult to draw.  Note 
that CYP genotyping and viral l oad PCR can be r un from the same blo od sample; see  footnote 16. 
12. Lymphoc yte subsets should include CD4 a nd CD8 assays. 
13. Subjects  should have  taken ETR for at least  7 consecuti ve days prior to the intensive PK, without missing a  dose.  Intensi ve PK should be scheduled so 
that a witnessed dose of ETR  is taken a pproximately 12  hours after t he pre vious dose. PK d osing wit hin a range of 11 to 13 hours after the previous dose 
is acceptable.  The team  suggests that an indwelling  catheter such as a  saline  or heparin lock be  used for the int ensive  PK. Once the subject  has arrivedat 
the clinic, he/she should be offered  a breakfast appropria te for their age. Within 30 minutes  following bre akfast, the PK medications sho uld be 
administered  followed by the PK sa mpling at the specified t ime points.  If the subject  vomits wit hin 15 minutes  of tak ing study drug, the dose should be 
repeated. Subjects may resume fo od intake 2 hours after their dose of ETR at t he intensi ve PK  visit. One (1) mL of blood will  be collected  at the 
following  time points: pre-dose,  1, 2, 4, 6, 9 and 12 h ours post dosing. To all ow for some flexibility, t he 9-hour sample can  be collected  with a  window 
 
 
IMPAACT P1090                                                                           Page 84 of 113                 10 March  2016  
Version 5.0  of 8 to 10 hours post -dose and the 12 hour sample with a window of 11 to 13 hours. If necessary, the 1 -hour post -dose sample and/or the 9 -hours post- 
dose sample can be deleted to reduce the amount of total blood drawn from 7 samples over 12 hours to 5 or 6 samples, over 12 hours.  
 
If a subject requires individual dose adjustment for low or high AUCs, they will be asked to return to clinic to have  an intensive PK evaluation between  
Day 7 -14 on the new dose.  
 
If a mini or full cohort fails, the failing subjects may have their ETR dose adjusted.  In those cases, subjects will be aske d to return to clinic to have a 
truncated intensive PK between Day 7-14 on the new dose with samples collected at the following time points: pre -dose, 2, and between 3 -5 hours post 
dosing.  
 
Note that a repeat EKG is required at the time of a PK visit required for any of the reasons described above.  
 
14. 0.5mL of blood  will be collected for each of the  population  pharmacokine tic samples.  NOTE:  An absolute min imum of 0.5 mL is necessary for  
population PK sa mple. 
15. Cohort III su bjects must wait until HIV -1 genotyping res ults are a vailable BEFORE they can start ETR  and OBR.  
16. Wherever possible, the CYP genotyping and viral l oad PCR can be r un from the same blo od sample.  The bl ood draw sh ould be collected and  spun 
down to isolate  pellets for PBMCs (for CYP  genotyping) and the plasma can be us ed for the viral load. Otherwise, a  separate  blood tube should be 
drawn. 
17. Sites sh ould also perform the palata bility assess ment at these visits. 
18. Subjects  must have  taken their ETR  doses as direct ed by t he study physician,  for 7 days prior to the intensive PK visit,  without any  missed doses.  Sites 
are strongly encouraged to ca ll the subject, the day  before  the intens ive PK  visit,  so that the site staff can  confirm  that the  subject has not missed  any 
doses in the previous 7 days.  If t he subject has missed  a dose, the PK vi sit must be re-scheduled wit hin the Day 14 (± 4 days) window. 
19. The ECG at the intensive PK visit sh ould be collected  following the 4 hour blood draw.  This time point is generally w hen the drug level is at its  highest. 
20. At we eks 4 and 24, one  sample should be timed to fall wit hin a window of 1 to 4 hours foll owing a dose of etravirine. 
21. At we ek 8, one sample should be  timed to fall within a window of 4 to 8 h ours following a dose of etr avirine. 
22. At wee ks 12 and 48, one sample should be timed  to fall wit hin a window of 8 to 12 hours following a dose of etra virine.  (See Section 9.36 for 
additional infor mation). 
23. If a subject is experienc ing virologic failure (as defined in section  6.3), a visit to  confirm  failure must be conducted be tween 1 to 4 wee ks of the initial 
suspected  failure or rebound. 
24. At virologic failure,  one sa mple may be coll ected at any time follow ing a dose of etr avirine.  
 
 
For insufficient blood draws, priorities are as f ollows: 
Hematology (0.5mL); C hemistry (1mL);  Pharmacology  (intensive [3.5mL] or population [0.5mL]);Virology (HIV -1 RNA PCR – 3mL); Resista nce testi ng (HIV 
genotype and phenotype – 4mL); L ymphoc yte subsets  (1mL); CYP  genotyping (2mL); Choleste rol / triglycerides (2mL); C oagulati on assays (2mL); Plas ma/cell 
pellet  for storage (2mL) 
 
 
IMPAACT P1090  Page 85 of 113 10 March  2016  
Version 5.0  APPENDIX ID : SCH EDULE OF EVA LUATION S FOR FOLLOW UP OF SUBJECTS WHO 
DISCONTINUE ETRAVIRINE (OFF STUDY DRUG – ON STUDY)  
 
 Week 4 post ETR dis continuation 
(±2 weeks)  
CLINICAL  EVALUATIONS 
History and  Physica l1 X 
CDC Classificati on X 
LABO RATORY EVALU ATIONS 
Hematology2 1mL 
Chemistries3 3mL 
Cholester ol / tri glyceri des4 1mL 
Virology  
HIV-1 RNA PCR5 3mL 
Immunology 
Lymphoc yte subsets6 2mL 
TOTAL BLO OD VOLUME (mL) 10mL 
 
 
NOTE:  Subjects w ho are  withdrawn fr om study drug wit hin the first 48 wee ks of study will not enter long term 
follow-up, but will ret urn to clinic 4 weeks after ETR  discontinuation, as per Appendix ID. Subjects with AEs 
will be followed until satisfact ory clinical res olution (i.e. value returns back to s ubjects baseline value) or 
stabilizati on (to be agreed upon with the sponsor). All grade 3 and grade 4 laboratory abnormalities as well as 
any laboratory abnormalities res ulting in an increase of  2 DAIDS  Grades from baseline, will be followed until 
return to baseline or within 1 Gra de from baseline.  If an AE  resolves within 4 wee ks of discontinuation of ETR, 
the subject should still ret urn for the final 4 week stu dy visit. 
 
Footnotes  
 
1. History  (including occurrence of adverse events since  last study  visit a nd any HIV-1 associated  
conditions) a nd physical e xam (including height [without sh oes], weight [with minimal clothing], vital 
signs [temperature,  pulse, respirations and blood pressure]). 
2. Hematology tests sh ould include complete bl ood count (CBC),  differe ntial and platelets.  
3. Electrol ytes (sodium, potass ium, and H CO3), glucose, creatinine, lipase, phosphorus, and LFT s.  
LFTs s hould include total bilirubin, indirect bilirubi n, direct bilirubin, alkaline phosphatase,  AST,  
ALT, a nd albumin.  If indirect bilirubin is n ot reported by the site lab oratory, it sh ould be calculated  
at the site and do cumented.  
The following (listed  in order of prefere nce) should be used to determine the upper limit  of normal (ULN)  
values for indirect bilirubin. 
a. "ULN"  values reported by the  laboratory report for the test, or 
b. "ULN" values routinely used/established by the site,  or 
c. "ULN" values as per the Harriet La ne Hand book 
Sites must be consistent with t he way to xicities are e valuated for all s ubjects in  the study; sites sh ould 
use the same source t hroughout the study.  Remember to have documentation of calc ulated  indirect 
bilirubin and source of "ULN", when not reported by your laboratory. 
4. If a s ubjects la boratory res ults show ele vated cholester ol/triglyceri des AND if t he subject is ≥1 year old, 
the subject sh ould be asked to return to clinic for fasti ng cholester ol/triglyceri des.  C hildren ≥1 year  to ≤2 
years of age, should be fasting for 4 hours.  Children >2 years of age, should be fasting overnight. 
5. Virology assa ys should be p erformed at an IMPAA CT/VQA approved laboratory. The Abbott plat form 
MUST be us ed for the HIV-1 RNA.  
6. Lymphoc yte subsets should include CD4 a nd CD8. 
 
 
 
 
IMPAACT P1090  Page 86 of 113 10 March  2016  
Version 5.0  For insufficient blood draws, priorities are as f ollows: 
Hematology (1mL); C hemistry (2mL); Vi rology (HIV-1 RNA PCR  – 3mL); L ymphoc yte subsets (2 mL); 
Cholester ol / tri glyceri des (2mL) 
 
 
IMPAACT P1090                                                                                     Page 87 of 113    10 March  2016  
Version 5.0  
  
APPENDIX IE: SCHEDULE OF EVALUATIONS  FOR LONG -TERM 
SAFETY FOLLOW -UP OF SUBJECTS RECEIVING STUDY -PROVIDED 
ETRAVIRINE  
 
 Every  12 weeks  
(±2 weeks)  Every  24 weeks  
(±2 weeks)  Early  
Disco ntinuation  14 Da ys Post Therapy 
(±1 week)  
CLINICAL  EVALUATIONS 
History and  Physical E xam1 X  X X 
Adherence  follow-up X   X 
CDC Classificati on X  X X 
STUDY D RUG 
Distribution of Study Drug X    
LABO RATORY EVALU ATIONS 
Chemistries2 X9 2mL 2mL 3mL 
Hematology3 X9 2mL 2mL 2mL 
Cholester ol/triglyceri des4 X9 2mL   
Urinalysis5  X X X 
Urine pregnancy test (if  applicable)6 X X X X 
Virology 
HIV-1 RNA PCR7 X9 3mL 3mL 3mL 
HIV ge notype & phenotype   4mL  
Immunology 
Lymphoc yte subset8 X9 2mL 2mL  
TOTAL BLO OD VOLUME None 11mL 13mL 8mL 
 
NOTE:   Visits during long term follow up are e very 12 wee ks with specific lab  tests being collected  every 24 wee ks (for additional  details,  see footnote 9  below). 
 
Footnotes  
 
1. History  (including occurrence of adverse events since  last study  visit a nd any HIV-1 associated  conditions) a nd physical ex am (including hei ght [without 
shoes], weight [with minimal clothi ng], vital signs  [temperat ure, pulse,  respirations  and blood pressure]). 
2. Electrol ytes (sodium, potass ium, and H CO3), glucose, creati nine, lipase, phosphorus, and LFTs.  LFTs  should include total bilirubin, indirect bilirubin, 
direct bilirubin, alkaline phosphatase, AST, ALT,  and alb umin.  If indirect bilirubin is not reported by the site laboratory, it sh ould be calc ulated  at the site 
and documented.  
 
 
IMPAACT P1090                                                                                     Page 88 of 113    10 March  2016  
Version 5.0  
 The following (listed  in order of prefere nce) should be used to deter mine the upper limit of normal (ULN) values for indirect bilirubin. 
a. "ULN"  values reported by the  laboratory report for the test, or 
b. "ULN" values routinely used/established by the site,  or 
c. "ULN" values as per the Harriet La ne Hand book 
Sites must be consistent with t he way to xicities are e valuated  for all s ubjects in  the study; sites sh ould use the same source throu ghout the study. Remember 
to have documentation of ca lculated  indirect bilirubin and source of "ULN",  when not reported by your lab oratory. 
3. Hematology tests sh ould include complete bl ood count (CBC),  differe ntial and platelets.  
4. If a s ubjects la boratory res ults show ele vated cholester ol/triglyceri des AND if t he subject is ≥1 year o ld, the subject should be asked to return to clinic for 
fasting cholesterol/triglycerides.  Children ≥1 year to  ≤2 years of age, should be fasting for 4 hours.  Children >2 years of age, should be fasting overnight. 
5. A urine dipstick  should be perfor med at each  of the  visits  indicated.  A co mplete microscopic  urine a ssessment is requ ired only if a  urine dipstick  is 
abnormal. 
6.    A  urine pregnancy test should be pe rformed at ev ery visit on  any female subject  who is capable of beco ming pr egnant.  
7.    Vi rology assays should be performed at an IMPAACT /VQA approved lab oratory. For protocol required plas ma RNA testi ng, the Abbott platform MUST be 
used.  During the long term follow up, any standard of care HIV-1 RNA r esults (i. e. those obtained at  non-protocol required time points) a vailable within ±4 
weeks  of the study visit sho uld also be reported on the study CRF, e ven if done using non -Abbott assays.  
8. Lymphoc yte subsets should include CD4 a nd CD8. 
9. If these tests are performed as part of standard of care for the sub ject wit hin ±4 wee ks of the visit, they should be recorded on the study CRFs. O therwise;  
these tests s hould not be done f or the study at this time point. 
 
 
 
For insufficient blood draws, priorities are as f ollows: 
Chemistry (2 mL); V irology (HIV-1 RNA PCR – 3mL); Ly mphoc yte subsets (2mL); H IV ge notype/phenotype (4mL); Choleste rol / triglycerides  (2mL) 
 
 
IMPAACT P1090  Page 89 of 113 10 March  2016  
Version 5.0  APPENDIX II : PLANNED LABORATORY TEST ING ON COLLECTED  SPECIMENS  
 
 
Speci men Assay  Investigator /  Laboratory  Notes  
EDTA blood Hematology Local I MPAACT laboratory  
EDTA blood Lymphoc yte subsets Local I MPAACT laboratory  
Serum or LiHeparin 
(site /method 
dependent) Chemistries/  
choleste rol 
/triglyceri des  
Local  IMPAACT laboratory  
 
EDTA plas ma  
HIV-1 RNA PCR 
(viral load)  
Local  IMPAACT laboratory  
Laboratory must be usi ng Abbott 
platform  and be VQA certifi ed 
 
EDTA plas ma  
Resistance Te sting 
(Genotyping) 
SCREE NING Only  U.S. Sites:  
University of  Washington 
Seattle  WA  
Speci mens should be sh ipped in 
real time 
Africa Sites:  
Contract  Laboratory S ervice s, 
Johannesburg, SA  
Speci mens should be sh ipped in 
real time 
South  America Sites:  
FioCruz, Brazil  
Speci mens should be  shipped in 
real time 
Thailand  Sites:  
PHPT  Laboratory 
Chiang Mai, T hailand  
Speci mens should be sh ipped in 
real time 
India Sites:  
Testi ng will be performed in 
country at a DAIDS network 
laboratory  
Speci mens should be sh ipped in 
real time 
 
EDTA plas ma  
Resistance Te sting 
(Phenotyping) 
SCREE NING Only  U.S. / Brazil S ites: 
Monogram  Sciences   
Speci mens should be sh ipped in 
real time 
All Ot her Sites:  
BRI Rep ository  
Speci mens should be sh ipped in 
real t ime and will ‘ pass-through’ 
BRI to Monogram  
 
EDTA Plasma  
Resistance Te sting 
(Genotyping) 
VIROLOG IC 
FAILURE  
/ EAR LY STUDY 
D/C U.S. Sites:  
University of  Washington 
Seattle  WA  
Speci mens should be  batch 
shipped quarterly  
All Ot her Sites:  
BRI Rep ository  
Speci mens should be  batch 
shipped quarterlya nd will ‘ pass- 
through’ BRI to Monogram 
 
EDTA Plasma  
Resistance Te sting 
(Phenotyping) 
VIROLOG IC 
FAILURE  
/ EAR LY STUDY 
D/C U.S. / Brazil S ites: 
Monogram  Sciences   
Speci mens should be  batch 
shipped quarterly  
All Ot her Sites:  
BRI Rep ository  
Speci mens should be  batch 
shipped quarterly  
 
  
 
 
IMPAACT P1090  Page 90 of 113 10 March  2016  
Version 5.0  APPENDIX III : ETRAVIRINE DRUG DOSING TABLE  FOR ORAL TABLET  
 
Note:  If the protoc ol team deter mines that a revised  starting  dose of etravirine  is needed, 
modeling  and simulation  will be used (incorp orating all available PK data at that time) to 
propose a  revised  weig ht-based  dosing table  for ETR for whi ch the calculated  chance  of success 
for a given  age cohort  (i.e., geometric mean AUC12h between  60 and  150% of adult s) will be at 
least 80%. For this,  available  doses of ETR  (based on available  formulations  of 100 mg  tablet 
and 25 mg scored  tablet)  between  12.5 mg orally  twice  daily  (BID) and  200 mg orally  twice 
daily,  in incre ments of 12.5 mg, will be conside red. The new dosing  table and clear  instructions 
on how to  handle  subjects will be provided  to all particip ating sites by the protoc ol team via a 
written  notification.  
 
DOSING TABLE  1:  1 year – 6 years  
 
Etravirine  (ETR)  dose per  weight  band  
Weight  Band  
(kg) Dose ( mg/kg)  Dose ( mg) Number of Tablet(s)  to 
Administer  Orally  per 
Dose  Frequency  
<8 8.8 50 mg 2 x 25 mg tablets  Twice  Daily  
8-<10 8.8 75 mg 3 x 25 mg tablets  Twice  Daily  
10-<13 8.8 100 mg 1 x 100 mg tablet  Twice  Daily  
13-<16 6.8 100 mg 1 x 100 mg tablet  Twice  Daily  
16-<20 5.2 100 mg 1 x 100 mg tablet  Twice  Daily  
20-<25 5.2 125 mg 1 x 100 mg tablet  PLUS  
1 x 25 mg tablet  
OR 
5 x 25 mg tablets  Twice  Daily  
25-<30 5.2 150 mg 1 x 100 mg tablet  PLUS  
2 x 25 mg tablets  
OR 
6 x 25 mg tablets  Twice  Daily  
>=30  5.2 200 mg 2 x 100 mg tablets  
OR 
8 x 25 mg tablets  Twice  Daily  
 
 
 
 
 
 
 
 
 
 
 
IMPAACT P1090  Page 91 of 113 10 March  2016  
Version 5.0  DOSING TABLE 2:   2 months to < 1 year  
 
Etravirine  (ETR)  dose per  weight  band  
Weight  Band  
(kg) Dose ( mg) Number of Tablet(s) to  
Administer Orally per Dose  Frequency  
<6 25 mg 1 x 25 mg tablet  Twice  Daily  
6-<8 37.5 mg 1 and a half scored 25 mg tablets  Twice  Daily  
8-<10 50 mg 2 x 25 mg tablets  Twice  Daily  
≥10 75 mg 3 x 25 mg tablets  Twice  Daily  
Note: as of the age of 1 year, doses should be adjusted according to the specific ETR dosing 
table for 1 year to 6 years (Dosing Table 1).  
  
 
 
IMPAACT P1090  Page 92 of 113 10 March  2016  
Version 5.0  APPENDIX IV: VISIT SCHEDULE FOR RA SH MANAG EMENT IN PED IATRIC SUBJECTS  
 
This visit schedule summarizes the visits and assess ments to be performed in case of 
rash. NOTE: At the investi gator’s discretio n, whenever follow-up visits, laborat ory 
tests or digital photos are NOT  required by this schedule, these evaluati ons may be 
performed at the investi gators  discreti on, if clinically  indicate d. All results should be 
documented in  the study CRFs.  
 
 Grade 1 Rash Grade 2 Rash Grade 3/4 Ra sh 
Day 01  Study medicati on MAY be  
CON TINUED 
 Unscheduled visit f or initial 
rash eva luation REQUIR ED. 
 Referral to dermatologist  
ONLY IF rash dia gnosis 
uncertain (within 24-48hr).  Study medicati on MAY be  
CON TINUED. 
 Unscheduled visit f or initial 
rash eva luation REQUIR ED. 
 Referral to dermatologist  
REQUIRED (within 24-48hr). 
 Blood sample for safety 
evaluations by local lab oratory 
ONLY IF requested by i nvesti gator 
or dermatologist.  
 Biopsy  ONLY IF re quired by 
dermatologist.   Study medicati on MUST be 
permanently DISCO NTINUED. Re- 
challenge  is NOT  ALLOWED. 
 Unscheduled visit f or initial 
rash eva luation REQUIR ED. 
 Referral to dermatologist  
REQUIRED (within 24-48hr). 
 Blood sample for safety 
evaluations by local lab oratory.  
 Biopsy REQUIRED  within 24 
hours after o nset of ra sh 
 Digital pictures REQUIRED.  
Day 1   Follow-up visit REQUIRED   Follow-up visit REQUIRED   Follow-up visit REQUIRED.  
 Digital pictures REQUIRED.  
Day 2  No follow-up visit req uired  Follow-up visit REQUIRED   Follow-up visit REQUIRED.  
Day 3  No follow-up visit req uired No follow-up visit req uired  Follow-up visit REQUIRED.  
Day 4  No follow-up visit req uired No follow-up visit req uired  Follow-up visit REQUIRED.  
Day 5  No Rash f ollow-up visit require d2 No Rash f ollow-up visit required2  Follow-up visit REQUIRED.  
Day 6  No Rash f ollow-up visit required  No Rash f ollow-up visit required  No Rash f ollow-up visit required  
Day 7   Follow-up visit REQUIRED.   Follow-up visit REQUIRED.  No Rash f ollow-up visit required  
Further 
Visits  If rash is unresolved after second 
follow-up visit, sub ject should be 
referred to a dermatologist  for 
further evaluation.  If rash is unresolved after second 
follow-up visit, sub ject should be 
referred to a dermatologist  for 
further evaluation.  Weekly follow-up visits 
REQUIRED (with digital pictures) 
until res olution of Gra de 3-4 rash  to 
Grade ≤ 2 rash (furt her follow-up 
visits accord ing to Gr ade 1 or Grade  
2 rash i nstruction s). 
Upon Rash  
Resolution/ 
Stabilizati on3 Complete fi nal rash  assess ment 
pages in the CRFs Complete fi nal rash  assess ment in 
the CRFs  Complete fi nal rash  assess ment 
pages in the CRFs 
Footnotes:  
1 Note that Day  0 of the rash is the first day of investigator assess ment and not the first day of rash  
as reported by the subject.  
2 In case  rash progresses  from  a Grade  1 or a  Grade 2 to a h igher Grade, start follow-up schedule 
for Grade 2, 3 or 4 ra sh as appropriate.  
  
 
 
IMPAACT P1090  Page 93 of 113 10 March  2016  
Version 5.0  APPENDIX V : GRADING FOR PR AND QTc  INTERVALS  
 
 
A.  TABLE  TO DETERM INE 98TH PERCENTILE  FOR PR RESULTS  IN LEAD II  
 
This table  should  be used when evaluating  ECGs for subjects  <8 years  of age.  This table  is 
to be follo wed in conjunction  with exclusion  criterion  4.211,  toxicity  manage ment section  
6.15, and  Appendix  IA-ID.  If you have  any questions  regarding  the implementation  of this 
table,  please contact  the core protocol team  at impaact.p109 0cmc@fstrf.or g. 
 
 
Subject’s  Age Normal PR-
Interv al 
(millisecon ds) 
3 to <6 months ≤ 150  
6 to <12 months  ≤ 160  
1 to <3 years  ≤ 150  
3 to <5 years  ≤ 160  
5 to <8 years  ≤ 160  
Source: The Electroca rdiogram in Infants and Children: A Systematic App roach. Arthur Gar son, Jr. Lea and 
Febig er Publisher s. Philadel phia, 1 983. (Original tabl e, labeled A-3 in the book, was modified by the 
IMPAACT P 1090 Protocol Team to suit t he specific ne eds of t he protocol) 
 
B.  DETERM ININGADVERSE  EVENTGRAD ING OFPROLONGED QTcINTERVALS 
Please  refer  to the DAIDS toxicity  tables  for adverse  event  grading  of prolonged  
QTc intervals.  The DAIDS Table  for Grading  the Severity  of Adult  and Pediatric  Adverse  
Events,  (DAIDS AE Gr ading Table),  Version 1.0, Dece mber 2004, Clarification  August 
2009, must be used and  is available  on the  RSC website  at (http://rsc.tech - 
res.co m/safetyandphar macovigilance/ ). 
 
 
 
C.  DETERM INING  ADVERSE EVENT  GRAD ING OF PROLONGED PR RESULTS  
 
Please  refer  to the DAIDS toxicity  tables  for adverse  event  grading  of prolonged  PR intervals. 
The DAIDS Table  for Grading  the Severity  of Adult  and Pediatric  Adverse Events,  (DAIDS 
AE Grading  Table),  Version 1.0, Dece mber 2004, Clarificati on August 2009, must be used 
and is available  on the  RSC website  at (http://rsc.tech -res.co m/safetyandphar macovigilance/ ). 
 
 
IMPAACT P1090  Page 94 of 113 10 March  2016  
Version 5.0  APPENDIX VI : SUPPLEMENTAL TOXICITY TABLE  FOR G RADING S EVERITY  OF 
NEU ROLOGIC ADV ERSE EVENTS  
 
 
 
 
For the  purposes of P1090, the  follo wing parameter and grading  criteria  are to be used in 
conjunction  with the DAIDS Table  for Grading  the Severity  of Adult  and Pediatric  Adverse 
Events,  dated  Dece mber 2004, Clarification  August 2009, in  grading  neurologic adverse events. 
This parameter supersedes  Row 1 (alteration  in personality -behavior  or in mood) and Row 2 
(altered  mental  status)  of the  neurologic  section  of the  DAIDS Toxicity  Table.  
 
  
Grade  1  
Grade  2  
Grade  3  
Grade  4 
 
Sleepines s, 
lethargy, irrita bility  
Transiently 
lethargic, irrita ble 
or fussy (above 
usual norm), but 
otherwise normal 
routine.  
More sleeping or 
crying than usual, 
not on normal 
routine without 
alternate 
explanation.  
≥7 days of a change  
in personality 
without alternate 
explanation and 
confirmed by 
objective 
observation by 
study  staff 
 
OR 
 
Somnolent,  needs 
to be stimulated to 
take feedings. Somnolent,  unable to 
be stimulated  to take 
feedings. 
OR 
Inconsolable 
irrita bility or crying 
with u nusually hi gh 
pitch or scre aming 
for > 3 hours 
 
 
IMPAACT P1090                                                                                         Page 95 of 113    10 March  2016  
Version 5.0   
APPENDIX VII -A: SUPPLEMENTAL TOXICITY TABLE  FOR G RADING  SEVERITY  AND MANAGEMENT  OF ADU LT AND 
PEDIA TRIC CUTANEOUS ADVERSE EXPERIEN CES 
 
 
Since cutaneous adverse events are of particular i nterest  for this dru g, the following guidelines on  monitoring and  management shou ld be follow ed.  Please 
refer to Ap pendix IV w hich descri bes the visit sc hedule for manage ment of cutaneous adverse  events. 
 
NOTE: These manage ment guidelines  are NOT applicable to rashes with  clear alter native eti ology, such as chicken pox, impetigo and cut aneous HSV. 
Cetirizi ne, lev ocetirizi ne, topical c orticosteroids and anti-pruriti c agents will be allowed  at the investigator’s discreti on for all grad es of rashe s. 
 
 
CUTAN EOUS  ADVE RSE EVENTS  
 Grade Descr iption Subject Management 
 
Cutaneous 
rash /  
reaction  GRADE  1 Localized  macular  rash  Subjects  with Grade 1 or Grade 2 rash may conti nue etravirine 
or temporarily i nterrupt therapy at t he investi gator’s discre tion. 
 Close cli nical f ollow up  is rec omme nded to  monitor 
progress ion of  rash.  
GRADE  2 Diffuse macular, maculopapular or morbilliform rash or 
target lesio ns  Subjects  with Grade 1 or Grade 2 rash may conti nue etravirine 
or temporarily i nterrupt therapy at t he investi gator’s discre tion. 
 Close cli nical f ollow up  is rec omme nded to  monitor 
progress ion of  rash.  
 All s ubjects with Grade 2 rash must be seen by a dermatologist 
within 24  to 48 h ours. 
 GRADE 3   Diffuse macular, maculopapular or morbilliform rash 
with vesicles  or limited number of bullae 
  Cutaneous reaction /rash with s uperficial ulcerati on of 
mucous membrane limited to 1 mucosal site  
  Cutaneous reaction/ra sh with at least 1 of  the following: 
o Elevations  of ALT/AST > 2x baseline but at least  
5x upper limit of laboratory  normal range (ULN)  
o Fever ≥38oC or 100.4oF 
o Serum  sickne ss-like reaction  
o Eosinophil count >1000/mm3  Subjects  exper iencing  a Grade  3 rash or cut aneous event must 
have  etravirine  discontinued permanentl y; but should remain 
on study for safety follow-up 
 OBR sho uld be held at t he discreti on of the site i nvestigator 
 Subjects  must also  be evaluated by a dermatologist wit hin 24 to  
48 hours 
 The p rotocol team should be  notified of a Gr ade 3 event at 
impaact.p1090 cmc@fstrf.org  
 
 
IMPAACT P1090                                                                                         Page 96 of 113    10 March  2016  
Version 5.0    
 
 GRADE 4   Extens ive or generalized bullous  lesions 
  Steve ns-Johnson syndrome (SJS)  
  Ulcerati on of mucous membrane involving 2 or more 
distinct mucosal sites  
  Toxic ep idermal necrolysis (TEN)   Subjects  exper iencing  a Grade  4 rash or cut aneous event must 
have  etravirine  discontinued permanentl y; but should remain 
on study for safety follow-up 
 OBR sho uld be held at t he discreti on of the site i nvestigator 
 Subjects  must also  be evaluated by a dermatologist wit hin 24 to  
48 hours 
 The p rotocol team should be  notified of a Gr ade 4 event at 
impaact.p1090 cmc@fstrf.org  
 
  
 
 
IMPAACT P1090                                                                                         Page 97 of 113    10 March  2016  
Version 5.0  APPENDIX VII -B: SUPPLEM ENTAL  TOXICITY  TABLE FOR G RADING S EVERITY  AND MANAGEMENT OF ADULT  AND 
PED IATRIC A CUTE SYSTEMIC ALLERGIC  ADVERSE  EXPERIENCES  
 
 
 
ACU TE SYSTEMIC ALLE RGIC ADVE RSE EXPERI ENCES 
 Grade Descr iption Subject Management 
Urticaria  GRADE  1 Localized urticaria with no  medical i ntervention indicated  Subject may conti nue intake of etrav irine 
GRADE 2  Localized urticaria with medical intervention indicated  
 Mild  angiodema with no  medical i ntervention indicated  Subject may conti nue intake of etrav irine 
GRADE 3  Generalized  urticaria  or angioedema with  medical 
intervention indicated  
 Symptomatic mild  bronchospasm  Subjects  with Grade 3 acute systemic aller gic reacti ons wi ll be 
permanently d iscontinued from the investigational medication  
(ETR) and background regimen but will be followed on  study on a 
modified sched ule (A ppendix IE) f or safety  outcomes 
 Subjects will be treated  as cli nically a ppropriate per the local 
physician  
GRADE 4  Acute  anaphylaxis 
 Life-threaten ing bronchospasm 
 Laryngeal edema  Subjects with  grade 4 acute syst emic allergic reactio ns will be 
permanently d iscontinued form the investigational medication  
(ETR) AND  background regimen (OBR)  but will be followed on 
study  on a modified schedule (Appendix IE) for safety outcomes 
 Subjects will be treated  as cli nically a ppropriate per the local 
physician  
 The p rotocol team should be  notified of a Gr ade 4 event at 
impaact.p1090 cmc@fstrf.org  
 
 
 
 
 
   IMPAACT P1090  Page 98 of 113 10 March  2016
 Version 5.0   
 APPENDIX VIII : SAMPLE INFORMED CONSENT  
 
DIVISION OF AIDS  
INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS 
GROUP (IMPAACT)  
 
A Phase I/II, Open -Label  Trial  to Evaluate  the Safety,  Tolerability,  Pharmacokinetics  and 
Antivi ral Activity  of Etravirine (ETR)  in Antiret roviral (ARV) Tre atment-Experien ced HIV-1 
Infected  Infants and Children,  Aged  ≥ 2 Months to  < 6 Years  
 
P1090, Version 5.0, dated  March  10, 2016  
 
SHORT TITLE  FOR THE  STUDY:  Safety  and Pharmacokin etics of Etravirine  in HIV-1 
Infected  Infants and Children  
 
INTRODUCTION  
Your child  is being  asked  to take part in this research  study  because  he/she is infected  with HIV. 
This study  is sponsored by the  National  Institutes  of Health  (NIH).  The  doctor  in charge  of this 
study  at this site is: (insert  name of Principal  Investigator) . Before  you decide  if you want  your 
child  to be a part of this  study,  we want  you to  know about  the study.  
 
This is a consent form. It gives  you info rmation  about  this study.  The study  staff will talk with 
you about  this infor mation.  You are  free to ask qu estions  about  this study at any time.  If you 
agree  to allow your child  to take part in this study, you will be asked  to sign this consent form. 
You will  get a copy  to keep.  
 
WHY IS THIS STUDY BEING DONE?  
This study  is being  done  to look at a new antiretroviral  HIV medication  called  etravirine.  This 
drug is  a type of medicine  called a non-nucleoside  reverse  transcri ptase inhibitor (NNRTI).  This 
drug has not  been  tested  in younger  children  before  but has been  tested  in animals, older  children 
(6 to <18 years  of age)and  adults  and is currently  approved  by the  FDA for use in  treatment- 
experienced  HIV-1 infected  adults  and children>6  years  of age.  The study  will help find the best 
amount or dose of etravirine  for infants  and younger  children,  when it  is taken  with other  
antiretrovir al medicatio ns. This study will also find out the safety of using  this medication  in 
infants  and children  and if there  are any side effects  from  the medication.  This medication  is 
produced  by Janssen Research  & Develop ment, a pharmaceutical  company.  
 
WHAT DOES MY CH ILD HAVE TO DO IF HE/SHE IS IN THIS S TUDY?  
If you deci de to allow  your child  to enroll  in this study,  you will  be asked  to bring  your child  to 
the clinic  approxi mately  11 times over 48 weeks.  Your child  will be asked  to take the study  drug 
(etravirine)  2 times a day, following  a meal, in addition  to his/her  regular  anti-HIV medici nes. 
Your child’s  regular  anti-HIV medications  will NOT be  provided  by the  study,  however, 
Darunavir  will be provi ded by the  study if not reasonably  available  locally. Etravirine  will be 
provided  for your child  by the  study,  at no cost  to you or your  insuran ce. It is available  in tablet  
form that can be swallowed  whole  or can  be dispersed  in a liquid.  The formulation  your child 
receives  will depend  on your child’s  age and whether  your child  can swallow pills.  
 
 
 
   IMPAACT P1090  Page 99 of 113 10 March  2016
 Version 5.0   
 (Sites should delete the foll owing  sentence  if appropriate ): 
The clinic will provide  you with  sterile  water  so that your c hild can take the medicati on safely.  
 
This study  will help doctors  to find the right  dose of study  drug for your chil d; the study will 
then keep  them  on that  dose to  look for any  side effects  your child  might experience.  
 
If your child  misses a dose of etravirine,  a dose of etravirine  should  be taken  if it is within  6 
hours of the  missed dose ti me. If your child  vomits within  15 minutes  of taking  a dose of 
etravirine,  a second  dose of etravirine  should  be taken.  
 
As part  of this study  your child  will be assigned  to a group (cohort),  based  on his/her  age. There 
are 3 coh orts in this study, each with a minimum of 12 participants.  
 
Screenin g: 
If you are  interested in allowing  your child  to enroll in this study, we will  see if your c hild is 
eligible  for the  study:  
 
 We will ask about  your child’s  medical  history including  questions  about your child’s 
health  and what  symptoms, medication s, and illnesses  your child  has had. 
 
 We will do a special  test called  an electr ocardiogram (ECG).  Your child  will have 
special  electrical  wires placed on their  chest  and a machine  will read your chil d’s heart 
rhyth m. This is a painless  test. 
 
 We will do a physical  exam  including  height,  weight and vital signs (temperat ure, blood 
pressure, pulse  and respiratory  rate).  
 
 We will also ask your c hild to provide a urine sample  for a urine  test. 
 
 We will take a little less than 3 teasp oons (14mL) of blood if your child is older than 1 year of 
age and a little more than 2 teaspoons (10mL) of blood  if your child is less than a year of age  
to check  the following:  
o The amount of HIV in  your child’s  blood;  
o How well  your child’s  immune  system  and kidneys are working  
o Whether  your child  is resistant  to certain  HIV medications  (if your child  is 
resistant  to the study  drug,  it will not work properly)  
You will  be given  the results of these tests as they beco me available.  
 
On Study:  
Your study  doctor  will tell you whether  your c hild is eligible for this  study. The study team  will 
deter mine this based  on the  number of children  in each age group that  have already  entered  the 
study  and your child’s  results  from  the laboratory  tests,  history  and physical  at screening.  
 
If your child  is eligible for this  study, your child  will come to the clinic approxi mately10  more 
times in about  48 weeks.  Most of the  visits  will last about 1 to 2 hours.  More vi sits will be 
needed  if the amount of study  drug (etravirine)  in your child’s  blood  is too low or too  high and 
your child’s  dose needs  to be adjusted. Your chi ld will come to the clinic for the  first study  visit 
 
 
   IMPAACT P1090  Page 100 of 113 10 March  2016
 Version 5.0   
 within  60 days of the  screening  visit.  
 
 At each  visit,  a medical  history  will be taken (including  questions  about  your child’s 
health  and what  symptoms, medications,  and any illnesses  your child  has had)  and your 
child  will have  a physical  exam. You will  also be asked  some  questions  to see if your 
child  has been  taking  his/her  medicine  as directed.  
 We will draw between  5 to 15mL (1- 3 teasp oons) of blood  at each visit, depen ding on 
the child’s  age and the specific study visit.  You will be informed of results  of routine 
blood  tests when available.  Some of the  blood  collected  will be stored  for later  tests.  
 We will also ask your c hild to provide a urine sample  for a urine  test. 
 A staff  member  from  the clinic  will call you t he day before  the intensive  PK visit  to make 
sure your child  did not miss any study  medications.  
 After  your child  has been  taking  the study  medication  for 14 days (±  4 days), your child 
will be asked  to come to the clinic  to have blood  drawn 7 ti mes over 12 hours during  one 
visit (Intensive  PK visit).  
 
o  Before  the intensive  PK visit:  Your child  will be asked  not to take their morning 
dose of etravirine  but to bring  it with them  to the clinic. It is very important  that 
your child  take all their etravirine  medicat ions as directed  by the  clinic,  for 7 days 
prior  to the PK visit.  
 
o  What will happen  at the inten sive PK visit:  
o This blood  test is done  to measure  the amount of study  drug in  your child’s 
blood.  
o Your child  will be offered break fast appropriate  for his/her  age prior  to taking 
their morning  dose of etravirine.  
o A small plastic catheter  will be placed in your c hild’s arm to draw blood 
samples up to  seven  times during  the visit.  A catheter is a needle that is 
placed  in a vein for an  extended  period of time, so that  blood can be collected 
several  times, without  having  to stick  your child  with a needle each time. The 
needle  will stay in place until all of the  blood  samples  are drawn.  
o We will do a special  test called  an electrocardiogram (ECG).  Your child  will 
have  special electrical  wires placed on their  chest and a machine  will read 
your child’s  heart  rhythm.  This is a painless  test. 
 
o  After the intensive  PK visit:   Based on the results, a change  in dose (eith er higher or 
lower)  maybe  required.  If this  test shows that  the amount of study  drug in  your 
child’s  blood  is not high enough  or is too high,  your child  will be asked  to take a 
higher  or lower  dose of etravirine  and return  to the clinic for an  additional  visit for 
a repeat  intensive  PK visit,  so that  blood can be collected  again,  up to  7 times over 
12 hours.  If you decide  not to have  this test repeated,  your child  will come off the 
study  drug.  An additio nal PK visit  may also be required,  if the results  of the  test 
are incomplete or hard to evaluate.  
 
 Approxi mately  four weeks after  your child  started  the study  medications,  your child  will 
be asked  to come back  to clinic  for a populat ion PK visit.  Your child  will have  a little 
between 1 and  2 teaspoons  of blood  drawn ( 6 to 9mL) for tests  depending on your 
 
 
   IMPAACT P1090  Page 101 of 113 10 March  2016
 Version 5.0   
 child’s age , as well  as a history  and physical exa m. Your child  will also be asked  to 
provide  a urine  sample. 
 
 Your child  will be asked  to come back  to clinic  for a repeat  population  PK visit  at week  
8, week  12, week  24 and  week  48 after  starting  study  medications.  Your child  will have 
approxi mately  6-15mL (1 - 3 teas poons)  drawn  at each visit for laborat ory tests,  as well as 
a history and physical  exam. Your child  will also be asked  to provi de a urine  sample. 
 
 The study  team  will be reviewing  the PK res ults of all  of the  children who have  been 
enrolled  and may determine  that your child  should  have  a higher  or lower  dose of 
etrav irine. If so, your child  will be asked  to return to the clinic  for an  additional  PK visit, 
so that  blood  can be collected  again,  but only 3 times over no more than 5 hours.  
 
 If during  this research  study,  your child  gets a rash, please  contact  the research  doctor 
immediately  (please insert a daytime and after hours contact number her e) and  make an 
appoint ment for your child  to be seen the same day. The research  doctor will help you 
decide  if your child  needs  to stop taking  etravirine.  Your study  doctor  may want  you to 
be seen by a dermatologist  (a doctor  that specializes  in skin proble ms). This visit will be 
paid for by the  study.  
 
 In the  case that your child  has a  severe  rash,  a skin doctor  (dermatologist)  may request  that 
a small piece  of skin  is taken to see what  type of rash it  is. This is called a skin biopsy. 
There  is a slight  risk of infection  or bleeding  or scar  formation  with this procedure.  The 
skin doctor  may wish to  take pictures  of the  rash so it  can be docu mented.  You may be 
asked  to sign a separate  consent  form to allow  the doctor  to do the  skin biopsy  and/or  take 
a photograph  of the  rash.  This  visit will be paid for by the  study.  
 
Long Term Follow -Up 
After  your child  has been on study  drug for approxi mately  48 weeks, he/ she will enter  the long 
term follow -up phase  of the  study  which  for up to  5 years.  Your child  will be asked  to come 
back  into the clinic every  12 weeks until the drug is availa ble in your c ountry  by prescri ption. 
Most vi sits will last about 30 minutes.  
 At each  visit, a medical  history  will be taken  and you/your  child will have a physical 
exam. You will  also be asked  if you h ave missed taking  any of your medications.  
 2 teaspoons  of blood  (10 mL) will be drawn e very 24 weeks (at  every  other visit). You 
will be infor med of results  of routi ne blood  tests as they  become available.  
Your child  must  continue  to take his/her  anti-HIV medications  during  the study  as prescribed  by 
your child’s  HIV care  provider.  If your child’s  HIV care  provider  changes  your c hild’s anti-HIV 
medications  during  the study,  your c hild can still take the study drug.  Your child  will be asked  
questions  about  taking  his/her  anti-HIV medications  and the schedu le he/she  takes  them  on and  if 
you he/she  has missed any medications.  
 
Blood  Samples 
Some of your child’s  blood samples will be shipped to a central reposito ry in the USA so that 
they can be sent to specialized  laboratories  for testing  later in the study.  You will  not receive  the 
results  of these tests.  
 
 
 
   IMPAACT P1090  Page 102 of 113 10 March  2016
 Version 5.0   
 FOR NICHD Sites:  
Some of your child’s  blood  speci mens collected  as part  of this  study  will be stored  for testing  at a 
later date as part  of this  study.  There  is a separate  consent  form  to explain  this and get your 
consent.  
 
For NIAID Sites:  
Storage  of Blood  Samples 
 
Some of your child’s  blood will be stored (with  usual protectors of identity)  and used for future 
IMPAACT -approved,  HIV-related  research.  About 1teaspo on (4 mL) of blood  will be taken  for 
this purpose.  
 
Your child ’s samples will be stored at a special laboratory  facility. Only approved  research ers 
will have  access to them.  People  who work at  the facility  will also have access  to your child’s 
samples to keep  track  of the m. These people  won’t have  information  that directly identifies your 
child.  Your child’s  samples will not be sold or directly  used to  produce  commercial products.  
All proposed research  studies  using  your child’s  samples will be reviewed  by the  National 
Institutes  of Health  (NIH).  There  is no time limit on how long  your child’s  samples will be 
stored.  
 
The researchers  do not  plan to contact  you or your child’s  regular  doctor  with the results  of 
studies  done  using  your child’s  stored samples. This is because  research  studies  are often  done 
with experi mental  procedures.  The results  of such studies  should  not be used to  make decisions 
about  your child’s  medical  care.  If the  researc hers decide  that the result  of a certain  study 
provides  importa nt infor mation  for your child’s  medical  care,  your child’s  study  doctor  will be 
notified.  If you  would like  to be contacted  with this sort of info rmation,  you must notify  the 
study  staff of any  changes  in your address or phone  number. 
 
You may decide that you do not  want  your child’s  samples stored  for future  research  studies. 
Your child  can still partici pate in this study  even  if you make this decision.  
 
You may withdraw  your consent  for the  storage  and use of your child’s  samples  at any time. If 
you withdraw  your consent,  these  stored  samples will be destroyed.  
 
Please  read the following  statement carefully  and then mark your initials  in the appropriate  space 
provided.  
 
 
I agree  to allow  my child’s  blood  samples to be stored  for use in  future  IMPAACT -approved, 
HIV-related research studies. 
 
   Yes    No    Date  
  
 
 
   IMPAACT P1090  Page 103 of 113 10 March  2016
 Version 5.0   
 OTH ER INFORMAT ION 
The information  collected in this study may be used for other  IMPAACT -approved  HIV-related 
research.  
 
HOW MANY CHILD REN WILL TAKE  PART IN THIS S TUDY?  
Up to  50 babies  and children  will take part in this study.  
 
HOW LONG WILL MY CHILD BE IN THIS STUDY?  
Your child  will be in this study  for at  least 48 weeks, depending  on when your child  joins, and 
how long  it takes  to find the right  dose of study  drug for children  in your child’s  age group.  As 
long as your child  is doing  well on the  medicine,  your child  will then enter  the long term safety 
follow -up phase  of the  study  and will continue  to come into clinic  every  12 weeks, until  the drug 
is available  in your country  by prescription.  
 
WHY WOULD THE  DOCTOR TAKE MY CHILD OFF THIS STUDY EA RLY? 
The study  doctor  may need  to take your chi ld off the  study  early  without  your per mission  if: 
 The study  is cancelled  by the  U.S. Food  and Drug Ad ministration (FDA), National 
Institutes  of Health  (NIH), the  drug c ompanies  supporting  this study,  the Office for 
Human Research  Protections  (OHRP) or other  govern mental  agencies,  or the  site’s 
Institutional  Review  Board  (IRB).  An IRB  is a committee that watch es over the 
safety  and rights  of research  subjects.  
 A Study  Monitoring  Committee  (SMC) recom mends that the study  be stopped  early.  
An SMC is  an outside  group of experts  that monitors  the study.  
 Your child  is not able to attend  the study  visits  as required  by the  study.  
 Your child  refuses to  undergo  repeat  intensive  PK for manage ment of individual  dose 
adjust ments. Your child  will have  etravirine therapy disconti nued and will be followed  
on study  but off study  drug.  
 
The study  doctor  may also need  to take your child  off the  study  drug(s) without  your per mission 
if: 
 Continuing  the study  drug(s) may be harmful  to your child  
 Your child  needs  a treatment that your child  may not take while  on the  study  
 Your child  is not able to take the study  drug(s)  as required  by the  study  
 
If your child  needs  to stop taking  etraviri ne during the first 48 weeks of the  study,  he/she will be 
asked  to come back  to clinic  four weeks after  they stop taking  etravirine  for a final study  visit. 
This visit will include  a medical  history,  physical  exam  and 2 teaspoons  (10mL) of blood  will be 
drawn for blood  tests to check  the amount  of HIV in your child’s  blood,  to see how well  your 
child’s immune  system  is working, and  for other  routine tests. Your child  will not enter  the long 
term follow -up phase  of the  study.  
 
IF MY CHILD HAS TO PERMANENT LY STOP  TAKING S TUDY -PROVID ED MEDICINE,  
OR ONCE HE/SHE L EAVES  THE STUDY, HOW  WOU LD THE  STUDY  MEDI CINE BE  
PROV IDED?  
 
During the  Study: 
If your child  must permanently  stop taking  study-provided  medicine  before  your child’s  study 
 
 
   IMPAACT P1090  Page 104 of 113 10 March  2016
 Version 5.0   
 participation  is over,  the study  staff will discuss other  options that may be of benefit  to your 
child.  
 
After  the Study:  
After  your child  leaves  the study,  if he/she  is gaining  benefit  from  the study -provided  drug 
(etravirin e), this drug will  continue  to be provided until it is available to your child  in your 
country.  
 
EAR LY STUDY  DISCONTINUATION  
In the  event that you or your child  decides  to withdraw  from  the study  prior  to Week 48, we will 
ask that  your child  returns  for a final visit.  At this  visit:  
 
 A medical  history  will be taken  (including  questions  about  your child’s  health  and what 
symptoms, medications,  and any illnesses  your child  has had)  and your child  will have  a 
physical  exam.  You will  also be asked some questions  to see if your child  has been 
taking  his/her  medicine as directed.  
 We will draw between  8 to 12mL (1½- 2½- teaspoons)  of blood  depending  on the  child’s 
age. 
 We will also ask your c hild to provide a urine sample  for a urine  test.  
WHAT A RE THE  RISKS OF THE STUDY?  
 
The drug used in  this study  (etravirine)  may have  side effects,  some of which  are listed  below. 
Please  note that these  lists do not  include  all the side effects  seen with this type of drug. These 
lists include  the more serious or co mmon side effects  with a known or possible  relationship.  If 
you have  questions  concerning  additional  study  drug side  effects  please ask the  medical  staff at 
your site.  It is important  to report  all side effects  to your study  doctor, even  if not listed  below.  If 
any of the  side effects  gets serious, contact  your study  doctor  immediately.  
 
Use of Combination  Antiretroviral  Drugs 
 
Immune  Reconstitution  Syndro me: In so me people  with advanced  HIV infection,  signs and 
symptoms of infl ammation  from  other  infections  may occur  soon after  anti-HIV treatment is 
started.  
 
The use of potent  antiretrovir al drug co mbinations  may be associated  with an abnor mal 
place ment of body fat  and wasting.  Some of the  body changes  include:  
 Increase  in fat around  the waist  and stomach area 
 Increase  in fat on the  back  of the  neck  
 Thinning  of the  face,  legs, and arms 
 Breast  enlarge ment 
 
Risks of Etravirine  
 
The following  side effects  have  been  associated  with the use of etravirine:  
 
 Serious and  life-threatening  rash and allergic  reactions  (hypersensiti vity). If you get  a 
rash with  any of the  following  symptoms contact  your child’s  HIV care provider  and the 
 
 
   IMPAACT P1090  Page 105 of 113 10 March  2016
 Version 5.0   
 study  doctor  or nurse right  away:  
 
 Fever  
 Muscle  or joint aches 
 Hives or sores in  your mouth,  or your skin  blisters  and peels  
 Trouble  swallowing  or breathing  
 Swelling  of the  face,  eyes,  lips, tongue or thr oat 
 Red or inflamed eyes,  like “pink  eye” (conju nctiviti s) 
 Yellowing  of the skin or whites  of the eyes,  dark urine,  or pain  on the  right  side of 
the stomach. 
 Your doctor  might also find some abnor malities  in a certain  type of your white 
blood  cells.  
 
 Other  serio us side effects:  
 
 Muscle  break  down causing  muscle  aches,  pain or weakness which  can be serious  
 
 Additional  side effects  include:  
 
 Skin rash, mostly  mild to moderate  was sometimes seen,  usually  during  the first 2 
weeks of taking  etravirine  and lasting  for about  a week.  In clinical  studies,  rash 
occurred  more frequently  in females than in males. 
 Mild  to moderate  diarrhea  (liquid  stool s), nausea  (upset  stomach or feeling  the 
need  to throw up), vo miting 
 Numbness, pain  or tingl ing in the hands or feet  
 Headache,  stuffy nose, tiredness  
 Some other  less com mon, but serious reported  side effec ts include  a decrease  in 
red blood  cells or a decrease  in the part of the  blood  that stops bleeding,  decrease 
in kidney  function,  high blood  pressure, increase  in blood  sugar, increase  in 
cholesterol  or fats  in your blood  and decreased  appetite  
 Other  less com monly occurring  side effects  of at least moderate  intensity  include 
gastro -esophageal  reflux  disease  (GERD), flatulence,  inflam mation  of the 
stomach, abdo minal pain,  anxiety,  inability to sleep,  and night  sweats.  
 
Immune  Reconstitution  Syndro me:  In some people with advanced  HIV infection, 
symptoms from other  infections  or cer tain diseases  may occur  soon after  starting 
combination  anti-HIV treatment. Other  non-infectious  diseases  characterized  by abnor mal 
functioning  of the  immune system  (so-called  autoi mmune  disorders, like Graves’ disease)  
have also been  reported after the start of anti-HIV treatment, but so metimes with a delay  of 
many months.  Some of these  sympto ms may be life threatening.  If you start  having  new 
symptoms, or notice  that existing  sympto ms are getting  worse after  starting  your 
antiretroviral  therapy,  tell your hea lthcare  provider  right away.  
 
 
Other  Risks  
There  is the risk of serious and/or  life threa tening  side effects  when  non-study medications  are 
taken  with etravirine.  For your child’s  safety,  you must tell your child’s  HIV care  provider  and 
the study  doctor  or nurse about  all medications  your child  takes  before the start of this  study  and 
also before  starting  any new medications  while  your child  is on the  study.  In addition,  you must 
 
 
   IMPAACT P1090  Page 106 of 113 10 March  2016
 Version 5.0   
 tell the study  doctor  or nurse bef ore enrolling  your child  in any other  clinical trials while on this 
study.  
 
The use of potent  antiretrovir al drug combinations  may also be associated  with abnor mal 
processing  of body and  dietary  fat including  elevated  triglycerides  (fatty acid in the blood)  and/or 
elevated  cholesterol.  
 
Other  side effects  besides  those  listed  and side effects  from  taking these  drugs together  may 
occur.  If any  unusual  sympto ms or changes  happen,  you should  call your child’s  doctor 
immediately.  It is also import ant that while  participating  in the study,  your child  does not  take 
any other  prescription  drugs or ov er-the-counter  medications  without  first talking  to your child’s 
doctor  or study  nurse.  
 
Blood  Drawing and  Heparin/Saline  Lock  Risks  
Blood  drawing  may cause  some disco mfort, bleeding  or bruising  where  the needle  enters  the 
body.  A small blood  clot may form at the site of venipuncture/heparin  lock or there  may be 
swelling  in the area.  There is a small risk of a  minor infecti on at the blood  draw/heparin  lock 
site. Lightheadedness  and fainting  can also occur.  
 
ARE THERE BEN EFITS  TO TAKING PART IN THIS S TUDY?  
If your child  takes  part in this study,  the amount of HIV in  your child’s  body may go down and 
your child’s  immune  system  may beco me stronger,  but no guarantee  can be made. Your child 
may receive  no benefit  from  being  in this study.  Information  learned  from  this study  may help 
others  who have  HIV.  
 
WHAT O THER CHOICES DOES MY CHILD  HAVE  BESIDES  THIS  STUDY?  
Instead  of being  in this study  you have  the choice  of: 
 Treat ment with prescription  drugs available  to your child  
 Treat ment with other  experi mental  drugs, if  your child  qualifies  
 
Please  talk to your doctor  about  these  and other  choices  available  to your child.  Your doctor  will 
explain  the risks and  benefits of these  choices.  
 
WHAT A BOUT CONFIDENTIAL ITY? 
(US sites only)  
To help us protect  your child’s  privacy,  we have  obtained  a Certificate  of Confidentiality  from 
the Natio nal Institutes  of Health.  With this Certificate,  the researchers  cannot be forced  to 
disclose  infor mation  that may identify  you, even  by a court  subpoena,  in any federal,  state,  or 
local  civil,  criminal, administr ative, legislati ve, or other  proceedings.  The researchers will use 
the Certificate  to resist  any demands for info rmation  that would identify  you, except  as 
explained below.  The Certificate  cannot  be used to  resist  a demand for info rmation  from  
personnel  of the  United  States  Govern ment that is used for au diting or eval uation  of federally  
funded  projects  or for info rmation  that must be disclosed  in order  to meet the require ments of 
the federal  Food and Drug Ad ministration  (FDA).  
 
People  who may review  your child’s  records  include  the U.S. Food and  Drug Ad ministration,  the 
site IRB (insert name of site IRB), t he Nation al Institutes of Health,  the Office of Human 
Subjects  Protection  (OHRP), host  country  regul atory agencies,  study  staff,  study  monitors, 
 
 
   IMPAACT P1090  Page 107 of 113 10 March  2016
 Version 5.0   
 Janssen R&D  and their designees.  
 
You should  understand  that a Certi ficate  of Confidentiality  does not prevent  you or a  member  of 
your f amily from  voluntarily  releasing  infor mation  about  you or your participation  in this 
research. If an insur er, employer,  or other  person obtains  your written  consent to receive 
research  information,  then the researchers  may not use the  Certificate  of Confidentiality  to 
withhold  that infor mation.  
 
(For sites o utside the U. S.) 
Efforts  will be made to keep  your child’s  personal infor mation  confide ntial. We cannot  guarantee 
absolute  confidenti ality. Your child’s  personal  information  may be disclosed  if required  by law.  
Any publication  of this  study  will not use your child’s  name or identify  your child  personally.   
Your child’s  records  may be reviewed  by the  Ministry  of Public  Health  in your country,  the FDA, 
the Office  of Human  Research  Protections  (OHRP), the  NIH, (insert  name of site)  IRB,  study 
staff,  study  monitors  and the drug co mpanies supporting  this study.  
 
WHAT ARE THE  COSTS TO MY CHILD?  
There  are no costs to  you/your  child  for study  drug (etravirine),  study  visits  or study  procedures. 
However, taking  part in this study may lead to added  costs to  you and  your insurance  company  if 
medical  complications  arise  or if your doctor  decides  extra tests are needed. You will  be 
responsible  for the  cost of your  child’s  anti-HIV medications  that are not provided  by the  study. 
In so me cases  it is possible  that your insuran ce company  will not pay for these  costs because  
you/your child  are taking  part in a research  study.  
 
WILL MY CHILD RECEIVE  ANY PAYMENT?  
You will  receive  [$XX] for each  study visit you attend.  If you attend  all study visits,  you may 
receive  up to  [$XX].  
 
WHAT HAPPENS IF MY CHILD IS INJURED?  
If you are/your  child  is injured  as a result  of being  in this study,  you/your child  will be given 
immediate  treatment for your/hi s/her injuries.  The cost for this treatment will be charged  to you 
or your insurance  company.  There  is no program  for co mpensation  either  through  this institution 
or the  National Institutes  of Health  (NIH).  You will  not be giving up any  of your/your  child’s 
legal  rights  by signing  this consent  form. 
 
WHAT A RE MY CHI LD’S RIGH TS AS A R ESEA RCH SUBJECT?  
Taking  part in this study  is completely  voluntary.  You may choose  not to take part/not  to allow 
your child  to take part in this study  or leave  this study/take  your child  out of the  study  at 
anyti me. Your decision  will not have  any impact on your participation  in other studies  
conducted  by the  NIH and  will not result in any penalty  or loss  of benefits  to which  you are  
otherwise  entitled.  
 
We will tell you about  new information  from  this or other  studies  that may affect  your health, 
welfare  or willingness  to stay in this study.  If you want  the results of the  study,  let the study  staff 
know.  
 
 
 
   IMPAACT P1090  Page 108 of 113 10 March  2016
 Version 5.0   
 WHAT DO I DO IF I HAVE QUE STIONS OR PRO BLEMS? 
For questions  about  this study  or a research -related  injury,  contact:  
 Name of the  investigator  or other  study  staff 
 Telephone  number of above  
 
For questions  about  your child’s  rights as a research  subject,  contact:  
 Name or title  of person on the  Institutional  Review  Board  (IRB) or other  organization 
appropriate  for the  site 
 Telephone  number of above  
 
 
 
  
 
 
   IMPAACT P1090  Page 109 of 113 10 March  2016
 Version 5.0   
 SIGNA TURE PAGE  
 
If you have  read this consent  form  (or had  it explained  to you), all  your questions  have  been 
answered  and you agree  to allow  your child  to take part in this study,  please  sign your na me 
below.  
 
 
 
 
Participa nt’s Name (print)  
 
 
 
 
 
Participa nt’s Mother  (print)  Mothe r’s Signature  and Date  
 
 
 
 
 
Father’s  Name Father’s  Signature  and Date  
(If father’s  consent  is required)  (If father’s  consent  is required)  
 
 
 
 
 
Participant’s  Legal  Guardian  (print)  Legal Guardian’s  Signature  and Date  
(As appropriate)  
 
 
 
 
Study  Staff  Conducting  Study  Staff  Signa ture and Date  
Consent  Discussion (print)  
 
 
 
 
Witness’  Name (print)  Witness’s  Signature  and Date  
(As appropriate)  
  
 
 
   IMPAACT P1090  Page 110 of 113 10 March  2016
 Version 5.0   
 APPENDIX IX : FACT SHEET and TEMPLATE CONSENT FORM for  SPECIMEN STORAGE 
AT REPOSITORIES FUNDED BY THE NATIONAL INSTITUE OF CHILD HEALTH AND 
HUMAN DEVELOPMENT (NICHD)  
 
When  your child  joins  this NICHD sponsored study, you will  be asked  to give permission  for 
having  some speci mens that the doctor or nur se will take from your chil d’s body saved  in a 
repository.  (A repository  is a special  laboratory  with freeze rs where  speci mens like blood  or 
tissue  cells and body fluids  that are taken  from  you during  a study  are kept.  Your child’s  name 
will not be on these  specimens, only a speci al study number. The people  who run the  repository 
laboratory  will not know your child’s  name.) 
 
Why  have  a repository?  
 
Researchers  can learn  a lot from  a study  but as time goes by the  tests that they used get  better  or 
brand  new tests  are developed,  and more  can be learned  with these  better  or new tests.  When 
study  volunteers  consent  to put speci mens in the repository  and consent  to the researchers  doing 
new tests  on the  speci mens at some time in the future  after their time in the study  is ended, 
resea rchers can learn new information  by being  able to use the  speci mens. Your child’s  rights 
and privacy will be protected in any of these  new studies.  
 
How will  my child’s privacy  be protected? 
 
The only record  that your child  participated  in this NICHD sponsored study  is at the clinic where 
it is kept separate  from  your chi ld’s health  records and locked  away.  
 
Your child’s  speci mens in the repository  will not have  your child’s  name on the m. The 
speci mens will have  a special  study  code.  It will be the same code  that is on your child’s 
infor mation  in the NICHD sponsored Study  from  your child’s  interviews  and examinations. 
Again,  none  of this  infor mation  will have  your child’s  name on it.  
 
How would a  researcher  get to use the  speci mens in the repository?  
 
If a researcher  wants to  do a test  on speci mens from  the NICHD sponsored repository  in the 
future,  he or she will  write up the  idea and it will have  to be approved  by a committee to make 
sure the  research is worthwhile.  If the idea is approved,  then coded  speci mens and coded 
infor mation  will be given to the researcher.  The researcher  will not know the  names, addresses, 
or phone  numbers  of the  people  who gave  the speci mens to the repository.  
 
Why  wouldn’t  I find  out the results of the research  using  my child’s speci mens? 
 
You will  not receive  the results  of research  done  with your c hild’s specimens.  This is because 
research  can take a long time and must use s pecimens from  many peop le before  results  are 
known. Results  from  research  using  your child’s  speci mens may not be ready  for many years. 
Often  when studies  are first done,  it is not always  clear  how to  use the  infor mation  from  the 
study  to change  the health  care that people  recei ve. So none  of these  study  results  is likely to 
affect  your child’s  care right  now, but  they may be helpful  to people  like your child  in the future. 
Your child’s  speci mens can last in the freezer  for many years  and there  is no time limit to when 
 
 
   IMPAACT P1090  Page 111 of 113 10 March  2016
 Version 5.0   
 studies  could  be done  in the future.  
 
Would  I ever  be contacted  in the future  about  research  using  my child’s  speci mens? 
 
All of the  studies  to be done in the future on your chil d’s speci mens in the repository  will be for 
the particular  reasons that  you agreed  to. Every  study  that is planned  to use speci mens from  your 
child  and others  from  this NICHD Study  has to  be reviewed  to make sure that  what  is planned  is 
the same kind of study  that you agreed  to. If it is, then the research  will go ahead  since  you 
would have  agreed  that these  particular  tests could  be done  without  anyone  contacting  you to  get 
your per mission  in the future.  
 
If the  study  to be done  is not like the kind of tests  you agreed  could  be done, then the committee 
will decide  if you need  to be contacted  to give permission  for the  new study.  
 
I gave  my permission  to testing  my child’s  speci mens in the repository,  but what  if I change  my 
mind? 
 
People  always  have  the right  to stop participating  in research.  So if you decide  that you do not 
want  researchers  to be able to use the  speci mens from  your child  in the repository,  you can 
contact  the clinic  staff.  They  will tell the repository that the specimens with the study  code 
number linked  to your child’s  name in the clinic  should  not be studied.  These  specimens  can be 
removed  from  the repository  and destroyed  if you tell  us to  do that.  
 
What  type of research  will be done  with my child’s  speci mens? 
 
Many different  kinds  of studies  use specimens. Some resear chers may develop  new tests  to find 
diseases.  Others may develop  new ways to  treat or even  cure diseases.  In the  future,  some of the 
research  may help to develop  new products,  such as tests  and drugs. If this  would happen  and 
these  tests or drugs make money,  there  are no plans to share  that money  with the people  who 
gave  the speci mens. 
 
As part  of this study  (insert  title) , your child  is being  asked  to have  some (insert  speci men 
source - blood, urine,  tissue, genital  fluid, saliva, etc.) taken.  These specimens  will go into  the 
NICHD repository  for research  to be done  at some time in the future  so that more information 
can come from your child’s  time in this NICHD sponsored Study. 
 
You do not  have  to agree  to store  your child’s  specimens for future  tests for your child  to take 
part in this study.  Your child  will not lose any benefits  to which  your child  is entitled  if you 
decide  against  storing  your child’s  speci mens. 
You will  also be asked  to agree  that these  partic ular tests can be done  without  anyone  contacting 
you to  get your per mission  sometime in the future. No one  doing  these  tests would know  that 
these  speci mens came from  your child  and no one  would contact  you or your doctor  or nurse 
with the results from these  tests that might happen  in the future. 
 
 
   IMPAACT P1090  Page 112 of 113 10 March  2016
 Version 5.0   
  TEMPLATE CONSENT FORM  
 
What  are the general  HIV-related studies  that can be done  with the repository  speci mens?  
 
Researchers  would like  to store  your chil d’s speci mens to understand  how HIV causes  disease  
and complications,  and how best  to treat or prevent HIV in fection  and its complicati ons. They 
need  specimens  from  people who have  HIV and  from  those  who do not.  Sometimes, too, the 
speci mens can be used to  learn  something  about new proble ms that people  with HIV have  like 
liver disease,  diabetes,  and heart  disease.  These general  studies  would  not include  any genetic 
testing  (looking  at your child’s  DNA).  
 
Benefits:  There are no direct  benefits  to your c hild. Your c hild will be helping  researchers  learn 
more  about  how to  help people  with HIV or at  risk of HIV infection.  
 
Risks:  The speci mens would be  collected  as part  of your child’s  study  visits.  (Insert  text about  
collection  procedures .) Once  in the repository,  there are few risks. Your chil d’s name  will not be 
available  to the repository or to the scientists  who may be doing  any future  test. 
 
 
 
I give  permission  for the  use of my child’s  stored  speci mens for the  purposes stated  in the 
prece ding section  (general  HIV-related  tests). 
 
 
 
Parent  or Legal Guardian  Signature  Witness  Signature  Date  
 
I give  my assent  to the use of my stored  specimens for the  purposes stated  in the preceding 
section  (general HIV-related  tests). 
 
 
 
Participa nt Signatu re Witness  Signature  Date  
 
 
 
What  are the special  HIV-related  studies  that can be done  with the repository  speci mens? 
 
Researchers  in this study  would  also like to store  your child’s  speci mens to understand  how HIV 
causes  disease  and complications,  and how best  to treat or prevent  HIV in fection  and its 
complicati ons through  looking  at how each  person ’s genetic  makeup  (your child’s  DNA) either 
protects  them  or puts  them  at greater  risk. It  may be that resea rchers  use so me of your child’s 
blood  to make a “cell  line”.  That means the blood  cells can keep  dividing  and give an endless 
supply  of your child’s  DNA for tests  to be done  in the future.  This kind of infor mation  will be 
particularly  important  as scientists work toward  a vaccine  that could  protect people  from  AIDS.  
They need  speci mens from  people  who have  HIV and  from  those  who do not.  
 
Benefits:  There are no direct  benefits  to your c hild. Your c hild will be helping  researchers  learn 
more  about  how to  help people  with HIV or at  risk of HIV infection.  
 
Risks:  The speci mens would be  collected  as part  of your child’s  study  visits.  (Insert  text about  
 
 
   IMPAACT P1090  Page 113 of 113 10 March  2016
 Version 5.0   
 collection  procedures .) Once  in the repository,  there are few risks. Your chil d’s name  will not be 
available  to the repository or to the scientists  who may be doing  any future  test. Since  there  are 
no plans  to give partici pants the results of the tests perfor med on their  stored speci mens, you will 
not receive  any infor mation  on your child’s  genetic  makeup.  
 
I give  permission  for the  use of my child’s  stored  speci mens for the  purposes stated  in the 
prece ding section  (special  HIV-related  tests). 
 
 
 
Parent  or Legal Guardian  Signature  Witness  Signature  Date  
 
I give  my assent  to the use of my stored  specimens for the  purposes stated  in the preceding 
section  (special  HIV-related  tests).  
 
 
 
Participa nt Signatu re Witness  Signature  Date  
 
 
 
What  if I have  more questions?  
 
If you have  any questions  about  the repository,  about  storage,  or the  use of your child’s  samples, 
contact  (Study  personnel)  at (phone) . 
 
If you have  questions  about  giving  consent  or your child’s  rights  as a research  volunteer,  contact 
the (Name of Instit ution) Institutional  Review  Board  at (phone). 
 
 
 
I refuse  to have any speci men collected  from  my child  stored  in the repository.  
 
 
 
Parent  or Legal Guardian  Signature  Witness  Signature  Date  
 